Document:

EX-10.30

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 Exhibit
10.30 
 PROCESS DEVELOPMENT AND MANUFACTURING 

SERVICES AGREEMENT 
 THIS AGREEMENT is
entered into by and between IDT and Aduro BioTech, as of the date indicated below. 
 Attached to this Agreement, incorporated by reference herein and made
an integral part hereof are the following: 
  

			
		
	PART I:		INTRODUCTORY STATEMENT, DEFINITIONS AND VARIABLE TERMS AND CONDITIONS
		
	PART II:		STANDARD TERMS AND CONDITIONS
		
	PART III:		EXHIBITS

 For and in consideration of the mutual covenants herein contained, and for other good and valuable consideration, the receipt
and sufficiency of which is hereby acknowledged by the Parties, the Parties hereto agree to perform and to be bound by their respective obligations and shall have the respective rights set forth in this Agreement. 

IN WITNESS WHEREOF, the Parties have executed this Agreement as of December 12, 2013 (“Effective Date”). 

 

									
	IDT Biologika GmbH				ADURO BIOTECH, INC.
					
	By:		 /s/ Ralf Pfirman
				By:		 /s/ Gregory Schafer

			
	Dr. Ralf Pfirmann, CEO				
					Gregory W. Schafer, COO
					
	By:		 /s/ Andreas Neubert
						
				
	Dr. Andreas Neubert,						
	Vice President Vaccines						

 Table of Contents 

 

							
		
	PART I: INTRODUCTORY STATEMENT, DEFINITIONS AND VARIABLE TERMS AND CONDITIONS		 	3	  
			
	ARTICLE 1:		DEFINITIONS		 	3	  
			
	ARTICLE 2:		PERFORMANCE OF SERVICES		 	10	  
			
	ARTICLE 3:		DELIVERY, SHIPMENT AND STORAGE OF PRODUCT		 	13	  
		
	PART II: STANDARD TERMS AND CONDITIONS		 	14	  
			
	ARTICLE 4:		REGULATORY MATTERS		 	14	  
			
	ARTICLE 5:		FEES AND PAYMENT		 	15	  
			
	ARTICLE 6:		AMENDMENTS TO THIS AGREEMENT		 	16	  
			
	ARTICLE 7:		NON-CONFORMING PRODUCTS		 	17	  
			
	ARTICLE 8:		CONFIDENTIALITY AND NON-USE		 	19	  
			
	ARTICLE 9:		INTELLECTUAL PROPERTY RIGHTS		 	20	  
			
	ARTICLE 10:		WARRANTIES		 	21	  
			
	ARTICLE 11:		INDEMNITY		 	25	  
			
	ARTICLE 12:		INSURANCE		 	26	  
			
	ARTICLE 13:		TERM AND TERMINATION		 	27	  
			
	ARTICLE 14:		ALLIANCE MANAGER(S)		 	30	  
			
	ARTICLE 15:		DISPUTE RESOLUTION		 	30	  
			
	ARTICLE 16:		MISCELLANEOUS		 	31	  
		
	PART III: EXHIBITS		 	36	  

  
  Aduro Biotech, IDT Biologika Process Development and
Manufacturing Services Agreement, page
 2
 of 36 
 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 PART I: INTRODUCTORY STATEMENT, DEFINITIONS AND VARIABLE TERMS AND CONDITIONS 

This Agreement sets forth the understanding of the Parties with respect to ADURO BIOTECH’s CRS-207 project relating to the performance of the Services by
IDT pursuant to the Work Plan and the payment for Services by ADURO BIOTECH, as well as other matters related thereto, all as more specifically set forth in the terms and provisions of this Agreement. 

ARTICLE 1: DEFINITIONS 
  

	1.1	Definitions. The following terms, whether used in the singular or plural, shall have the meanings assigned to them below for the purposes of this Agreement. 

 

	 	1.1.1	“ADURO BIOTECH” means Aduro BioTech, Inc., and its permitted successors and assigns. 

  

	 	1.1.2	“ADURO BIOTECH Arising IP” shall have the meaning set forth in Section 9.5. 

  

	 	1.1.3	“ADURO BIOTECH Materials” shall mean the materials (including Cell Lines) and information supplied by or on behalf of ADURO BIOTECH to IDT for use in connection with the development of the Process and the
development and Manufacture of Product. For clarity, ADURO BIOTECH Materials shall include the CRS-207 master cell bank (the “Cell Lines”). 

  

	 	1.1.4	“Affiliate” means any corporation, partnership, or other entity Controlling, Controlled by, or under common Control with (directly or indirectly) either Party. 

 

	 	1.1.5	“Agreement” means this Process Development And Manufacturing Services Agreement including the signature page, Part I – Introductory Statement, Definitions and Variable Terms and Conditions, Part II –
Standard Terms and Conditions; and Part III – Exhibits, and all amendments to this Agreement that have been properly executed by the Parties in accordance with the provisions of Section 6.1.4. 

 

	 	1.1.6	“Alliance Manager(s)” has the meaning set forth in Section 14.1. 

  

	 	1.1.7	“Amendment Procedures” has the meaning set forth in Section 6.1. 

  

	 	1.1.8	“Applicable Law” means all U.S., EU, and German applicable laws, rules, regulations, guidelines and standards in effect during performance of this Agreement, including GMP, relating to the Services, the
Product, and the facilities where any Services occur. 

  
  Aduro Biotech,
IDT Biologika Process Development and Manufacturing Services Agreement, page
 3
 of 36 
 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	1.1.9	“Arising IP” shall have the meaning set forth in Section 9.5. 

  

	 	1.1.10	“Batch” means a specific quantity of a Product comprising of number of units mutually agreed upon between IDT and ADURO BIOTECH, and that (a) is intended to have uniform character and quality, within
specified limits, and (b) is produced during one cycle of Manufacture. 

  

	 	1.1.11	“Business Day” means a day other than a Saturday or Sunday on which banking institutions in Dessau-Rosslau, Germany and New York, New York, USA are open for business. 

 

	 	1.1.12	“Claim” means any claim, personal injury claim, demand, liability (including any and all liabilities, actions, proceedings, claims and demands), product liability claim, suit, expense, action or proceeding.

  

	 	1.1.13	“Commercial Supply Period” shall have the meaning set forth in Section 1.3.2. 

  

	 	1.1.14	“Confidential Information” shall have the meaning set forth in Section 8.1. 

  

	 	1.1.15	“Consent” means the consent or approval, in writing, of an authorized officer of a Party to do the act or thing for which such consent or approval is solicited, or the act of granting such written consent or
approval, as the context may require. 

  

	 	1.1.16	“Control” refers to the possession, directly or indirectly, of the power to direct, or cause the direction of, the management or policies of either Party, whether through the ownership of voting securities, by
contract or otherwise, including, the ownership of fifty percent (50%) or more of the voting stock of such Party. 

  

	 	1.1.17	“Damages” mean damages, losses, costs, and expenses, including reasonable legal fees, arising from Claims. 

  

	 	1.1.18	“Defective Product” has the meaning set forth in Section 7.1. 

  

	 	1.1.19	“Deliverables” mean the reports, data and other deliverables, including Products, to be delivered by IDT to ADURO BIOTECH as well as items to be delivered by ADURO BIOTECH TO IDT, pursuant to the respective
Work Packages. 

  

	 	1.1.20	“Delivery” has the meaning set forth in Section 3.1. 

  

 Aduro Biotech, IDT Biologika Process Development and Manufacturing Services Agreement, page
 4
 of 36 
 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	1.1.21	“Development Product” has the meaning set forth in Section 2.9. 

  

	 	1.1.22	“Effective Date” means the date set forth on the signature page of this Agreement. 

  

	 	1.1.23	“Equipment” has the meaning set forth in Section 2.7.1. 

  

	 	1.1.24	“Exhibits” mean those documents and materials attached to this Agreement as Exhibits in Part III hereof, incorporated in this Agreement by reference and made an integral part hereof. 

 

	 	1.1.25	“cGMP” means (a) the current Good Manufacturing Practice regulations as promulgated by the EU Guidelines for Good Manufacturing Practice for medicinal products (Eudralex Vol. 4 and Annexes thereto),
(b) any other relevant EU or national legislation and guidance documents, and (c) current Good Manufacturing Practice regulations promulgated by the FDA published at 21 CFR Part 210 et seq., as any such regulation may be amended from time
to time. 

  

	 	1.1.26	“IDT” means IDT Biologika GmbH, and its permitted successors and assigns. 

  

	 	1.1.27	“IDT Production Facilities” means the Manufacturing facilities of IDT located in Dessau-Roßlau, Germany, where the Services will be performed, except as otherwise set forth in this Agreement.

  

	 	1.1.28	“Initial Payment” has the meaning set forth in Section 5.6.2. 

  

	 	1.1.29	“Intellectual Property” includes rights in patents, patent applications, formulae, processes, data, know-how, trademarks, trademark applications, trade names, inventions, copyrights, and industrial designs, or
any rights in material derived from any of the foregoing. 

  

	 	1.1.30	“Licensee” shall mean any Third Party to which ADURO BIOTECH granted rights and licenses in and to a Product for commercial use, including but not limited to, licensees, partners or joint developers.

  

	 	1.1.31	“Manufacture” and “Manufacturing” means all steps and activities necessary to produce the Product, including by way of enumeration, the manufacturing, processing, quality control, quality assurance,
testing, and release of the Product in compliance with the terms and conditions of this Agreement. For purposes of this Agreement and subject to the provisions of Section 2.9, the manufacturing, processing, quality control, quality assurance,
testing, and release of the Product may be included, as required and agreed in writing by the Parties, as part of the Services in a Work Plan. 

  

 Aduro Biotech, IDT Biologika Process Development and Manufacturing Services Agreement, page
 5
 of 36 
 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	1.1.32	“Master Production Record” means the documentation that contains the detailed description of the Process and instructions for Product production, as approved by ADURO BIOTECH in writing. 

 

	 	1.1.33	“Milestone” has the meaning set forth in Section 1.3.1. 

  

	 	1.1.34	“Notice” means a writing containing the information required or permitted by this Agreement to be communicated by either Party to the other Party at the address set forth in Section 16.1, or such other
address provided by a Party, delivered by overnight courier, two-day international courier, or in person and received by, a Party. Notwithstanding the foregoing provisions, any Notice relating to scheduling of the Manufacture of Product, or other
operational issues, or as otherwise expressly permitted by the provisions of this Agreement may be given by electronic mail. For clarity, Notices do not constitute agreements or amendments to this Agreement, all of which must be in writing and
executed by both Parties. 

  

	 	1.1.35	“Party” means IDT or ADURO BIOTECH as the context dictates and “Parties” means both IDT and ADURO BIOTECH. 

  

	 	1.1.36	“Process” means the Manufacturing process for the Product as provided by ADURO BIOTECH and further developed hereunder. 

  

	 	1.1.37	“Product” means CRS-207 in any of its forms that include mesothelin as the sole heterologous antigen, including but not limited to the final form for use in clinical trials and the form Manufactured by IDT
pursuant to this Agreement (including the Quality Agreement and all of its other Exhibits, and as described in each of the applicable Specifications). 

  

	 	1.1.38	“Quality Agreement” means the Quality Agreement between the Parties attached as Exhibit B. 

  

	 	1.1.39	“Rejection Notice” has the meaning set forth in Section 7.1. 

  

	 	1.1.40	“Regulatory Authority” means any national (such as the FDA), supra-national (such as the European Medicines Agency), or other national, supra-national, regional, state, or local regulatory agency, department,
bureau, commission, council, or other governmental entity with authority and/or jurisdiction over any aspect of the Product. 

  

	 	1.1.41	“Service Fees” means the fees for Services performed by IDT pursuant to each Work Package set forth as part of the Work Plan attached hereto as Exhibit A. 

 
  Aduro Biotech, IDT Biologika Process Development and Manufacturing Services Agreement,
page
 6
 of 36 
 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	1.1.42	“Services” means the work required by ADURO BIOTECH under the relevant Work Packages which is ordered by ADURO BIOTECH and included as a part of the Work Plan. 

 

	 	1.1.43	“Specifications” means those specifications for the Product as set forth in in the respective Work Packages relating to the Product, which shall amend automatically Attachment B of the Quality Agreement
(which is attached as Exhibit B to this Agreement), which itself may be amended with the Parties ́ prior Consent. 

  

	 	1.1.44	“Term” has the meaning set forth in Section 13.1 of this Agreement. 

  

	 	1.1.45	“Third Party” means a person or entity other than IDT or ADURO BIOTECH or their respective Affiliates. 

  

	 	1.1.46	“Work Plan” means the plan attached hereto as Exhibit A and a part hereof. Said Work Plan sets forth the specific Work Packages which describe, among other things, the Services to be performed by IDT under
this Agreement. Each Work Package may designate certain Products as “Development Products” that are subject to the provisions of Section 2.9. 

  

	 	1.1.47	“Work Package” means the document, signed by the Parties, that sets forth the Deliverables of the Parties, including the Services to be performed by IDT. With respect to deliverables of IDT, a Work Package may
describe Product quantities and Manufacturing Instructions, Delivery/release date, reports, data and any other documentation or work result as set forth by the Parties in said Work Package. With respect to deliverables of ADURO BIOTECH, a Work
Package may describe materials, documentation and approvals to be provided and the respective timelines related thereto, payment terms and other relevant terms and conditions. Each such Work Package shall contain the following terms: (i) Title
and Date; (ii) Performance Timelines; (iii) Detailed Description of Deliverables by ADURO BIOTECH; (iv) Detailed Description of Services and Deliverables by IDT; (v) Amendments to this Agreement as required under such Work
Package, if any; (vi) Amendments to the Quality Agreement as required under such Work Package, if any; (vii) Price, Payment; and (viii) other terms and conditions. 

 

	1.2	Interpretation. The interpretation and construction of this Agreement shall be subject to the following provisions: 

  

	 	1.2.1	the words “including” and “include” and words of similar effect shall not be deemed to limit the general effect of the words which precede them such that “including” means “including
without limitation”; 

  
  Aduro Biotech, IDT Biologika Process
Development and Manufacturing Services Agreement, page
 7
 of 36 
 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	1.2.2	where the context requires, (i) all pronouns used herein will be deemed to refer to the masculine, feminine or neuter gender as the context requires, and (ii) the singular context will include the plural and
vice versa; 

  

	 	1.2.3	reference to any agreement, contract, document or deed shall be construed as a reference to it as amended in a writing signed by the Parties thereto; 

 

	 	1.2.4	words importing persons shall include firms, companies and bodies, authorities, corporate and vice versa; words importing any one gender shall include either other gender; 

 

	 	1.2.5	construction of this Agreement shall ignore the headings which are for reference only; 

  

	 	1.2.6	references to a numbered Article, Section, Exhibit or paragraph are references to the Article, Section, Exhibit or paragraph of or to this Agreement so numbered; 

 

	 	1.2.7	any reference to any legislative provision shall be deemed to include any subsequent re-enactment or amending provision; and 

  

	 	1.2.8	in the event of a conflict between the provisions of this Agreement and the Quality Agreement regarding any issue not related to a quality control or quality assurance matter, the provisions of this Agreement shall take
precedence. The provisions of the Quality Agreement will take precedence regarding any issue solely related to a quality control or quality assurance matter. For the sake of clarity, if there is uncertainty as to whether the provisions of this
Agreement or the provisions of the Quality Agreement prevail, any such uncertainty shall be resolved by giving precedence to the provisions in this Agreement. 

  

	 	1.2.9	Subject to the provisions of Section 1.2.8, in the event of a conflict between the provisions of this Agreement and the provision of any Exhibit, the provisions of this Agreement shall take precedence.

  

	1.3	Development Milestones and Commercial Manufacture. 

  

	 	1.3.1	Development Milestones. As part of the completion of the Work Plan, IDT agrees to use its commercially reasonable efforts to fulfill its obligations to provide the Deliverables which are set forth in the Work
Plan as agreed in writing by the Parties and to complete the following milestones (each, a “Milestone”) on the timelines and the other terms and conditions set forth herein which, for clarity, includes the terms and conditions in the Work
Plan. 

  
  Aduro Biotech, IDT Biologika Process Development and
Manufacturing Services Agreement, page
 8
 of 36 
 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	1.3.1.1	Milestone 1. Upon completion of [ * ], the Parties intend to have [ * ]. [ * ] shall [ * ]. 

  

	 	1.3.1.2	Milestone 2. Upon completion of [ * ]. 

  

	 	1.3.1.3	Milestone 3. Upon completion of [ * ]. 

  

	 	1.3.2	Commercial Manufacture. After Milestone 3, ADURO BIOTECH shall purchase and IDT shall Manufacture and Deliver to ADURO BIOTECH the Product for commercial supply to meet [ * ] of the worldwide requirements
of ADURO BIOTECH and its Affiliates and its Licensees, for such Product until the end of [ * ] months after [ * ]. Notwithstanding the foregoing provision, in the event that [ * ], shall be [ * ] after the date of [ *
], then the [ * ] period shall commence to run independently, i.e. from the date [ * ]. The period of time calculated under the preceding sentences is referred to herein as the “Commercial Supply Period”. The Parties
agree that all such commercial Product shall (i) be at [ * ] per dose (final product, labeled and in bulk packaging) agreed in good faith by the Parties but not exceeding [ * ] per dose, and (ii) be delivered in whole lot
quantities not more than [ * ] days after the same is ordered by ADURO BIOTECH. 

  

	 	1.3.3	Orders Prior to Approval. ADURO BIOTECH may order any commercial Product prior to the first date of regulatory approval, provided that in such case as in all instances of Product so ordered by ADURO BIOTECH and
delivered by IDT to ADURO BIOTECH under IDT’s QP release procedures, ADURO BIOTECH shall pay for such Product even though it may not be usable or saleable by ADURO BIOTECH due to IDT Production Facilities not having been approved by Regulatory
Authorities for the Manufacture of such Product or due to other regulatory reasons. IDT agrees to supply all such quantities so ordered. For the sake of clarity, IDT shall have no liability for Product ordered by ADURO BIOTECH prior to approval
which Product cannot be used or sold by ADURO BIOTECH due to any of the foregoing reasons. 

  

	 	1.3.4	Commercial Supply Agreement. By no later than the completion of [ * ], the Parties shall commence good faith negotiations of a Commercial Supply Agreement covering the purchase and supply of the Product to
the end market to be executed by the Parties within [ * ] months after the start of said negotiations. Such Commercial Supply Agreement shall include, among other matters, the terms and conditions set forth in Section 1.3.2.

  

	 	1.3.5	License Agreement. In the event that ADURO BIOTECH during the Term enters into a license agreement Licensee pursuant to which ADURO BIOTECH grants a license to said Licensee to undertake the 

 
  Aduro Biotech, IDT Biologika Process Development and Manufacturing Services Agreement,
page
 9
 of 36 
 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	
Manufacture of Product during the Term (“License Agreement”), then ADURO BIOTECH shall cause the following provision to be included in the License Agreement: 

Licensee acknowledges that ADURO BIOTECH has contracted with IDT Biologika GmbH (“IDT”) for the development of CRS-207 (the
“Development Agreement”). Licensee agrees that if it (whether on its own or through an Affiliate or subcontractor) decides within the Term (as defined in the Development Agreement) to have any CRS-207 manufactured in commercial quantities
for commercial sale in the US or the EU, said Licensee shall adhere to the terms set forth in Section 1.3 of the Development Agreement. Licensee agrees to insert in any sublicense agreement, in which its relevant rights described herein are
sublicensed to a third party, a provision binding the sublicense, and its sub-licensees, to the obligations above set forth. 
 IDT
hereby agrees that ADURO BIOTECH may share this Agreement with any potential Licensee so such Licensee may fully understand its obligations related hereto. 

ARTICLE 2: PERFORMANCE OF SERVICES 
  

	2.1	General. During the Term, IDT shall undertake the performance of the Services including the Manufacture of Product in accordance with the Work Plan and the terms and conditions of this Agreement and
Applicable Law. ADURO BIOTECH shall pay the Service Fees for such Services, or the Product price in case of commercial Manufacture, and perform its obligations in accordance with the Work Plan and the terms and conditions of this Agreement and
Applicable Law. The Parties hereby terminate the purchase order and related terms and conditions dated October 9, 2013 between the Parties (the “PO”) as of the Effective Date hereof. The PO is of no force or effect and all terms and
conditions related to the Services set forth in the PO are hereby governed by this Agreement. 

  

	2.2	Quality Agreement. Subject to the provisions of Sections 1.2.7 and 2.9, the Quality Agreement attached hereto as Exhibit B shall govern all quality related matters pertaining to each Party’s
obligations under this Agreement. 

  

	2.3	Work Plan. The Parties have given their Consent to the Work Plan attached as Exhibit A. Said Work Plan may only be amended in a writing signed by both Parties pursuant to the provisions of
Section 6.1.4. It shall contain, or shall be 

  
  Aduro Biotech, IDT
Biologika Process Development and Manufacturing Services Agreement, page
 10
 of 36 
 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	
amended respectively by the Parties to contain, a detailed description of all development work including, but not limited to, Phase 3, consistency and validation batches to be used by ADURO
BIOTECH in applications for registration and marketing approval. The Services to be provided under a given Work Package shall commence on receipt by IDT from ADURO BIOTECH of the Initial Payment for such Work Package, which Initial Payment
obligation is due as set forth in the respective Work Package. Notwithstanding the foregoing, the start of performance of [ * ] shall be commenced by IDT no later than upon successful completion of [ * ], upon which commencement IDT
shall invoice the Initial Payment for [ * ] and ADURO BIOTECH shall pay such Initial Payment within [ * ] days of receipt of said invoice. 

  

	2.4	Facilities. At all times during the Term, IDT Production Facilities used in connection with Manufacturing under this Agreement shall comply with all Applicable Laws. 

 

	2.5	Manufacture Compliance. Subject to the provisions of Section 2.9 relating to Development Product, all of the Manufacturing performed by IDT shall be in accordance with: (a) cGMP; (b) the
applicable Specifications; (c) this Agreement, including the Quality Agreement and all other Exhibits; and (d) Applicable Law. 

  

	2.6	Subcontracting. IDT will Manufacture the Product at the IDT Production Facilities, and may subcontract single quality control tests to qualified test laboratories with ADURO BIOTECH’s prior Consent.
In the event that IDT subcontracts any of its obligations hereunder, IDT will (i) identify each subcontractor in writing to ADURO BIOTECH; (ii) require the subcontractor to agree in writing to comply with the applicable provisions of this
Agreement which shall include written confidentiality obligations not less onerous than those set forth in Article 8; (iii) be responsible in the event of any non-compliance by the subcontractor with the terms of this Agreement and
(iv) ensure the rights of ADURO BIOTECH to audit such subcontractors in accordance with the Quality Agreement. 

  

	2.7	Equipment. Certain new capital equipment is required by IDT in order to perform the Manufacture. 

  

	 	2.7.1	The details and costs of said new capital equipment, including the purchase price of the equipment and ancillary costs relating to installation, qualification and start-up of said equipment, is listed in Exhibit
C (hereinafter referred to as “Equipment”). 

  

	 	2.7.2	ADURO BIOTECH shall be the owner of said Equipment and reimburse IDT for the costs of said Equipment as further specified in Exhibit C within [ * ] days of receipt of an invoice from IDT for said costs.

  
  Aduro Biotech, IDT Biologika Process Development and Manufacturing
Services Agreement, page
 11
 of 36 
 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	2.7.3	During such time period that said Equipment is the property of ADURO BIOTECH, IDT shall maintain and repair said Equipment in accordance with IDT’s standard equipment maintenance and repair procedures and ADURO
BIOTECH shall pay the reasonable costs of such maintenance and repair within [ * ] days of receipt from IDT of an invoice for the same, any such invoice being issued by IDT to ADURO BIOTECH not more often than quarter-annually.

  

	 	2.7.4	At the expiration or termination of this Agreement, the items of said Equipment that are installed as part of an IDT production line shall be retained by IDT. With respect to the items of Equipment that are not so
installed at the expiration or termination of this Agreement in an IDT production line, IDT will, at IDT’s option set forth in a Notice to ADURO BIOTECH, either (a) ship to ADURO BIOTECH, at ADURO BIOTECH’s expense, said items of
Equipment; (b) dispose, at ADURO BIOTECH’s expense, of said items of Equipment, or (c) continue to retain the items of said Equipment as ADURO BIOTECH property to be used for commercial Manufacturing of the Product in commercial
quantities if so agreed by the Parties, or (d) pay to ADURO BIOTECH the depreciated book value of said items of Equipment and thereafter retain and own said items of Equipment, which payment shall be made within [ * ] days after the date
of the option Notice referenced above. 

  

	2.8	ADURO BIOTECH Materials. IDT agrees that the ADURO BIOTECH Materials shall only be used as specified in writing by ADURO BIOTECH in this Agreement or the applicable Work Plan, and not for any other
purpose. ADURO BIOTECH Materials shall be maintained, handled and stored in accordance with the written directions of ADURO BIOTECH. Title to the ADURO BIOTECH Materials shall at all times remain in ADURO BIOTECH. IDT agrees that it shall not make
any claim or place any lien or encumbrance on any ADURO BIOTECH Materials. Upon direction of ADURO BIOTECH, IDT shall provide ADURO BIOTECH with an accounting of the ADURO BIOTECH Materials and a list of persons with access to the ADURO BIOTECH
Materials, and will return to ADURO BIOTECH all ADURO BIOTECH Materials supplied by ADURO BIOTECH. Title in all Cell Lines prepared from the ADURO BIOTECH Materials (whether development of the line is in-process or complete) shall vest in ADURO
BIOTECH on creation and shall be deemed ADURO BIOTECH Materials and Cell Lines. Risk of loss to Cell Lines, except for any risk of loss that is inherent in the Cell Lines and/or that is due to the negligence or wilful acts of ADURO BIOTECH or its
agents, shall remain with IDT while ADURO BIOTECH Materials are in IDT’s control pursuant to a written agreement pursuant to which IDT takes receipt of such Materials and which sets forth the replacement value of such Materials. ADURO BIOTECH
shall have the absolute right upon reasonable Notice and reasonable request to recover the ADURO BIOTECH Materials and IDT shall cooperate in the same. 

  

 Aduro Biotech, IDT Biologika Process Development and Manufacturing Services Agreement, page
 12
 of 36 
 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	2.9	Development Product. Certain of the Products are designated in the Work Plan as “Development Products”. Notwithstanding any other provision herein set forth, the following terms and conditions
apply to Development Products: 

  

	 	2.9.1	The Parties acknowledge and agree that due to the nature of the Work Plan Deliverables relating to any Development Product, IDT cannot and does not guarantee or warrant, and shall provide no indemnity with respect to,
any such Work Plan Deliverables or any such Development Product. Notwithstanding this, IDT warrants that any reports comprised in the Work Plan Deliverables will be accurate and complete (except in immaterial respects) and not misleading.

  

	 	2.9.2	IDT’s obligation in respect of its performance of any work or Services in connection with any Development Product is limited to performance of such work or Services in a diligent manner, with reasonable skill and
care applying its professional standards and using its commercially reasonable endeavours to meet the estimated timelines and goals set out in the applicable Work Packages. 

 

	 	2.9.3	cGMP shall not apply to the development, Manufacture, Specifications (meaning the “Product Specifications for Development Use” as listed in Attachment B to the Quality Agreement) or any other aspect of any
Development Product or to any Work Plan Deliverables relating thereto, except to the extent specified by the Parties in the respective Work Packages. 

ARTICLE 3: DELIVERY, SHIPMENT AND STORAGE OF PRODUCT 
  

	3.1	Delivery. Delivery of each Deliverable shall occur upon release thereof as is set forth in the applicable Work Package (“Delivery”). Risk of loss for each Work Plan Deliverable shall transfer
from IDT to ADURO BIOTECH [ * ]. Title shall vest in ADURO BIOTECH [ * ]. On the date of Delivery, IDT shall submit an invoice to ADURO BIOTECH for amounts then due pursuant to the Work Package and the provisions of this Agreement.
ADURO BIOTECH shall pay the amount of each said invoice by bank wire transfer within [ * ] days following the date of receipt thereof by ADURO BIOTECH. For the sake of clarity, “release” for purposes of “Delivery” shall be
determined pursuant to the applicable provisions of the Quality Agreement. 

  

	3.2	Shipment. Upon written request from ADURO BIOTECH, IDT shall ship Product directly to ADURO BIOTECH or, on behalf of ADURO BIOTECH, ship Product to the customer/CRO/clinical site of ADURO BIOTECH and in
connection therewith render such services and provide such assistance as are set forth by ADURO BIOTECH or, as applicable, in accordance with the instructions for shipping and packaging specified in the applicable Work Package. The procedures
relating to each shipment shall be agreed by the Parties and described 

  

 Aduro Biotech, IDT Biologika Process Development and Manufacturing Services Agreement, page
 13
 of 36 
 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	
in the Quality Agreement. Each shipment of Product shall be [ * ] (Incoterms 2010), unless otherwise agreed by the Parties. ADURO BIOTECH shall reimburse or pay directly all costs of
whatever kind incurred in connection with each shipment, including insurance, freight, duties and handling. A bill of lading will be furnished to ADURO BIOTECH with respect to each shipment of Product. IDT shall cooperate in ADURO BIOTECH exporting
Product from Germany including providing ADURO BIOTECH all required Manufacturing-related documentation. In no event shall IDT’s liability arising in connection with any shipping services rendered by IDT for ADURO BIOTECH under this Agreement
exceed [ * ]. 

  

	3.3	Storage. IDT shall, at ADURO BIOTECH’s request, provide storage of Product at IDT for at least [ * ] days after Delivery at no charge to ADURO BIOTECH. Storage of Product longer than said time
period shall be subject to IDT’s standard storage fee as set forth in Exhibit A hereto, which fees will be billed to ADURO BIOTECH quarterly. IDT shall store all of the raw materials and other ingredients/disposables, primary packaging
and the Products as set forth in the respective Specifications and as directed by Applicable Laws. IDT shall be responsible for all loss of or damage to all Product, including drug substance, as well as all materials and other
ingredients/disposables used in the Manufacturing of the Products while such items are in the possession or control of IDT, to the extent that such loss or damage is covered by IDT ́s insurance; provided, however, that if such loss or damage is
a result of IDT’s gross negligence or wilful misconduct, IDT shall be responsible for such loss or damage regardless of whether such loss or damage is covered by IDT’s insurance. IDT will use commercially reasonable efforts or as governed
by provisions in this Agreement to replace and/or reproduce as soon as commercially reasonable, any such Product which is lost or damaged. 

PART II: STANDARD TERMS AND CONDITIONS 

ARTICLE 4: REGULATORY MATTERS 
  

	4.1	Unless otherwise agreed in writing by the Parties, ADURO BIOTECH shall be entitled to and have the sole responsibility for filing all documents with applicable Regulatory Authorities and taking any other actions that
may be required or necessary in order to obtain from said Regulatory Authorities approval for the use of the Product in clinical trials or in order to obtain marketing authorization for the Product. IDT shall provide ADURO BIOTECH with assistance
and cooperation in connection with the foregoing to the extent described in the Work Plan. 

  

	4.2	Within [ * ] Business Days of any contact with, or after receipt of any communication from, a Regulatory Authority that may be reasonably expected to affect the Manufacture of the Product, each Party shall
without undue delay forward to the other Party a copy or description of the same and shall confer with 

  

 Aduro Biotech, IDT Biologika Process Development and Manufacturing Services Agreement, page
 14
 of 36 
 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	
the other Party with respect to the best means to comply with any new or modified requirements of such Regulatory Authority. IDT shall provide ADURO BIOTECH with a copy of all draft responses for
comment as soon as possible and shall consider ADURO BIOTECH’s comments in good faith. ADURO BIOTECH shall submit any comments on said draft responses within [ * ] Business Days or within such longer period of time as agreed by the
Parties. IDT shall also provide ADURO BIOTECH with a copy of all final responses for review and approval, which shall not be unreasonably withheld or delayed, at least [ * ] Business Days prior to submission thereof. 

ARTICLE 5: FEES AND PAYMENT 
  

	5.1	ADURO BIOTECH agrees to pay IDT in accordance with the provisions set forth in this Article 5 and in the relevant Work Packages. Each invoice shall reference the applicable provisions of the relevant Work Package and
this Agreement. 

  

	5.2	The Service Fees and other amounts to be paid by ADURO BIOTECH do not include VAT or other taxes to be paid by ADURO BIOTECH, if any, all of which taxes will be estimated in the respective Work Packages. IDT agrees that
it is responsible for compliance with federal, state and local tax requirements relating to payments made by ADURO BIOTECH to IDT under this Agreement. 

  

	5.3	Payment shall be made by ADURO BIOTECH to IDT by bank wire transfer within [ * ] days following the date of ADURO BIOTECH’s receipt of invoice from IDT or as otherwise set forth in the relevant Work Package.

  

	5.4	IDT may charge a fee equal to the current base rate established by the German Federal Bank plus [ * ] annually calculated on a daily basis, on all amounts past due under any invoice issued by IDT to ADURO BIOTECH
under this Agreement. 

  

	5.5	The Services Fees set forth in any Work Package shall not be changed or amended other than to reflect the written agreement of the Parties relating to any change or amendment of the Services covered by said Work
Package. In particular, no Service Fees shall be decreased or increased after execution of a Work Plan unless agreed to in an amendment signed by the Parties. 

  

	5.6	ADURO BIOTECH shall pay IDT pursuant to the following payment schedule. 

  

	 	5.6.1	For the [ * ], ADURO BIOTECH shall pay to IDT [ * ] of the aggregate Services Fees set forth therein, which is agreed to be [ * ]. 

 

	 	5.6.2	For [ * ] and for any subsequent Work Package, ADURO BIOTECH shall pay to IDT [ * ] of the aggregate Service Fees set forth therein (the “Initial Payment”) prior to the Services for the Work
Package being initiated by IDT on the initiation date as set forth in the Work Package hereto, or alternatively in the Work Plan, Exhibit A. IDT shall invoice the 

 
  Aduro Biotech, IDT Biologika Process Development and Manufacturing Services Agreement,
page
 15
 of 36 
 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	
remaining [ * ] upon Delivery of the Deliverables under said Work Package pursuant to section 3.1 and as such set forth in the respective Work Package. 

 

	 	5.6.3	The payment provisions of Sections 5.1 to 5.4 shall apply to the payments of the above-referenced Service Fees to be made by ADURO BIOTECH to IDT. 

 

	 	5.6.4	In the event that this Agreement is terminated by ADURO BIOTECH for material default or insolvency of IDT pursuant to Section 13.2, IDT shall reimburse to ADURO BIOTECH an amount equal to the Service Fees paid by
ADURO BIOTECH pursuant to orders as set forth in the Work Packages, minus the full value of the Deliverables under the Services completed by IDT on or prior to the date of said termination. If the result is a negative number, then IDT shall invoice
ADURO BIOTECH for the difference. 

 ARTICLE 6: AMENDMENTS TO THIS AGREEMENT 

 

	6.1	Amendments. Set forth in this Article 6 are the procedures to be followed by the Parties in connection with amendments to this Agreement and to its Exhibits, including the Work Plan and the Work Packages
(“Amendment Procedures”), except as may be expressly provided otherwise in this Agreement. 

  

	 	6.1.1	If a Party desires an amendment of this Agreement or of its Exhibits, such Party shall send to the other Party a Notice containing an amendment proposal describing in reasonable detail said amendment and the reasons for
it and including supporting documentation demonstrating the need for the amendment (“Amendment Proposal”). Each Amendment Proposal shall comply with any specific provisions that may be set forth in the Section of this Agreement under which
the Amendment Proposal arises. 

  

	 	6.1.2	The Party receiving said Amendment Proposal shall respond to it with a Notice within [ * ] calendar days from the date of receipt or within such longer period of time as the Parties mutually agree (“Proposal
Response”). Said Proposal Response shall either accept the Amendment Proposal or set forth suggestions for changes desired by said receiving Party or reject the Amendment Proposal. 

 

	 	6.1.3	Unless the Amendment Proposal has been rejected pursuant to the provisions of Section 6.1.2, the Parties will negotiate the terms of any such Amendment Proposal in good faith. 

 

	 	6.1.4	All amendments, including any amendment to the provisions of this Section 6.1, shall be in writing and signed by both Parties to be valid. 

 
  Aduro Biotech, IDT Biologika Process Development and Manufacturing Services Agreement,
page
 16
 of 36 
 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	6.1.5	Notwithstanding the provisions set forth in Section 6.1 above, amendments to the Quality Agreement relating to quality assurance or quality control shall be made in accordance with the applicable change control
provisions set forth in the Quality Agreement. 

 ARTICLE 7: NON-CONFORMING PRODUCTS 

 

	7.1	Defective Product. Subject to the provisions of Section 2.9, any Product produced by IDT under this Agreement that does not comply with the Specifications and the warranties set forth in
Section 10.1.5 at the time of Delivery of such Product (“Defective Product”) may be rejected by ADURO BIOTECH pursuant to a Notice sent by ADURO BIOTECH to IDT (“Rejection Notice”) within [ * ] days after ADURO
BIOTECH’s receipt of the alleged Defective Product and all Batch Documentation. 

  

	7.2	Evaluation Report. The Rejection Notice shall be accompanied by a sample of the alleged Defective Product, if feasible. Within [ * ] days after receipt of the Rejection Notice, IDT shall undertake
an evaluation of the sample and give to ADURO BIOTECH a written report of the results of such evaluation. In the event that the Parties disagree upon whether or not any Product is a Defective Product, such disagreement shall be resolved as set forth
in Section 7.4 of this Agreement. 

  

	7.3	Defects Discovered After Time of Delivery. If any defects are not evident immediately to ADURO BIOTECH at the time of Delivery of the Product, the Rejection Notice by ADURO BIOTECH to IDT shall be made no
later than [ * ] Business Days after discovery by ADURO BIOTECH. 

  

	 	7.3.1	Defects Caused by IDT. If such defect is determined to have been caused by IDT, including, as a result of materials provided to IDT by its suppliers for whom IDT is responsible under the applicable
provisions of the Quality Agreement, then IDT shall Manufacture and deliver, at IDT’s expense, to ADURO BIOTECH, as soon as commercially reasonable, replacement of Product in accordance with an amended production plan reasonably agreed to by
the Parties. If the Defective Product had already been shipped to ADURO BIOTECH or to a Third Party designated by ADURO BIOTECH, the replacement Product will be shipped at IDT’s expense. If ADURO BIOTECH has paid for such Defective Product, IDT
shall issue to ADURO BIOTECH a refund in the amount of the Service Fees so paid by ADURO BIOTECH. IDT shall be entitled to invoice ADURO BIOTECH for the Service Fees of the replacement Product, provided that the Service Fees of the replacement
Product shall not exceed the Service Fees that had been invoiced by IDT for the Defective Product, and ADURO BIOTECH shall pay said invoice within [ * ] days of receipt thereof. 

 
  Aduro Biotech, IDT Biologika Process Development and Manufacturing Services Agreement,
page
 17
 of 36 
 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	7.3.2	Defects Caused by ADURO BIOTECH. If such defect is determined to have been caused by ADURO BIOTECH, including any Product being defective due to ADURO BIOTECH’s provision of incomplete or inaccurate
Specifications or due to improper handling of Product by ADURO BIOTECH, by any Affiliate of ADURO BIOTECH or by any Third Party (on behalf of ADURO BIOTECH or any of its Affiliates) or due to any defect in ADURO BIOTECH’s proprietary production
processes being used by IDT in the performance of the Manufacturing (if any), IDT shall Manufacture and deliver to ADURO BIOTECH, as soon as commercially reasonable, replacement Product in accordance with an amended production plan reasonably agreed
to by the Parties (and, to the extent possible, prior to the time ADURO BIOTECH is obligated to deliver the Product to its customer). ADURO BIOTECH shall be required to pay the Service Fees of the Product (determined to be Defective Product caused
by ADURO BIOTECH) and the Service Fees of the replacement Product. 

  

	7.4	Expert. If the Parties cannot agree as to whether Product is Defective Product, within [ * ] days after delivery of the aforesaid IDT evaluation report to ADURO BIOTECH, the Parties shall submit the
relevant materials to a mutually agreed upon independent testing laboratory or other appropriate expert acceptable to the Parties (“Expert”) for evaluation. The Parties shall cooperate fully and promptly with the Expert’s reasonable
requests for assistance or information in connection with its evaluation hereunder. Within [ * ] days thereafter, the Expert shall determine whether the Products are Defective Products and, if possible, the cause of the defect as soon as
reasonably possible. The findings of the Expert shall be final, binding and determinative on the Parties, absent manifest error. The expenses of the Expert(s) shall be borne by IDT if the Expert(s) determines that the Product is Defective Product,
but the expert does not attribute the sole cause of the defect to ADURO BIOTECH under Section 7.3.2. If the expert concludes that ADURO BIOTECH is the sole cause of the defect, then the costs will be paid by ADURO BIOTECH. 

 

	7.5	[ * ]. The remedies for Defective Product caused by IDT pursuant to this Article 7 shall [ * ]. 

  

	7.6	Recall. Each Party shall give Notice to the other Party immediately upon learning of any event that would be expected to give rise to a recall of Product or other corrective measure related to the Product.
ADURO BIOTECH shall be responsible for all such recalls and actions, provided that IDT shall fully cooperate in the same. All costs of a Product recall or other corrective measure related to the Product shall be the sole responsibility of ADURO
BIOTECH except to the extent such recall is due to Defective Product caused by IDT under the provisions of Section 7.3 above, in which event IDT shall also be liable for the direct costs of said recall. Direct costs under this Section 7.6
shall be limited to costs of transport, safe destruction of Defective Product, travel and communication services for the handling of the recall and corrective measures. 

 
  Aduro Biotech, IDT Biologika Process Development and Manufacturing Services Agreement,
page
 18
 of 36 
 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 ARTICLE 8: CONFIDENTIALITY AND NON-USE 

 

	8.1	Defined. As used in this Agreement, the term “Confidential Information” shall mean all information disclosed in writing or by oral communications by either Party to the other Party including any
information relating to the Product, the Manufacturing Specifications, formulations and compositions; scientific know-how; chemical compound, biological material and composition data; Manufacturing processes; analytical methodology; Product
applications including safety and efficacy data; current and future Product and marketing plans and projections; and other information of a technical or economic nature related to the Product, the Manufacture of the Product and the matters set forth
in any Work Plan. The existence and content of this Agreement shall also be considered Confidential Information of both Parties. The Process, the Master Production Record, ADURO BIOTECH Intellectual Property, and ADURO BIOTECH Arising IP are
Confidential Information of ADURO BIOTECH. 

  

	8.2	Limited Disclosure. All Confidential Information disclosed hereunder shall remain the property of the disclosing Party and shall be maintained in confidence and not disclosed by the receiving Party to any
person except to officers, employees, and consultants to whom it is necessary to disclose the information for the purposes of this Agreement. Each Party shall take all steps it would normally take to protect its own Confidential Information to
ensure that the received Confidential Information shall be maintained in confidence and not disclosed, but not less than reasonable care. 

  

	8.3	Use. Unless otherwise agreed in writing, all Confidential Information disclosed hereunder shall be used by that Party only to fulfill its obligations under this Agreement. 

 

	8.4	Exceptions. The obligations of the Parties under this Article 8 shall not apply to: 

  

	 	8.4.1	Information which, at the time of disclosure, is in the public domain or thereafter comes into the public domain other than as a result of breach of this Agreement; or 

 

	 	8.4.2	Information which the receiving Party can establish was in its possession at the time of disclosure by the disclosing Party; or 

  

	 	8.4.3	Information which was received by the receiving Party from an Affiliate or from a Third Party not under an obligation of confidentiality towards the disclosing Party; or 

 
  Aduro Biotech, IDT Biologika Process Development and Manufacturing Services Agreement,
page
 19
 of 36 
 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	8.4.4	Information which the receiving Party can establish was independently developed without reference to Confidential Information received hereunder. 

 

	8.5	Mandatory Disclosure. Notwithstanding the limitations above, each Party may disclose Confidential Information belonging to the other Party to the extent such disclosure is required by mandatory legal
provisions, provided, however, in the event a Party is required to make a disclosure of the other Party’s Confidential Information pursuant to this Section 8.5, it will give reasonable advance Notice to the other Party of such disclosure
obligation and will cooperate with the other Party’s attempt to obtain a protective order or confidential treatment. 

  

	8.6	Return. Upon termination of this Agreement, each Party agrees to return to the other Party or destroy all written or other physical embodiments of the other Party’s Confidential Information, except
for one (1) copy, which may be retained in a confidential manner exclusively for legal archival purposes. The obligations under this Article 8 shall be binding on any Affiliate, successor or assignee of IDT or ADURO BIOTECH as if it was a Party
to the Agreement. 

  

	8.7	Duration. The obligations of confidentiality and non-use of the Confidential Information under this Agreement shall continue throughout the Term of this Agreement and shall survive the termination or
expiration of this Agreement for [ * ] years. 

 ARTICLE 9: INTELLECTUAL PROPERTY RIGHTS 

 

	9.1	Ownership. All Intellectual Property owned or controlled by IDT shall remain the property of IDT. All Intellectual Property owned or controlled by ADURO BIOTECH shall remain the property of ADURO BIOTECH.
The Process and the Master Production Record are hereby the sole and exclusive property of ADURO BIOTECH. 

  

	9.2	License to IDT. ADURO BIOTECH grants to IDT a non-exclusive, royalty-free, license to use for the performance of the Services under this Agreement all of ADURO BIOTECH’s Intellectual Property that
ADURO BIOTECH provides to IDT to perform the Services under this Agreement. The duration of said license shall be for the Term of this Agreement. In no event shall IDT be permitted to use ADURO BIOTECH’s Intellectual Property for any other
purpose or for any other customer of IDT without the prior Consent of ADURO BIOTECH. 

  

	9.3	IDT Intellectual Property and Third Party Intellectual Property. IDT shall not incorporate any of its IDT Intellectual Property or Third Party Intellectual Property into the Process or Master Production
Record without the prior Consent of ADURO BIOTECH. 

  

	9.4	IDT’s Proprietary Intellectual Property. IDT hereby agrees to use such of IDT’s Intellectual Property as is required in order to perform the Services under 

 
  Aduro Biotech, IDT Biologika Process Development and Manufacturing Services Agreement,
page
 20
 of 36 
 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	
this Agreement. IDT hereby grants to ADURO BIOTECH an irrevocable, fully paid, non-exclusive worldwide license, with the right to grant and authorize sublicenses through multiple layers of
sub-licensees, under any and all IDT Intellectual Property including any Arising IP that IDT incorporates pursuant to this Agreement into the Process, Master Production Record, and Specifications, to make, have made, use, have used, sell, offer for
sale, have sold, import, have imported, export, have exported, develop, have developed, commercialize, and have commercialized any product. 

  

	9.5	Inventions. Any Intellectual Property that shall be created or conceived by IDT as a result of, or be derived from, the performance of the Services under this Agreement (“Arising IP”) and that is
not ADURO BIOTECH Arising IP and relates to any IDT Manufacturing processes or to any other IDT Intellectual Property shall be owned by and be the sole and exclusive property of IDT. Any Arising IP related to the Product or related to, based on, or
incorporating any other ADURO BIOTECH Intellectual Property shall be owned by and hereby is the sole and exclusive property of ADURO BIOTECH (“ADURO BIOTECH Arising IP”). 

 

	9.6	Other Acts. Each Party shall undertake all necessary or appropriate acts, including signing assignment or other documents to give effect to the provisions of this Article 9. IDT covenants to take all
reasonable actions necessary to obtain all right, title and interest in and to any and all inventions related to this Agreement that are conceived or reduced to practice by any of its employees or contractors including negotiation of necessary
agreement and payment of all amounts advisable or required under German or EU law. 

 ARTICLE 10: WARRANTIES 

 

	10.1	IDT warrants that: 

  

	 	10.1.1	IDT has the power, authority and legal right to enter into this Agreement and to perform its obligations hereunder. This Agreement has been duly executed and delivered on behalf of IDT, and constitutes a legal, valid,
binding obligation, enforceable against IDT in accordance with its terms. 

  

	 	10.1.2	All necessary licenses, permits, consents, approvals and authorizations of all Regulatory Authorities required to be obtained by IDT in connection with this Agreement have been obtained or will be obtained as required
prior to undertaking the Manufacture. IDT shall adhere to all Applicable Laws. 

  

	 	10.1.3	The Intellectual Property utilized by IDT, other than the Intellectual Property provided by ADURO BIOTECH, in connection with this Agreement: (i) may be lawfully used in connection therewith, and (ii) such use
does not infringe any Third Party rights. IDT has the requisite 

  
 
Aduro Biotech, IDT Biologika Process Development and Manufacturing Services Agreement, page
 21
 of 36 
 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	
intellectual property rights, including in its equipment and facility, to be able to perform its obligations under this Agreement, (iii) IDT’s use of its equipment and facility as
contemplated in this Agreement will not give rise to a potential Claim by a Third Party against ADURO BIOTECH for infringement or another violation of intellectual property rights, (iv) IDT will not incorporate into the Product or utilize in
connection with this Agreement any Third Party Intellectual Property without the prior Consent of ADURO BIOTECH unless ADURO BIOTECH provides to IDT any Third Party Intellectual Property for incorporation into Product, and (v) the Product does
not include, and was not Manufactured by IDT utilizing, any Third Party Intellectual Property, unless such Third Party Intellectual Property was provided or approved in writing by ADURO BIOTECH for use in the Product. 

 

	 	10.1.4	IDT has the necessary facilities, equipment, know-how and personnel to carry out the Services in accordance with this Agreement. 

  

	 	10.1.5	Subject to the provisions of Section 2.9, any Product Manufactured by IDT pursuant to this Agreement other than Development Product, at the time of Delivery: (a) conforms to the Specifications; (b) was
Manufactured in accordance with the Master Production Record; (c) was Manufactured in accordance with cGMP using a process, components, and a facility that comply with all Applicable Laws; (d) is delivered free and clear of any liens or
encumbrances of any kind; and (e) has not been adulterated. 

  

	 	10.1.6	IDT will use commercially reasonable efforts to perform the Services as set forth in the Work Plan and in the operational documents related thereto. 

 

	 	10.1.7	IDT will use commercially reasonable efforts to agree with ADURO BIOTECH on the details of the Work Plan, the Work Packages and the operational documents related thereto. 

 

	 	10.1.8	IDT represents and certifies it will not use in any capacity the services of any person, or organization that employs any person that is or has been debarred under Section 306 of the Generic Drug Enforcement Act,
is an excluded party from doing business with the U.S. Federal Government (Excluded Parties List System published by GSA), Office of Inspector General’s List of Excluded Individuals/Entities (LEIE), is included on any other government exclusion
list of persons or entities with whom U.S. companies and individuals are prohibited from doing business (e.g. OFAC List of Blocked Persons), or is similarly debarred or excluded under the Applicable Law in any other jurisdiction. Upon written
request of ADURO BIOTECH, IDT shall, within [ * ] Business Days, provide written confirmation that it has complied with the foregoing obligation. 

  

 Aduro Biotech, IDT Biologika Process Development and Manufacturing Services Agreement, page
 22
 of 36 
 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	
IDT agrees to promptly disclose in writing to ADURO BIOTECH if any employee or agent is debarred or excluded, or if any action or investigation is pending or, to the best of its knowledge,
threatened, relating to the debarment or exclusion of it or any person performing Services related to this Agreement. 

  

	10.2	ADURO BIOTECH warrants that: 

  

	 	10.2.1	ADURO BIOTECH has the power, authority and legal right to enter into the Agreement and to perform its obligations hereunder. This Agreement has been duly executed and delivered on behalf of ADURO BIOTECH, and
constitutes a legal, valid, binding obligation, enforceable against ADURO BIOTECH in accordance with its terms. 

  

	 	10.2.2	All necessary licenses, permits, consents, approvals and authorizations of all Regulatory Authorities required to be obtained by ADURO BIOTECH in connection with this Agreement have been obtained or will be obtained as
required prior to undertaking Manufacturing. ADURO BIOTECH shall adhere to all Applicable Laws. 

  

	 	10.2.3	The Intellectual Property provided by ADURO BIOTECH, in connection with the Manufacturing may be lawfully used in connection with such Manufacture. 

 

	 	10.2.4	ADURO BIOTECH will use commercially reasonable efforts to perform its obligations in order for IDT to perform the Services as set forth in the Work Plan and in the operational documents related thereto.

  

	 	10.2.5	ADURO BIOTECH will use commercially reasonable efforts to agree with IDT on the details of the Work Plan, the Work Packages and the operational documents related thereto 

 

	10.3	LIMITATION OF LIABILITY. With respect to Claims made by or against IDT, ADURO BIOTECH, or any Affiliate of either, the following provisions shall apply: 

 

	 	10.3.1	IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR SPECIAL, INDIRECT, INCIDENTAL, OR CONSEQUENTIAL DAMAGES (INCLUDING WITHOUT LIMITATION LOSS OF PROFIT) ARISING OUT OF THIS AGREEMENT, WHETHER BASED ON CONTRACT, TORT, OR
ANY OTHER LEGAL THEORY, AND WHETHER OR NOT IT HAS BEEN ADVISED OR IS OTHERWISE AWARE OF THE POSSIBILITY OF SUCH LOSS OR DAMAGE, HOWEVER CAUSED. 

  

	 	10.3.2	FOR ANY CLAIM BASED ON ANY LEGAL THEORY OTHER THAN ALLEGED GROSS NEGLIGENCE, IDT ́S MAXIMUM 

  

 Aduro Biotech, IDT Biologika Process Development and Manufacturing Services Agreement, page
 23
 of 36 
 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	
DIRECT AND INDIRECT LIABILITY FOR ANY SINGLE CLAIM WHICH IS BEYOND AMOUNTS PAID BY ONE OR MORE OF IDT’S INSURERS AND WHICH IS BROUGHT UNDER THIS AGREEMENT BY ADURO BIOTECH, BY ANY AFFILIATE
OF ADURO BIOTECH AND/OR BY ANY THIRD PARTY SHALL NOT EXCEED, DIRECTLY OR INDIRECTLY, AN AMOUNT WHICH EQUALS [ * ], PROVIDED HOWEVER THAT, SUBJECT TO THE PROVISIONS OF SECTION 10.3.4, IDT’S LIABILITY UNDER THIS SECTION 10.3.2 SHALL NOT EXCEED A
MAXIMUM AMOUNT OF [ * ]. 

  

	 	10.3.3	FOR ANY CLAIM BASED ON ALLEGED GROSS NEGLIGENCE, IDT ́S MAXIMUM DIRECT AND INDIRECT LIABILITY FOR ANY SINGLE CLAIM WHICH IS BEYOND AMOUNTS PAID BY ONE OR MORE OF IDT’S INSURERS AND WHICH IS BROUGHT UNDER
THIS AGREEMENT BY ADURO BIOTECH, BY ANY AFFILIATE OF ADURO BIOTECH AND/OR BY ANY THIRD PARTY SHALL NOT EXCEED, DIRECTLY OR INDIRECTLY, AN AMOUNT WHICH EQUALS [ * ], PROVIDED HOWEVER THAT, SUBJECT TO THE PROVISIONS OF SECTION 10.3.4, IDT’S
LIABILITY UNDER THIS SECTION 10.3.3 SHALL NOT EXCEED A MAXIMUM AMOUNT OF [ * ] 

  

	 	10.3.4	IDT’S MAXIMUM AGGREGATE LIABILITY FOR ALL SUCH CLAIMS WHICH ARE BEYOND AMOUNTS PAID BY ONE OR MORE OF IDT’S INSURERS AND WHICH ARE BROUGHT UNDER THIS AGREEMENT BY ADURO BIOTECH, BY ANY AFFILIATE OF ADURO
BIOTECH AND/OR BY ANY THIRD PARTY SHALL NOT EXCEED, DIRECTLY OR INDIRECTLY, AN AMOUNT WHICH EQUALS [ * ]. 

  

	 	10.3.5	THE FOREGOING LIABILITY LIMITATION PROVISIONS SHALL NOT APPLY TO CLAIMS BASED ON ALLEGED WILLFUL MISCONDUCT BY IDT. 

  

	 	10.3.6	For the sake of clarity, the Parties expressly agree that, subject to Section 10.3.3, any liability limitation in this Agreement will not limit potential recovery from any insurer of IDT for losses covered by
policies issued by such insurer which are incurred in connection with Claims. The scope and extent of liability for IDT’s insurers shall be governed exclusively by the terms and limitations of the policies issued by such insurers. 

  

	 	10.3.7	THE PARTIES’ RESPECTIVE LIABILITY SHALL BE FURTHER LIMITED AS PROVIDED IN SECTIONS 12.3 AND 12.4. 

  

 Aduro Biotech, IDT Biologika Process Development and Manufacturing Services Agreement, page
 24
 of 36 
 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	10.3.8	ADURO BIOTECH expressly agrees that ADURO BIOTECH will be liable for, and will indemnify IDT against, all Claims of ADURO BIOTECH, of any Affiliate of ADURO BIOTECH, and of any Third Party which Claims are not satisfied
by IDT’s insurance coverage and/or by payments made by IDT within the maximum aggregate liability limitations provided for in Sections 10.3.2., 10.3.3 and 10.3.4. The forgoing shall not be construed as co-insurance and neither ADURO BIOTECH nor
its Affiliates or insurers shall be construed as co-insurers by virtue of this provision. 

  

	 	10.3.9	THE REPRESENTATIONS AND WARRANTIES SET FORTH IN THIS AGREEMENT ARE IN LIEU OF ALL OTHER REPRESENTATIONS AND WARRANTIES NOT EXPRESSLY SET FORTH HEREIN, AND EACH PARTY HEREBY EXPRESSLY DISCLAIMS ANY AND ALL OTHER
REPRESENTATIONS AND WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING WITHOUT LIMITATION THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR ANY PARTICULAR PURPOSE. 

ARTICLE 11: INDEMNITY 
  

	11.1	ADURO BIOTECH’s Indemnity. ADURO BIOTECH shall indemnify, defend and hold harmless IDT (except to the extent IDT is obligated to indemnify ADURO BIOTECH as set forth below) from and against all
Claims, Damages and liabilities asserted by a Third Party to the extent arising out of: 

  

	 	11.1.1	the distribution, marketing, sale, and/or use of any Work Plan Deliverable or any Product, including the use of any such Deliverable or Product in any clinical trials; 

 

	 	11.1.2	a material breach of any of this Agreement by ADURO BIOTECH; or, 

  

	 	11.1.3	ADURO BIOTECH’s willful misconduct or negligence; or 

  

	 	11.1.4	defective or erroneous or incomplete ADURO BIOTECH Materials, Process or Specifications provided by ADURO BIOTECH to IDT for the Manufacture of Product. 

 

	11.2	IDT’s Indemnity. IDT shall indemnify, defend and hold harmless ADURO BIOTECH (except to the extent ADURO BIOTECH is obligated to indemnify IDT as set forth above) against all Claims, Damages, and
liabilities asserted by a Third Party, to the extent arising out of: 

  

	 	11.2.1	subject to the provisions of Section 2.9, any failure of Product supplied by IDT hereunder to conform to Specifications and the requirements of the Agreement at Delivery; 

 
  Aduro Biotech, IDT Biologika Process Development and Manufacturing Services Agreement,
page
 25
 of 36 
 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	11.2.2	a material breach of any of this Agreement by IDT; or, 

  

	 	11.2.3	IDT’s willful misconduct or negligence. 

  

	11.3	Procedures. The Party seeking indemnification (“Indemnified Party”) pursuant to this Article 11 shall promptly provide Notice to the indemnifying Party (“Indemnifying Party”) of such
Claim in reasonable detail, provided that the failure to provide such Notice shall not affect the obligations of the Indemnifying Party unless and only to the extent said Indemnifying Party is actually materially prejudiced thereby. The Indemnified
Party shall furnish promptly to the Indemnifying Party copies of all papers and official documents received in respect of any claim. Commencing within [ * ] days after receipt of the aforesaid Notice, the Indemnifying Party shall undertake,
conduct and control, through counsel of its own choosing (but reasonably acceptable to the Indemnified Party) and at its own expense, the settlement or defense of the claim, provided that the Indemnified Party may participate in such settlement or
defense through counsel chosen by the Indemnified Party and reasonably acceptable to the Indemnifying Party. The Indemnifying Party shall not, without the Consent of the Indemnified Party, settle or compromise any claim, unless such settlement or
compromise includes an unconditional release of the Indemnified Party. The Indemnifying Party and the Indemnified Party shall cooperate fully in all aspects of any investigation, defense, pre-trial activities, trial, compromise, settlement or
discharge of any claim in respect of which indemnity is sought pursuant to this Article 11, including, but not limited to, providing the other Party with reasonable access to employees and officers (including as witnesses) and other information.

 ARTICLE 12: INSURANCE 
  

	12.1	ADURO BIOTECH General. ADURO BIOTECH will maintain, at all times during the term of this Agreement and for [ * ] years thereafter, a products liability insurance policy (the “Insurance
Policy”), with a per occurrence limit of at least Five Million Dollars ($5,000,000) and an aggregate limit of at least Five Million Dollars ($5,000,000), and will provide a certificate of insurance to IDT that the Insurance Policy has been
endorsed to designate IDT as an additional insured. ADURO BIOTECH will provide IDT with at least [ * ] days’ Notice prior to termination of or reduction in coverage under such Insurance Policy. 

 

	12.2	IDT General. IDT will maintain, at all times during the term of this Agreement and for [ * ] years thereafter, a liability insurance policy (the “IDT Insurance Policy”), with a per
occurrence limit of at least Five Million Euro (5.000.000 €) and an aggregate limit of at least Five Million Euro (5.000.000 €). IDT will provide ADURO BIOTECH with at least [ * ] days’ Notice prior to termination of or
reduction in coverage under such IDT Insurance Policy. 

  

	12.3	IDT’s Obligation. IDT shall use commercially reasonable efforts to maintain in force the insurance coverage referenced in Section 12.2 above, provided, 

 
  Aduro Biotech, IDT Biologika Process Development and Manufacturing Services Agreement,
page
 26
 of 36 
 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	
however, that IDT shall have no liability in the event that its insurance provider reduces, cancels or denies any such insurance coverage for reasons outside the reasonable control of IDT. In the
event that IDT is not able to procure or maintain the amount of insurance coverage as set forth in Section 12.2, IDT shall inform ADURO BIOTECH without undue delay. 

 

	12.4	ADURO BIOTECH’s Obligation. ADURO BIOTECH shall use commercially reasonable efforts to maintain in force the insurance coverage referenced in Section 12.1 above, provided, however, that ADURO
BIOTECH shall have no liability in the event that its insurance provider reduces, cancels or denies any such insurance coverage for reasons outside the reasonable control of ADURO BIOTECH. In the event that ADURO BIOTECH is not able to procure or
maintain the amount of insurance coverage as set forth in Section 12.1, ADURO BIOTECH shall inform IDT without undue delay. 

ARTICLE 13: TERM AND TERMINATION 
  

	13.1	Term. This Agreement shall commence on the Effective Date and shall remain in full force and effect until and during the Commercial Supply Period as defined in Section 1.3.2, unless earlier terminated
as permitted herein. In the event that no [ * ] within five (5) years of the Effective Date, then this Agreement shall terminate on the tenth (10th) anniversary of said Effective
Date, unless earlier terminated as permitted herein. The time period between said Effective Date and the termination date of this Agreement as set forth in this Section 13.1 is herein called the “Term”. 

 

	13.2	Early Termination by ADURO BIOTECH. ADURO BIOTECH may terminate this Agreement or a Work Plan in whole or in part at any time with a prior Notice of termination to IDT in the event that: 

 

	 	13.2.1	Termination for Default. ADURO BIOTECH sends to IDT a default Notice alleging IDT’s failure to perform a material obligation under this Agreement or a Work Plan, and IDT fails to cure said default
within forty-five (45) days of receiving such Notice, ADURO BIOTECH may terminate this Agreement. 

  

	 	13.2.2	Insolvency. In the event IDT enters into bankruptcy proceedings (whether voluntary or involuntary) or proceedings leading to bankruptcy, IDT agrees to send to ADURO BIOTECH a Notice setting forth the
details of such event. This Notice shall be furnished within ten (10) days of the initiation of the proceedings relating to the bankruptcy. This obligation remains in effect until final payment under this Agreement. Bankruptcy or insolvency is
deemed to be a material breach of this Agreement and may, at the sole discretion of ADURO BIOTECH constitute the basis for a termination for default without further Notice. 

 
  Aduro Biotech, IDT Biologika Process Development and Manufacturing Services Agreement,
page
 27
 of 36 
 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	13.2.3	Termination for Termination of Development. ADURO BIOTECH and IDT shall each have the right to terminate this Agreement upon thirty (30) days’ Notice to the other Party in the event that ADURO
BIOTECH decides to end its program for use of Product, solely for the reasons of clinical inefficacy or safety, or an action of a Regulatory Authority not granting approval despite commercially reasonable efforts to gain approval. In the event of
any such termination under the provisions of this Section 13.2.3, ADURO BIOTECH shall certify that during the Term neither ADURO BIOTECH nor its Affiliates, Licensees, permitted assigns and successors, will restart the program for use of the
Product, and if said program is restarted , that its purchase obligations and IDT ́s related performance obligations shall revive assuming that IDT agrees in writing to fulfill its obligations remaining hereunder as of the date of termination
as such obligations may be modified based on the then-current regulatory strategy, and ADURO BIOTECH, its Affiliates, Licensees, permitted assigns and successors shall immediately Notify IDT in this case. In the event of such termination of this
Agreement under the provisions of this Section 13.2.3, IDT shall invoice and ADURO BIOTECH shall pay within [ * ] days of the date of invoice [ * ] plus [ * ], plus all raw materials and external work procured by IDT in
order to perform [ * ], both to the extent not covered by any advanced payment for the Work Plan upon its initiation. 

  

	 	13.2.4	Other Termination. Either Party may terminate this Agreement upon Notice to the other Party, if the other Party is not able to procure or maintain its respective amount of insurance coverage as set forth
in Sections 12.1 or 12.2, as the case may be. 

  

	13.3	Early Termination by IDT. IDT may terminate this Agreement in whole or in part at any time with a prior Notice of termination, in the event that: 

 

	 	13.3.1	Termination for Default. IDT sends to ADURO BIOTECH a default Notice alleging ADURO BIOTECH’s failure to perform a material obligation under this Agreement or a Work Plan, and ADURO BIOTECH fails to
cure said default within forty-five (45) days of receiving such Notice, IDT may terminate this Agreement. 

  

	 	13.3.2	Insolvency. In the event ADURO BIOTECH enters into bankruptcy proceedings (whether voluntary or involuntary) or proceedings leading to bankruptcy, ADURO BIOTECH agrees to send to IDT a Notice setting forth
the details of such event. This Notice shall be furnished within ten (10) days of the initiation of the proceedings relating to the bankruptcy. This obligation remains in effect until final payment under this Agreement. Bankruptcy or insolvency
is deemed to be a material breach of this Agreement and may, at the sole discretion of IDT constitute the basis for a termination for default without further Notice. 

 
  Aduro Biotech, IDT Biologika Process Development and Manufacturing Services Agreement,
page
 28
 of 36 
 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	13.4	Effects of Termination. 

  

	 	13.4.1	Accrued Rights. Termination of this Agreement for any reason will be without prejudice to any rights that have accrued to the benefit of a Party prior to such termination. Such termination will not relieve
a Party of obligations that are expressly indicated to survive the termination of this Agreement. 

  

	 	13.4.2	Disposition of Remaining ADURO BIOTECH Materials, Property, and Confidential Information. Upon termination or expiration of this Agreement, IDT will store any remaining ADURO BIOTECH property and, at ADURO
BIOTECH’s option, return or destroy any ADURO BIOTECH property and Confidential Information in the possession or control of IDT. Likewise, ADURO BIOTECH will, at IDT’s option, return or destroy any IDT Confidential Information in the
possession or control of ADURO BIOTECH. Notwithstanding the foregoing provisions: (i) IDT may retain and preserve, at its sole cost and expense, samples and standards of each Product following termination or expiration of this Agreement solely
for use in determining IDT’s rights and obligations hereunder; and (ii) each Party may retain a single copy of the other Party’s Confidential Information for documentation purposes only and which shall remain subject to the
obligations of nonuse and confidentiality set forth in this Agreement. 

  

	 	13.4.3	Unless the termination of this Agreement (a) is for the uncured material breach of the Agreement by ADURO BIOTECH, or (b) is by ADURO BIOTECH pursuant to the provisions of Section 13.2.3, IDT agrees that
it will cooperate with ADURO in performing a technology transfer which includes the transfer of the Process to ADURO BIOTECH or its designee.. Any such technology transfer shall be made pursuant to a written order from ADURO BIOTECH to IDT which has
been accepted by IDT, such acceptance not to be unreasonably withheld, and which contains, among other relevant matters, the details of such transfer and the commercially reasonable price to be paid by ADURO BIOTECH. 

 

	 	13.4.4	Disposition of Remaining IDT Materials, Property, and Confidential Information. Upon termination or expiration of this Agreement, ADURO BIOTECH will store any remaining IDT property and, at IDT’s
option, return or destroy any IDT property and Confidential Information in the possession or control of ADURO BIOTECH. Likewise, ADURO BIOTECH will, at IDT’s option, return or destroy any IDT Confidential Information in the possession or
control of ADURO BIOTECH. Notwithstanding the foregoing provisions: (i) ADURO BIOTECH may retain and preserve, at its sole cost and expense, samples and standards of each Product following termination or expiration of this Agreement solely for
use in determining ADURO BIOTECH’s rights and obligations 

  
  Aduro
Biotech, IDT Biologika Process Development and Manufacturing Services Agreement, page
 29
 of 36 
 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	
hereunder; and (ii) each Party may retain a single copy of the other Party’s Confidential Information for documentation purposes only and which shall remain subject to the obligations
of nonuse and confidentiality set forth in this Agreement. 

  

	13.5	No Liability. Neither Party shall incur any liability whatsoever for any damage, loss or expense of any kind suffered or incurred by the other (or for any compensation to the other) arising from or
incident to such Party’s termination of this Agreement which complies with the terms of this Agreement whether or not such Party is aware of any such damage, loss or expense. 

 

	13.6	Survival of Certain Provisions. Termination or expiration this Agreement for any reason shall not affect the rights, obligations and responsibilities of the Parties pursuant to Sections 2.7.4, 2.8, 2.9,
3.3, 5.6.4 and 13.4 and Articles 7, 8, 9, 10, 11, 12, 15 and 16 all of which survive any termination, along with any additional terms in this Agreement necessary to give effect to such provisions. 

ARTICLE 14: ALLIANCE MANAGER(S) 
  

	14.1	Alliance Managers. Each Party shall appoint one or more managers (“Alliance Manager(s)”) to serve as the point of contact for communications between the Parties on matters arising under this
Agreement. 

  

	14.2	Responsibility. Each Party’s Alliance Manager(s) shall be primarily responsible for reporting to the other Party’s Alliance Manager(s) on the progress of the activities for which said Party is
responsible as set forth in the Work Plan and each Alliance Manager shall in general provide the opportunity to exchange views and to discuss issues in relation to IDT’s and ADURO BIOTECH’s obligations under this Agreement.

  

	14.3	Meetings. The Alliance Managers from IDT and ADURO BIOTECH shall meet in person or by video or telephone conference not less than once every calendar month during the Term of this Agreement. Written
minutes shall be kept of each meeting between the Alliance Managers from IDT and ADURO BIOTECH. 

 ARTICLE 15: DISPUTE
RESOLUTION 
  

	15.1	Dispute Resolution Procedures. If a Party has a dispute with the other Party, then the Party raising the dispute may send a Notice (the “Notice of Dispute”) of the dispute to the other Party. The
Notice of Dispute must thoroughly describe the basis for the dispute. 

  

	 	15.1.1	Senior Executives. With respect to a Notice of Dispute, the Parties, through appropriately senior executives who are authorized to resolve the dispute on behalf of their respective company, shall first meet and
attempt to resolve the dispute in face-to-face or telephonic negotiations. This first attempt at resolution shall occur within [ * ] days upon receipt of Notice 

 
  Aduro Biotech, IDT Biologika Process Development and Manufacturing Services Agreement,
page
 30
 of 36 
 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	
of Dispute by a Party of such dispute. If no resolution is reached through the Senior Executives within [ * ] days of the first attempt to resolve the dispute, each Party is entitled to
have the dispute be resolved by binding arbitration before an arbitrator appointed in accordance with the Rules of Arbitration of the International Chamber of Commerce (the “ICC”) with no less than [ * ] years of experience in the
biotechnology industry, including experience in manufacturing or other contract disputes with respect thereto. The Parties agree that the Arbitration shall take place only before the ICC (and no other tribunal) and shall be under the rules of
procedure of the ICC in conjunction with the Convention on the Recognition and Enforcement of Foreign Arbitral Awards (the “New York Convention”). 

  

	 	15.1.2	Venue. The venue for any arbitration under this Article shall be New York, and the language of the proceedings (including all documentation) shall be in English. 

 

	 	15.1.3	Damages. Damages shall be governed by the limitation of liability clause in Section 10.3, as well as any other relevant clauses in this Agreement. 

 

	 	15.1.4	Final Judgment. The Parties irrevocably agree that a final judgment in any arbitration proceeding relating to this Agreement shall be binding (except for manifest error) and shall be enforceable in any court
having jurisdiction thereof, provided, however, that the arbitrators shall not have authority to alter any explicit provision of this Agreement. 

ARTICLE 16: MISCELLANEOUS 
  

	16.1	Notices. Notices by either Party to the other Party shall be sent to the address below: 

If to IDT: 
 IDT
Biologika GmbH 
 Attn: CEO 

Am Pharmapark 
 D-06861
Dessau-Rosslau 
 Germany 

Fax: [ * ] 
 If to
ADURO BIOTECH: 
 Aduro BioTech, Inc. 

Attn.: Director, Technical Operations and Biodefense 

626 Bancroft Way, 3C 
  

 Aduro Biotech, IDT Biologika Process Development and Manufacturing Services Agreement, page
 31
 of 36 
 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
Berkeley, CA 94710-2224 
 USA Fax: [ * ] 

or to such other address as the addressee shall have last furnished in writing to the addressor. 

 

	16.2	Severability. In the event that any provision of this Agreement is judicially determined to be void or unenforceable, such provision shall be construed to be separable from the other provisions of this
Agreement and the other provisions of this Agreement shall remain in full force and effect. Notwithstanding the foregoing, if a provision is judicially determined to be void or unenforceable and that provision is essential to the purpose of the
Agreement such that separating that provision from the Agreement would frustrate the original purpose of the Agreement, then there shall be no separation and the entirety of the Agreement shall be deemed void and unenforceable. 

 

	16.3	Special Transactions. 

  

	 	16.3.1	For purposes of this Section 16.3, (a) the assignment by either Party of its rights and obligations under this Agreement to an Affiliate or as part of a merger, consolidation, or a sale of all or substantially all
of such Party’s assets, to a Third Party, (b) the sale by ADURO BIOTECH to a Third Party of all of its business and/or all of its assets to which this Agreement relates, (c) the sale by ADURO BIOTECH to a Third Party of all of its
business and/or assets related to the Product, and (d) the acquisition of Control, directly or indirectly, of either Party by a Third Party or by an Affiliate of said Party, are all referred to herein as “Special Transactions”.

  

	 	16.3.2	Notwithstanding the foregoing provisions, the events described in Sections 16.3.1 (b), (c) and (d) above shall only constitute Special Transactions if the pro forma financial condition of the Third Party or
Affiliate referenced therein immediately following consummation of the Special Transaction as reasonably determined by IDT’s independent accountants in accordance with internationally generally accepted accounting principles, is comparable to
or better than the financial condition of ADURO BIOTECH immediately prior to the consummation of such Special Transaction. ADURO BIOTECH shall cooperate with said accountants in making said determination of financial condition by providing to IDT,
without undue delay, such financial statements and documents as are reasonably requested by IDT and reasonably sufficient for said purpose. 

  

	 	16.3.3	Neither Party shall have a right, directly or indirectly, to assign or to transfer or to otherwise make this Agreement part of any transaction, without the Consent of the other Party, which Consent shall not be
unreasonably withheld or delayed, provided, however, that each Party 

  
 
Aduro Biotech, IDT Biologika Process Development and Manufacturing Services Agreement, page
 32
 of 36 
 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	
may engage in any Special Transaction without the other Party’s Consent, subject to the provisions of Sections 16.3.2, 16.3.4 and 16.3.5. Any permitted assignment of this Agreement by either
Party will be conditioned upon such Party’s permitted assignee agreeing in writing to comply with all the terms and conditions contained in this Agreement. In the event that such permitted assignee does not agree in writing to so comply, the
assignment shall not be permitted. 

  

	 	16.3.4	As part of any such Special Transaction, the Party engaged in such Special Transaction shall cause this Agreement in its entirety, without alteration, modification or amendment of any kind whatsoever (other than minor
changes that are necessary to account for the assignment in connection with the Special Transaction), to be assigned or transferred or otherwise made part of the Special Transaction. Not less than [ * ] Business Days prior to the occurrence
of any such Special Transaction, said Party engaged therein shall send to the other Party a Notice, signed by an officer of said Party, that: (a) informs the other Party of the date of the Special Transaction; (b) identifies the Third
Party or the Affiliate involved in said Special Transaction, as applicable; and (c) certifies that this Agreement in its entirety, without alteration, modification or amendment of any kind whatsoever (other than minor changes that are necessary
to account for the assignment of the Special Transaction), will be assigned or transferred pursuant to such Special Transaction and remains in full force and effect in accordance with its terms and that this Agreement has not be amended in any
material manner. Notice confirming assignment will be sent without undue delay after the Special Transaction is closed. 

  

	 	16.3.5	The assigning or selling Party shall be liable for all damages incurred by the other Party for the assigning Party’s failure to comply with the provisions of Section 16.3.3 and Section 16.3.4 above.

  

	16.4	Headings. All headings, titles, and captions in this Agreement are for convenience purposes only and shall not be of any force or substance. 

 

	16.5	Waiver. Failure by either Party to enforce any rights under this Agreement shall not be construed as a waiver of such rights nor shall a waiver by either Party in one or more instances be construed as
constituting a continuing waiver or as a waiver in other instances. No waiver by any Party of any term, provision or condition contained in this Agreement (including any exhibit hereto), whether by conduct or otherwise, in any one or more instances,
shall be deemed to be or construed as a further or continuing waiver of any such term, provision or condition or of any other term, provision or condition of this Agreement (including any exhibit hereto). 

 
  Aduro Biotech, IDT Biologika Process Development and Manufacturing Services Agreement,
page
 33
 of 36 
 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	16.6	Public Disclosure. No Party shall disclose to any Third Party or originate any publicity, news release or public announcement, written or oral, whether to the public or the press, or otherwise, referring
to the terms of this Agreement, the performance under it or any of its specific terms and conditions, except by such announcements as are: (i) mutually agreed upon by the Parties in writing; or (ii) required by law or regulation. If a
Party believes a public announcement to be required by law or regulation with respect to this Agreement, it will give the other Party such Notice as is reasonably practicable and an opportunity to comment upon the announcement. 

 

	16.7	Independent Contractor. Each Party is acting under this Agreement as an independent contractor and not as the partner, joint venturer, agent, or employee of the other Party. Each Party understands and
agrees that it has no authority to assume any obligation on behalf of the other Parties and that it shall not hold out to Third Parties that it has any authority to act on any other Party’s behalf except as expressly permitted herein.

  

	16.8	Performance by Affiliates. Each Party may have one or more Affiliates perform or otherwise act on its behalf under this Agreement (including Exhibits). Each Party shall be responsible for the compliance by
its Affiliates performing or otherwise acting under this Agreement on its behalf with the terms and conditions of this Agreement. 

  

	16.9	Entire Agreement. This Agreement (including, the Exhibits hereto) constitutes the entire Agreement between the Parties concerning the subject matter of said Agreement, and supersedes all written or oral
Agreements or understandings with respect thereto. 

  

	16.10	Force Majeure. 

  

	 	16.10.1	Force Majeure. Any delay in the performance of any of the duties or obligations of either Party (except the payment of money hereunder) shall not be considered a breach of this Agreement; provided that
such delay has been caused by or is the result of circumstances beyond the reasonable control of the relevant Party which may include acts of God, acts of the public enemy, war, civil commotion, terrorism, epidemic disease, quarantine restrictions,
freight embargoes, unusually severe weather, insurrections, riots, embargoes, general labor disputes or strikes, fires, explosions, shortages of energy, accident, fire, flood, storm, earthquake, government action or inaction in its sovereign
capacity (including acts of any country to which Product is supplied by ADURO BIOTECH or Germany, and/or an act by any political subdivision thereof), or other unforeseen causes, in each case provided that such delay is beyond the reasonable control
and without the fault or negligence of the Party so affected (each a “Force Majeure Event”). Notwithstanding the foregoing, in the event of a complete or partial regulatory shutdown of 

 
  Aduro Biotech, IDT Biologika Process Development and Manufacturing Services Agreement,
page
 34
 of 36 
 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	
a facility or service or other act by a Regulatory Authority that (a) specifically impacts a Party’s operations (i.e., without shutting down facilities owned by Third Parties) and
(b) is due to a Party’s negligence, willful misconduct or non-compliance with Applicable Laws, such shutdown shall not constitute a “Force Majeure Event”. 

 

	 	16.10.2	Notice. If either Party is affected by a Force Majeure Event, the affected Party shall Notify the other Party within three (3) days of the Force Majeure Event which caused, threatens to cause or will
cause a delay in performance under this Agreement. The affected Party shall take reasonable actions to avoid, mitigate or remove the cause of the affected Party’s non-performance. 

 

	 	16.10.3	No Breach. Neither Party shall be in breach of this Agreement, nor otherwise be liable to the other Party by reason of any delay in performance, or non-performance, of any of its obligations hereunder to
the extent that such delay or non-performance is due to any Force Majeure Event of which it has notified the other Party and the time for performance of that obligation shall be extended accordingly. 

 

	 	16.10.4	Cooperation. The Parties shall cooperate in good faith to reschedule any Manufacture of Product that has been delayed or postponed by reason of a Force Majeure Event. 

 

	 	16.10.5	Termination. In the event that a Force Majeure Event continues for more than [ * ] months, the Parties will use good faith efforts to work out a mutually agreeable solution. Should no mutually
agreeable solution be found within a further period of six (6) months, either Party may terminate this Agreement upon notice to the other Party. 

  

	16.11	Counterparts. This Agreement shall be signed in two (2) counterparts each of which shall be deemed to be an original and both of which taken together shall constitute one and the same instrument.
Facsimile or e-mail transmission of executed counterparts of this Agreement shall constitute evidence of the execution of this Agreement by the Parties. 

  

	16.12	Governing Law. This Agreement will be governed by and construed in accordance with the internal laws of the State of New York, without giving effect to its conflicts of law provisions; provided, however,
that the arbitration undertaking provided for in Section 15.1.1 of this Agreement shall be governed by and construed and interpreted in accordance with the New York Convention and the implementing U.S. legislation, 9 U.S.C. sections 101 et seq.
The 1980 U.N. Convention on the International Sale of Goods shall not apply to this Agreement. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER, IT
BEING 

  
  Aduro Biotech, IDT Biologika Process Development and
Manufacturing Services Agreement, page
 35
 of 36 
 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	
AGREED THAT ALL DISPUTES WILL BE RESOLVED PURSUANT TO THE DISPUTE RESOLUTION PROCEDURES SET FORTH IN ARTICLE 15 OF THIS AGREEMENT. 

 

	16.13	Exhibits. All exhibits referred to herein form an integral part of this Agreement and are incorporated into this Agreement by such reference. 

 

	16.14	No Presumption Against Drafter. For purposes of this Agreement, the Parties hereby waive any rule of construction that requires that ambiguities in this Agreement (including any exhibit hereto) be
construed against the drafter. 

 PART III: EXHIBITS 

EXHIBIT A WORK PLAN AND SERVICE FEES 
 EXHIBIT B
QUALITY AGREEMENT 
 EXHIBIT C EQUIPMENT 
  

 Aduro Biotech, IDT Biologika Process Development and Manufacturing Services Agreement, page
 36
 of 36 
 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.EX-10.31

 Exhibit 10.31 

BANCROFT WAY, LLC 
 Fourth
Addendum to Office Lease 
 THIS FOURTH ADDENDUM TO OFFICE LEASE (the “Fourth Addendum”) is made and entered into as of February 20, 2015, by and
between BANCROFT WAY, LLC, a California limited liability company (“Landlord”) and ADURO BIOTECH, INC., a Delaware corporation, the successor in interest to Oncologic, Inc. (“Tenant”). 

Recitals 
 A. Landlord and Tenant
or its predecessor have heretofore entered into that certain lease dated June 1, 2005 (the “Lease”) for premises described as Suite C (the “Premises”), initially containing approximately 8,073 rentable square feet, in the
building located at 626 Bancroft Way, Berkeley, California (the “Building”), which forms part of the mixed-use building development commonly known as the 600-630 Bancroft Way Development (the “Development”) with a street address
of 600-630 Bancroft Way, Berkeley, California. The square footage of the Development is 48,358. 
 B. The Lease has heretofore been amended
or assigned by the following instruments: (i) letter agreement dated September 1, 2008 (the “First Letter Agreement”), under which the Term of the Lease was extended through August 31, 2010; (ii) letter agreement dated
February 11, 2010 (the “Second Letter Agreement, under which the Term of the Lease was extended through August 31, 2012; (iii) that certain First Addendum to Office Lease dated as of May 12, 2011 (the “First
Addendum”), under which the Term of the Lease was extended through August 31, 2014, and the Premises were expanded by the addition thereto of approximately 5,800 rentable square feet of space known as Suite D in the Building;
(iv) that certain Second Addendum to Office lease dated as of May 1, 2013 (the “Second Addendum”), under which the rentable square footage of Suite C increased from its former level of 8,073 rentable square feet of space to
8,421 square feet of rentable space and the Term of the Lease was extended for an additional period of two (2) years; and (v) that certain Third Addendum to Office Lease dated as of April 28, 2014 (the “Third Addendum”),
under which the parties agreed to expend the Premises by the addition thereto of Suite B in the Building containing approximately 3,990 rentable square feet of space and certain other related changes. 

C. The parties mutually desire to amend the terms of the Lease to expand the Premises, to extend the Term, and to make certain other related
changes, all on and subject to the terms and conditions hereof. 
 Agreement 

Now, therefore, in consideration of the mutual terms and conditions herein contained and of other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties agree as follows: 
 1 EFFECT OF
ADDENDUM. Landlord and Tenant agree that, notwithstanding anything contained in the Lease to the contrary, the provisions set forth below will be deemed to be part of the Lease and shall supersede, to the extent they differ, any
contrary provisions in the Lease. Terms defined in the Lease shall have the same meanings in this Fourth Addendum, unless a different definition is set forth in this Fourth Addendum. The term Lease as used herein shall be deemed to
include the First Letter Agreement, the Second Letter Agreement, the First Addendum, the Second Addendum, and the Third Addendum, each of which may also be referred to separately herein. A true, complete, and correct copy of the Lease as heretofore
amended is attached hereto as Exhibit A and incorporated herein by reference. 
 2 EFFECTIVE
DATE. The amendments and changes specified in this Fourth Addendum shall become effective on March 9, 2015 (the “Effective Date”). Notwithstanding the foregoing, this Fourth Addendum shall constitute the
fully-binding agreement and contract of the parties from and after the date of the parties’ execution and delivery of this Fourth Addendum to each other. 

 3 LEASE TERM. The Term of the Lease
specified in § 1.2 of the Lease as heretofore amended under the Second Addendum shall extended for an additional period of twenty-eight (28) months commencing on September 1, 2016, and the Expiration Date is thus amended to December
31, 2018. 
 3.1 Option to Renew. Tenant is hereby granted one (1) option to extend (the “Extension Option”)
the Term of the Lease for one (1) additional period of two (2) years (the “Extension Period”). For the avoidance of doubt, this Extension Option supersedes and cancels all previous options grants under the Lease as heretofore amended,
including the options stated in the First Addendum and the Third Addendum, and Landlord’s nullification right stated in ¶ 4.1(b) of the First Addendum is hereby deleted and of no further force or effect. The Extension Period term
shall begin the first day following the Expiration Date and shall take effect on the same terms and conditions in effect under the Lease on December 31, 2018, except that (i) Tenant shall have no further option to extend the Term of the
Lease and (ii) monthly Base Rent shall be the rate which is Fair Market Value (as defined below). The “Fair Market Value” shall be the effective rent (face rate less free rent) being charged for comparable space in comparable
buildings in the vicinity of the Building leased on comparable terms and shall be limited the rates charges in such comparable transactions for tenants renewing or extending their leases. 

(a) Exercise of Option. The Extension Option may be exercised only by (i) delivering in person to
Landlord’s Building Manager in the Building Office written notice of Tenant’s irrevocable election to exercise no earlier than ten (10) months and no later than six (6) months prior to the commencement of the Extension Period, and
(ii) collecting and retaining in exchange for such notice of exercise an original written receipt therefor signed and dated by Landlord’s Building Manager. Tenant’s exercise of its Extension Option shall not be effective or valid if
there is any deviation in the timing or manner of exercise prescribed herein. 
 (b) Failure to Exercise. If Tenant shall fail
validly and timely to exercise the Option herein granted, said Option shall terminate and shall be null and void and of no further force and effect. 

(c) Fair Market Value. Provided that Tenant has validly exercised its Option when and as required hereunder, not less than one
hundred and eighty (180) days prior to the commencement of the Extension Period, Landlord shall provide written notice to Tenant of its determination of the Fair Market Value. Within ten (10) days after receiving such determination
(“Tenant’s Review Period”), Tenant shall irrevocably elect, in writing, to do one of the following: (i) accept Landlord’s determination; or (ii) object to Landlord’s determination and with such objection set forth in writing
Tenant’s determination of the Fair Market Value. If Tenant so objects, Landlord and Tenant shall attempt in good faith to agree upon such Fair Market Value using their best good-faith efforts. If Landlord and Tenant fail to reach agreement
within fifteen (15) days following Tenant’s Review Period (the “Outside Agreement Date”), then each party’s determination shall be submitted to arbitration in accordance with the then-current rules and procedures of the American
Arbitration Association, but subject to the instructions set forth in this ¶ 3.1 et seq.. If Tenant objects to Landlord’s determination of Fair Market Value, Tenant shall pay Rent at the Fair Market Value determined by Landlord
until the matter is resolved by binding arbitration as provided below subject to retroactive adjustment after the matter is so resolved. If Tenant fails so to accept or object to Landlord’s determination of Fair Market Value in writing within
Tenant’s Review Period, Tenant shall conclusively be deemed to have approved of the Fair Market Value as determined by Landlord. The determination of the arbitrators shall be limited solely to the issue of whether Landlord’s or
Tenant’s submitted Fair Market Value for the Premises is the more accurate as determined by the arbitrators, taking into account the requirements of this ¶ 3.1 et seq. 

  

					
			Fourth Addendum to Office Lease		
	Bancroft Way, LLC :: Aduro Biotech, Inc. fka NanoTx Corp.
	aduro 4a5-022615.doc (2/26/2015)		page 2 of 9		[Suites A, B, C & D, (24,339 rsf)]

 (d) Appointment of Arbitrators. Not later than fifteen (15) days following the
Outside Agreement Date, Landlord and Tenant shall each appoint one arbitrator who shall by profession be a real estate broker who shall have been active over the ten-year period ending on the date of such appointment in the leasing of commercial
properties within Alameda County. The determination of the arbitrators shall be limited solely to the issue of whether Landlord’s or Tenant’s submitted Fair Market Value for the Premises is the more accurate as determined by the
arbitrators, taking into account the requirements of this ¶ 3.1 et seq. 
 (e) Appointment of Third
Arbitrator. The two (2) arbitrators so appointed shall within fifteen (15) days of the date of the appointment of the last-appointed arbitrator agree upon and appoint a third arbitrator, who shall be qualified under the same criteria as set
forth hereinabove for qualification of the initial two arbitrators. 
 (f) Arbitrators’ Decision. The three
(3) arbitrators shall, within thirty (30) days of the appointment of the third arbitrator, reach a decision as to whether the parties shall use Landlord’s or Tenant’s submitted Fair Market Value, and shall notify Landlord and Tenant
thereof. The decision of the majority of the three (3) arbitrators shall be binding upon Landlord and Tenant. The arbitrators shall not be permitted to set Fair Market Value to any level other than either Landlord’s or Tenant’s submitted
Fair Market Value. 
 (g) Failure to Appoint. If either Landlord or Tenant fails to appoint an arbitrator within fifteen (15)
days after the Outside Agreement Date, the arbitrator timely appointed by one of the parties shall reach a decision, notify Landlord and Tenant thereof, and such arbitrator’s decision shall be binding upon Landlord and Tenant. If the two (2)
arbitrators fail to agree upon and appoint a third arbitrator, both arbitrators shall be dismissed and the matter to be decided shall be forthwith submitted to arbitration under the Commercial Arbitration Rules of the American Arbitration
Association then in effect, but subject to the instructions set forth in this ¶ 3.1 et seq.. 
 (h) Cost of
Arbitration. The cost of arbitration shall be paid by Landlord and Tenant equally. 
 (i) Default. Tenant’s exercise
of the Option shall, at Landlord’s election, be null and void if Tenant is in Default on the date of Tenant’s notice of exercise or at any time thereafter and prior to commencement of the Extension Period. Tenant’s exercise of the
Extension Option shall not operate to cure any Default by Tenant nor to extinguish or impair any rights or remedies of Landlord arising by virtue of such Default. If the Lease or Tenant’s right to possession of the Premises shall terminate
before Tenant shall have exercised the Extension Option, then immediately upon such termination the Extension Option shall simultaneously terminate and become null and void. 

(j) Time. Time is of the essence of the Extension Option granted hereunder. 

4 EXPANSION OF PREMISES. On the Effective Date the Premises shall be expanded by the addition
thereto of Suite A in the Building containing approximately 6,476 rentable square feet of space (the “Expansion Space” or “Suite A”) for all purposes under the Lease, as reflected in the Table below and as depicted on
the space plan attached hereto as Exhibit B and incorporated herein by reference (the “Space Plan”). All references in the Lease to the “Premises” shall refer to Premises as so augmented by the addition thereto
of Suite A from and after March 9, 2015 (the “Expansion Space Commencement Date”). From and after the Expansion Space Commencement Date, Suite A shall become an integral part of the Premises pursuant to the basic
terms specified in the Table below regarding Term, Base Rent, Tenant’s Share of increases in Operating Expenses and Taxes, and the Base Year for the purposes of calculating Additional Rentable payable with respect to Suite A. 

  

					
			Fourth Addendum to Office Lease		
	Bancroft Way, LLC :: Aduro Biotech, Inc. fka NanoTx Corp.
	aduro 4a5-022615.doc (2/26/2015)		page 3 of 9		[Suites A, B, C & D, (24,339 rsf)]

 4.1 Right of First Offer. Tenant shall have a continuing right of first opportunity
(the “RFO”) to lease any space in the Development that becomes available from time to time during the Term of the Lease as extended hereunder (the “RFO Space”), prior to the RFO Space’s being offered to a third party, on the
terms then in effect under the Lease as modified herein, subject to the terms and conditions set forth in this ¶ 4.1 et seq. 

4.1.1 Landlord’s Notice. Within thirty (30) days after any RFO Space becomes legally available to lease or, at
Landlord’s option, such earlier time as Landlord shall be in a position to project when the RFO Space will be legally available to lease, Landlord shall notify Tenant in writing advising Tenant of such projected date. 

4.1.2 Tenant’s Exercise. Promptly after receipt of Landlord’s notice of availability, Landlord and Tenant shall meet to
discuss and attempt in good faith to agree on the term and base rent that would be applicable to the RFO Space; provided, however, in no event shall the base rent for the RFO Space exceed the rate which is Fair Market Value. Tenant shall then have
fourteen (14) days after receipt of Landlord’s notice of availability issued pursuant to ¶ 4.1.1 above in which to notify Landlord in writing that Tenant irrevocably exercises Tenant’s right to lease the RFO Space on the terms
described herein. If the parties fail to come to agreement as to the base rent and term that would be applicable to Tenant’s lease of the RFO Space, Tenant’s RFO shall lapse, and Landlord thereafter may rent the RFO Space to a third party
on such terms and conditions as Landlord is able to negotiate with such third party, and Tenant shall have no further right with respect to such particular RFO Space. The process of notice of availability, negotiation of terms, and notice of
exercise shall be repeated each time a new RFO Space becomes available to lease, and Tenant’s failure to exercise its RFO as to any particular RFO Space shall not prejudice its right to receive notice and negotiate as to the lease of any
subsequent RFO Space that may become available during the Term of the Lease. 
 4.1.3 Failure to Exercise. If Tenant shall fail
to exercise such RFO after notice by Landlord of the availability of any particular RFO Space, as provided herein, such right shall be deemed to have lapsed and expired, and shall be of no further force or effect. Landlord may thereafter freely
lease all or a portion of such particular RFO Space to any other party, at any time, on any terms, in Landlord’s sole discretion. 

4.1.4 Commencement and Term. If Tenant exercises its RFO as to any particular RFO Space that may become available from
time to time, the term of the Lease for such particular RFO Space shall commence on the date agreed by the parties with respect to such RFO Space (the “RFO Commencement Date”) and shall continue thereafter for the term agreed by the
parties, which Tenant acknowledges and agrees may extend beyond the Expiration Date of the Term of the Lease as extended hereunder. 

4.1.5 RFO Space Rent. In addition to the Rent reserved in the Lease, Tenant shall pay Base Rent for any particular RFO Space at
the such rate per rentable square foot per month as Landlord and Tenant may agree in their negotiation following Tenant’s receipt of Landlord’s notice of availability of each particular RFO Space as they become available from time to time,
subject to adjustment on each Adjustment Date, as provided in the Lease. In addition, Tenant shall pay Tenant’s Prorata Share of Taxes and Operating Expenses for the RFO Space, and Tenant’s Prorata Share shall be increased accordingly to
reflect the addition of the RFO Space to the Premises. 
 4.1.6 Tenant’s Improvements. Unless agreed otherwise in the
parties’ negotiation following Tenant’s receipt of Landlord’s notice of availability of each particular RFO Space as they become available from time to time, Landlord shall have no obligation to improve the RFO Space for Tenant, to
provide any tenant improvement allowance, or otherwise to construct or finance any improvements which Tenant may desire in the RFO Space. 

  

					
			Fourth Addendum to Office Lease		
	Bancroft Way, LLC :: Aduro Biotech, Inc. fka NanoTx Corp.
	aduro 4a5-022615.doc (2/26/2015)		page 4 of 9		[Suites A, B, C & D, (24,339 rsf)]

 4.1.7 Confirmatory Documentation. After Tenant validly exercises the right of first
opportunity provided herein, the parties shall execute an amendment to the Lease, adding the RFO Space, or such other documentation as Landlord or Tenant shall reasonably require, promptly after Landlord shall prepare the same, in order to confirm
the leasing of such RFO Space to Tenant; but an otherwise valid exercise of the RFO contained herein shall be fully effective, whether or not such confirmatory documentation is executed. 

4.1.8 Entire RFO Space. The foregoing right of first opportunity shall apply only with respect to the entire RFO Space offered to
Tenant from time to time and may not be exercised with respect to only a portion thereof, unless only a portion shall first become available (in which case, the foregoing right of first opportunity shall apply to such portions, as the same become
available). 
 4.1.9 Delay in Delivery. If Tenant shall exercise the right of first opportunity granted herein, Landlord does
not guarantee that the any particular RFO Space will be available on the agreed RFO Commencement Date, if the then existing occupants of the RFO Space shall hold over, or for any other reason beyond Landlord’s reasonable control. In such event,
the agreed Rent with respect to the RFO Space shall be abated until Landlord legally delivers the same to Tenant, as Tenant’s sole recourse. 

4.1.10 Tenant’s Default. The RFO herein shall, at Landlord’s election, be null and void, if Tenant is in Default on the
date Tenant exercises the RFO as to any particular RFO Space or at any time thereafter and prior to the agreed RFO Commencement Date. Tenant’s exercise of such RFO shall not operate to cure any Default nor to extinguish or impair any rights or
remedies of Landlord arising by virtue of such Default. If the Lease or Tenant’s right to possession of the Premises shall terminate before Tenant shall have exercised the RFO, then immediately upon such termination the RFO shall simultaneously
terminate and become null and void. 
 4.1.11 Time. Tenant agrees that time is of the essence of this RFO. 

4.2 Asbestos TEM Move Credit. Tenant agrees to pay to Asbestos TEM, the current occupant of Suite A, an amount equal to Two
Hundred Fifty Thousand Dollars ($250,000.00) (the “Move Credit”) as an inducement to Asbestos TEM to relocate its Premises from Suite A to approximately 5,500 rentable square feet of space known as Suites A & D of
Building 1 in the Development. Tenant acknowledges that the payment of the Move Credit to Asbestos TEM is for the express benefit of Landlord as an intended third-party beneficiary, and Tenant’s failure to pay the Move Credit to Asbestos
TEM as and when required hereunder shall constitute a material Event of Default under the Lease. Tenant shall pay the Move Credit to Asbestos TEM on or before the Expansion Space Commencement Date, and Tenant shall provide further commercially
reasonable assistance with the relocation of Asbestos TEM as provided in ¶ 4.2.1 below. Tenant agrees that Asbestos TEM shall have the right to allocate and spend the Move Credit in any manner decided by Asbestos TEM in its sole and
absolute discretion, subject to Tenant’s right to review Asbestos TEM’s accounting of its relocation costs as set forth in ¶ 6.1 below. 

4.2.1 Asbestos TEM Move Assistance. In addition to payment of the Move Credit as described in ¶ 4.1.1 above, Tenant
agrees, for the benefit of Landlord as an intended third-party beneficiary, to utilize commercially reasonable efforts to assist Asbestos TEM with the management of its relocation to Building 1 to the extent such assistance is requested by
Asbestos TEM. In addition, on or before the date which is ten (10) days after the Effective Date Tenant agrees to make available to Asbestos TEM two (2) existing six-foot fume hoods with acid base cabinets from Suite A and to permit Asbestos
TEM at its sole cost and expense to relocate the same into Asbestos TEM’s relocation premises in Building 1, if such fume hoods and cabinets have not already been removed and relocated by the Effective Date. 

  

					
			Fourth Addendum to Office Lease		
	Bancroft Way, LLC :: Aduro Biotech, Inc. fka NanoTx Corp.
	aduro 4a5-022615.doc (2/26/2015)		page 5 of 9		[Suites A, B, C & D, (24,339 rsf)]

 5 BASE YEAR. As specified in the Table below, the Base Year for the
purposes calculating Tenant’s Additional Rent under § 2.3 of the Lease as heretofore amended shall be calendar year 2013 from and after the Expansion Space Commencement Date. 

6 MONTHLY BASE RENT. The Base Rent for the Premises specified in § 2(a) of the Lease as
heretofore amended shall be the amounts specified as Monthly Base Rent in the Table below for the various periods and spaces set forth in the Table from and after the Effective Date. For the avoidance of doubt and in order to clarify the
parties’ agreement hereunder, the Monthly Base Rent numbers shown in the Table reflect the Base Rent in effect on the original Commencement Date of the Lease as increased by the Base Rent Adjustment as provided in § 2.2 of the Lease.
The parties agree that application of the Base Rent Adjustment has resulted in a Base Rent rate of $1.79 per rentable square foot of space as to Suites B, C, and D, which rate has been in effect since September 1, 2014. The Base Rent
specified in the Table below for the entire Premises shall be subject to further adjustment on the next Adjustment Date and each subsequent Adjustment Date through the Expiration Date. 

6.1 Suite A Prepaid Base Rent. Tenant agrees to pre-pay to Landlord Base Rent with respect to Suite A in
the amount of Seventy-Five Thousand Dollars ($75,000.00) (the “Prepaid Base Rent”) upon Tenant’s execution and delivery of this Fourth Addendum to Landlord as an inducement to Landlord to complete the related leasing
transaction necessary in the Development to accommodate Tenant’s expansion into Suite A. The schedule for applying the credit for the Prepaid Base Rent to Tenant’s account is set forth in ¶ 6.2 below. The parties acknowledge
and agree that Landlord will use the Prepaid Base Rent to assist Asbestos TEM with the costs of its relocation as described in ¶ 4.2 above. Asbestos TEM has agreed that Landlord may share with Tenant its accounting of the costs of its
relocation and its use of the Move Credit and the Prepaid Base Rent, and Landlord agrees to make Asbestos TEM’s accounting of its relocation costs available for Tenant’s review at no cost to Tenant. 

6.2 Timing of Base Rent Credits. Commencing on March 9, 2015, and on the first day of each calendar month thereafter,
Landlord shall credit to Tenant’s account an amount equal to Twenty Thousand Dollars ($20,000.00) per month as recognition of credit owing to Tenant by Landlord against the aggregate amount of (a) the Rent Credit (as defined in
¶ 8.1.2 below) plus (b) the Prepaid Base Rent (as defined in ¶ 6.1 above until the maximum aggregate amount of such credits (One Hundred Twenty-Nine Thousand Dollars ($129,000.00)) has been used up and credited to
Tenant’s account for Base Rent owing under the Lease. 
 7 SUMMARY TABLE. The Table set forth in
§ 1 of the Lease as heretofore amended is hereby superseded and replaced in its entirety by the following table, which shall constitute the Table under § 1 of the Lease for all purposes from and after the Effective Date of this
Fourth Addendum: 
  

																			
	 Period
	  	Suite
No.	  	Square
Footage	 	  	Monthly
Base Rent	 	  	Pro Rata
Share	 	 	Base
Year	 
	 March 9, 2015 thru August 31, 2015
	  	C	  	 	8,421	  	  	$	15,073.59	  	  	 	51.050	% 	 	 	2013	  
	  	D	  	 	5,800	  	  	$	10,382.00	  	  	 
	  	B	  	 	3,990	  	  	$	7,142.10	  	  	 
	  	A	  	 	6,476	  	  	$	14,247.20	  	  	 
						
	 September 1, 2015 thru December 31, 2018
	  	C	  	 	8,421	  	  	$	15,073.59	  	  	 	51.050	% 	 	 	2013	  
	  	D	  	 	5,800	  	  	$	10,382.00	  	  	 
	  	B	  	 	3,990	  	  	$	7,142.10	  	  	 
	  	A	  	 	6,476	  	  	$	14,247.20	  	  	 

  

					
		 	Fourth Addendum to Office Lease	 	
	Bancroft Way, LLC :: Aduro Biotech, Inc. fka NanoTx Corp.
	aduro 4a5-022615.doc (2/26/2015)	 	page 6 of 9	 	[Suites A, B, C & D, (24,339 rsf)]

 8 CONDITION OF PREMISES. Tenant shall accept the Expansion
Space, any existing Improvements in the Expansion Space, and the Systems and Equipment serving the same in an “as is” condition on the Expansion Space Commencement Date, and Landlord shall have no obligation to improve, alter,
remodel, or otherwise modify the Expansion Space in connection with Tenant’s occupancy of the Premises as expanded by the Expansion Space from and after the Expansion Space Commencement Date. 

8.1 Tenant’s Work. The facilities, materials, and work to be furnished, installed, and performed in Suite A by Tenant
are referred to as the “Tenant’s Work,” which shall include any and all installations, materials, and work which may be undertaken by or for the account of Tenant to prepare, equip, decorate, and furnish the Expansion Space for
Tenant’s occupancy and shall include the connection and/or rewiring of Tenant’s telephone and data lines. Tenant shall not permit any liens to accrue or be filed against the Building or Development in connection the Tenant’s
performance of Tenant’s Work; provided, however, Tenant shall have the right to furnish a surety bond in the amount of a contested lien and to contest the validity of any such lien filed without the same being an Event of Default. Tenant’s
Work shall be completed in compliance with all applicable Laws and codes and in accordance with the highest standards of best construction practices. The parties agree that Tenant’s Work, to be completed by Tenant under Landlord’s
supervision, as provided in the Lease, at Tenant’s sole cost and expense as soon as reasonably feasible after the Effective Date, shall be planned, approved, and completed in accordance with ¶¶ 8.1.1 through 8.1.4 below. 

8.1.1 Plans & Approval. Tenant shall submit plans for any and all Tenant’s Work to Landlord for approval, which shall
not be unreasonably withheld, conditioned, or delayed. Tenant shall comply with all applicable Laws in connection with the performance of Tenant’s Work. 

8.1.2 Cost of Tenant’s Work and Rent Credit. Notwithstanding anything to the contrary herein, Tenant shall bear the entire
cost of Tenant’s Work described in ¶ 8.1 above at Tenant’s sole cost and expense; provided, that Landlord shall extend to Tenant a credit against the Base Rent first due under the Lease with respect to Suite A in an amount
equal to a maximum of Sixty-Four Thousand Dollars ($64,000.00) (the “Rent Credit”), subject to the terms and conditions stated in this ¶ 8.1.2. The Rent Credit shall be credited to Tenant only to the extent that Tenant
expends an equal amount of money for the installation of tenant improvements in Suite A (“Tenant’s TI Spend”), and the amount of the Rent Credit shall be limited to a dollar-for-dollar match of the amount of Tenant’s TI
Spend. The aggregate amount of Tenant’s TI Spend plus the Rent Credit shall be used only for the cost of construction of tenant improvements and fixtures (including the installation of Tenant’s furniture, trade fixtures, and equipment in
Suite A, but not the cost of purchasing any such items) and may not be used or expended for any other purpose. The schedule of application of the Rent Credit to Tenant’s account is set forth in ¶ 6.2 above. 

8.1.3 Contractor & Vendor Selection. Tenant shall have the right to select its own contractors and vendors for the
performance of Tenant’s Work, subject to Landlord’s reasonable approval, which shall not be unreasonably withheld, conditioned, or delayed. Tenant shall give Landlord sufficient written notice before the commencement of any work so that
Landlord can post notices of non-responsibility with respect to Tenant’s Work. 
 8.1.4 Restoration. Tenant shall have the
right to configure its existing office and laboratory space to its own specifications, subject to Landlord’s reasonable approval, which shall not be unreasonably withheld, conditioned, or delayed; provided, that Tenant shall be required to
restore the Premises to their original condition on or before the Expiration Date as the same may be extended hereunder, unless Landlord’s waives the restoration requirement in writing in connection with granting its consent to any proposed
changes. 
 8.2 Notice of Defects. It shall be conclusively presumed that the Expansion Space was in satisfactory condition
(except for latent defects) as of the Expansion Space Commencement Date, unless within thirty (30) days after the Expansion Space Commencement Date Tenant shall give Landlord notice in writing specifying the respects in which the Expansion
Space was not in satisfactory condition. 

  

					
			Fourth Addendum to Office Lease		
	Bancroft Way, LLC :: Aduro Biotech, Inc. fka NanoTx Corp.
	aduro 4a5-022615.doc (2/26/2015)		page 7 of 9		[Suites A, B, C & D, (24,339 rsf)]

 9 SECURITY DEPOSIT. Tenant’s Security Deposit specified in
§ 3 of the Lease as heretofore amended shall be increased in consequence of the parties’ execution and delivery of this Fourth Addendum to each other from its current level to Nintey-Five Thousand Sixty-One Dollars and Forty-Two
Cents ($95,061.42). Tenant shall pay the increase in the Security Deposit to Landlord upon Tenant’s execution and delivery of this Fourth Addendum to Landlord. Tenant shall have the right to deliver up to a maximum of
fifty percent (50%) of the Security Deposit to Landlord in the form of an irrevocable on-demand sight-draft letter of credit in a form reasonably satisfactory to Landlord and drawn on an institution reasonably satisfactory to Landlord. 

10 ACCESS INSPECTION DISCLOSURE. Pursuant to California Civil Code
§ 1938, Landlord hereby notifies Tenant that, as of the date of this Fourth Addendum, the Premises have not undergone inspection by a “Certified Access Specialist” to determine whether the Premises meet all applicable
construction-related accessibility standards under California Civil Code § 55.53, and the Premises have not been determined to meet all applicable construction-related accessibility standards pursuant to Civil Code § 55.53. 

11 NO DISCLOSURE. Tenant agrees that it shall not disclose any of the matters set forth in this Fourth Addendum or
disseminate or distribute any information concerning the terms, details, or conditions hereof to any person, firm, or entity without obtaining the express written approval of Landlord. 

12 DEFINED TERMS. Terms used herein that are defined in the Lease shall have the meanings therein defined,
unless a different definition is set forth in this Fourth Addendum. In the event of any conflict between the provisions of the Lease, and this Fourth Addendum, the terms of this Fourth Addendum shall prevail. 

13 SURVIVAL. Warranties, representations, agreements, and obligations contained in this Fourth Addendum shall survive the
execution and delivery of this Fourth Addendum and shall survive any and all performances in accordance with this Fourth Addendum. 
 14
COUNTERPARTS. This Fourth Addendum may be executed in any number of counterparts, which each severally and all together shall constitute one and the same Fourth Addendum. 

15 ATTORNEYS’ FEES. If any party obtains a judgement against any other party or parties by reason of breach
of this Fourth Addendum, reasonable attorneys’ fees and costs as fixed by the court shall be included in such judgement against the losing party or parties. 

16 SUCCESSORS. This Fourth Addendum and the terms and provisions hereof shall inure to the benefit of and be binding upon the
heirs, successors, and assigns of the parties. 
 17 AUTHORITY. Each of the individuals executing this Fourth Addendum
represents and warrants that he or she is authorized to execute this Fourth Addendum on behalf of the party for whom he or she is executing this Fourth Addendum and that by his or her signature such party is legally bound by the terms, covenants,
and conditions of this Fourth Addendum. 
 18 GOVERNING LAW. This Fourth Addendum shall be construed and
enforced in accordance with the laws of the State of California. 
 19 CONSENT. This Fourth Addendum is subject to, and
conditioned upon, any required consent or approval being granted without any fee or charge that is unacceptable to Landlord by Landlord’s mortgagees or ground lessors. If any such consents shall be denied or granted subject to the payment of
unacceptable fees or charges hereunder, the Lease shall remain in full force and effect. If Landlord fails to notify Tenant to the contrary within sixty (60) days after this Fourth Addendum has been executed and delivered by both parties, Tenant may
assume that such consent has been granted, or that the same is not required. 
 20 CONTINUING VALIDITY
OF LEASE. Except as expressly modified herein, the Lease remains in full force and effect. 

  

					
			Fourth Addendum to Office Lease		
	Bancroft Way, LLC :: Aduro Biotech, Inc. fka NanoTx Corp.
	aduro 4a5-022615.doc (2/26/2015)		page 8 of 9		[Suites A, B, C & D, (24,339 rsf)]

 21 EXHIBITS. The following exhibits have been attached
to this Fourth Addendum by the parties prior to their execution and delivery of the same to each other, which are incorporated herein by reference: 

Exhibit A—The Lease 

Exhibit B—Space Plan 
 22
WHOLE AGREEMENT. The mutual obligations of the parties as provided herein are the sole consideration for this Fourth Addendum, and no representations, promises, or inducements have been made by the parties
other than as appear in this Fourth Addendum, which supersedes any previous negotiations. There have been no representations made by the Landlord or understandings made between the parties other than those set forth in this Fourth Addendum. This
Fourth Addendum may not be amended except in writing signed by all the parties. 
 In witness whereof, the parties have executed this Fourth
Addendum as of the date first above written. 
  

									
	Landlord:	 		 	Tenant:
			
	BANCROFT WAY, LLC, a California limited liability company	 		 	ADURO BIOTECH, INC., a Delaware corporation
					
	             By:  
	 	     /s/ S. Goldin
	 		 	             By:  
	 	     /s/ Gregory W. Schafer

					
		 	     S. Goldin
	 		 		 	     Gregory W. Schafer

		 	[name typed]	 		 		 	[name typed]
					
	            Its:  	 	    Managing Member	 		 	            Its:  	 	     COO

  

					
		 	Fourth Addendum to Office Lease	 	
	Bancroft Way, LLC :: Aduro Biotech, Inc. fka NanoTx Corp.
	aduro 4a5-022615.doc (2/26/2015)	 	page 9 of 9	 	[Suites A, B, C & D, (24,339 rsf)]

 BANCROFT WAY, LLC 

Third Addendum to Office and Lab Lease 
 THIS
THIRD ADDENDUM TO OFFICE LEASE (the “Third Addendum”) is made and entered into as of April 28, 2014, by and between BANCROFT WAY, LLC, a California limited liability company (“Landlord”) and ADURO BIOTECH,
INC., a Delaware corporation (“Tenant”). 
 Recitals 

A. Landlord and Tenant or its predecessor have heretofore entered into that certain lease dated June 1, 2005 (the “Lease”) for
premises described as Suite C (the “Premises”), initially containing approximately 8,073 rentable square feet, in the building located at 626 Bancroft Way, Berkeley, California (the “Building”), which forms part of the mixed-use
building development commonly known as the 600-630 Bancroft Way Development (the “Development”) with a street address of 600-630 Bancroft Way, Berkeley, California. The square footage of the Development is 48,358. 

B. The Lease has heretofore been amended or assigned by the following instruments: (i) letter agreement dated September 1,
2008 (the “First Letter Agreement”), under which the Term of the Lease was extended through August 31, 2010; (ii) letter agreement dated February 11, 2010 (the “Second Letter Agreement, under which the Term of the Lease
was extended through August 31, 2012; (iii) that certain First Addendum to Office Lease dated as of May 12, 2011 (the “First Addendum”), under which the Term of the Lease was extended through August 31, 2014, and the
Premises were expanded by the addition thereto of approximately 5,800 rentable square feet of space known as Suite D in the Building; and (iv) that certain Second Addendum to Office lease dated as of May 1, 2013 (the “Second
Addendum”), under which the rentable square footage of Suite C increases from its former level of 8,073 rentable square feet of space to 8,421 square feet of rentable space and the Term of the Lease was extended for an additional period
of two (2) years. 
 C. The parties mutually desire to amend the terms of the Lease to expand the Premises and make certain other
related changes, all on and subject to the terms and conditions hereof. 
 Agreement 

Now, therefore, in consideration of the mutual terms and conditions herein contained and of other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties agree as follows: 
 1 EFFECT OF
ADDENDUM. Landlord and Tenant agree that, notwithstanding anything contained in the Lease to the contrary, the provisions set forth below will be deemed to be part of the Lease and shall supersede, to the
extent they differ, any contrary provisions in the Lease. Terms defined in the Lease shall have the same meanings in this Third Addendum, unless a different definition is set forth in this Third Addendum. The term Lease as used herein shall
be deemed to include the First Extension Agreement, the Second Extension Agreement, and the First Addendum, and the Second Addendum, each of which may also be referred to separately herein. A true, complete, and correct copy of the Lease as
heretofore amended is attached hereto as Exhibit A and incorporated herein by reference. 
 2 EFFECTIVE
DATE. The amendments and changes specified in this Third Addendum shall become effective on June 1, 2014 (the “Effective Date”). Notwithstanding the foregoing, this Third Addendum shall
constitute the fully-binding agreement and contract of the parties from and after the date of the parties’ execution and delivery of this Third Addendum to each other. 

3 LEASE TERM. The Term of the Lease specified in § 1.2 of the Lease as heretofore amended
under the Second Addendum shall remain unchanged, and the Expiration Date is August 31, 2016. 

  
 Third Addendum to
Office and Laboratory Lease 
 Bancroft Way, LLC:: Aduro Biotech, Inc. 

page 1 of 6 
 [Suites B, C
& D, 18,211 rsf) 

 1.1 Option to Renew. Tenant is hereby granted one (1) option to extend (the “Extension
Option”) the Term of the Lease for one (1) additional period of two (2) years (the “Extension Period”). The Extension Period term shall begin the first day following the Expiration Date and shall take effect on the same
terms and conditions in effect under the Lease immediately prior to the first Extension Period, except that (i) Tenant shall have no further right to extend and (ii) monthly Base Rent shall be the rate which is Fair Market Value (as
defined below). The Fair Market Value shall be the effective rent (face rate less free rent) being charged for comparable space in comparable buildings in the vicinity of the Building leased on comparable terms and shall be limited the rates charges
in such comparable transactions for tenants renewing or extending their leases. 
 (a) Exercise of Option. The Extension Option
may be exercised only by (i) delivering in person to Landlord’s Building Manager in the Building Office written notice of Tenant’s irrevocable election to exercise no earlier than ten (10) months and no later than six
(6) months prior to the commencement of the Extension Period, and (ii) collecting and retaining in exchange for such notice of exercise an original written receipt therefor signed and dated by Landlord’s Building Manager.
Tenant’s exercise of its Extension Option shall not be effective or valid if there is any deviation in the timing or manner of exercise prescribed herein. 

(b) Failure to Exercise. If Tenant shall fail validly and timely to exercise the Option herein granted, said Option shall
terminate and shall be null and void and of no further force and effect. 
 (c) Fair Market Value. Provided that Tenant has
validly exercised its Option when and as required hereunder, not less than one hundred and eighty (180) days prior to the commencement of the Extension Period, Landlord shall provide written notice to Tenant of its determination of the Fair
Market Value. Within ten (10) days after receiving such determination (“Tenant’s Review Period”), Tenant shall irrevocably elect, in writing, to do one of the following. (i) accept Landlord’s determination; or
(ii) object to Landlord’s determination and with such objection set forth in writing Tenant’s determination of the Fair Market Value. If Tenant so objects, Landlord and Tenant shall attempt in good faith to agree upon such Fair Market
Value using their best good-faith efforts. If Landlord and Tenant fail to reach agreement within fifteen (15) days following Tenant’s Review Period (the “Outside Agreement Date”), then each party’s determination shall be
submitted to arbitration in accordance with the then-current rules and procedures of the American Arbitration Association, but subject to the instructions set forth in this § 1.1 et seq.. If Tenant objects to Landlord’s
determination of Fair Market Value, Tenant shall pay Rent at the Fair Market Value determined by Landlord until the matter is resolved by binding arbitration as provided below subject to retroactive adjustment after the matter is so resolved. If
Tenant fails so to accept or object to Landlord’s determination of Fair Market Value in writing within Tenant’s Review Period, Tenant shall conclusively be deemed to have approved of the Fair Market Value as determined by Landlord. The
determination of the arbitrators shall be limited solely to the issue of whether Landlord’s or Tenant’s submitted Fair Market Value for the Premises is the more accurate as determined by the arbitrators, taking into account the
requirements of this § 1.1 et seq. 
 (d) Appointment of Arbitrators. Not later than fifteen (15) days
following the Outside Agreement Date, Landlord and Tenant shall each appoint one arbitrator who shall by profession be a real estate broker who shall have been active over the ten-year period ending on the date of such appointment in the leasing of
commercial properties within Alameda County. The determination of the arbitrators shall be limited solely to the issue of whether Landlord’s or Tenant’s submitted Fair Market Value for the Premises is the more accurate as determined by the
arbitrators, taking into account the requirements of this § 1.1 et seq. 

  
 Third Addendum to
Office and Laboratory Lease 
 Bancroft Way, LLC:: Aduro Biotech, Inc. 

page 2 of 6 
 [Suites B, C
& D, 18,211 rsf) 

 (e) Appointment of Third Arbitrator. The two (2) arbitrators so appointed
shall within fifteen (15) days of the date of the appointment of the last-appointed arbitrator agree upon and appoint a third arbitrator, who shall be qualified under the same criteria as set forth hereinabove for qualification of the initial
two arbitrators. 
 (f) Arbitrators’ Decision. The three (3) arbitrators shall, within thirty (30) days of the
appointment of the third arbitrator, reach a decision as to whether the parties shall use Landlord’s or Tenant’s submitted Fair Market Value, and shall notify Landlord and Tenant thereof. The decision of the majority of the three
(3) arbitrators shall be binding upon Landlord and Tenant. The arbitrators shall not be permitted to set Fair Market Value to any level other than either Landlord’s or Tenant’s submitted Fair Market Value. 

(g) Failure to Appoint. If either Landlord or Tenant fails to appoint an arbitrator within fifteen (15) days after the
Outside Agreement Date, the arbitrator timely appointed by one of the parties shall reach a decision, notify Landlord and Tenant thereof, and such arbitrator’s decision shall be binding upon Landlord and Tenant. If the two (2) arbitrators
fail to agree upon and appoint a third arbitrator, both arbitrators shall be dismissed and the matter to be decided shall be forthwith submitted to arbitration under the Commercial Arbitration Rules of the American Arbitration Association then in
effect, but subject to the instructions set forth in this § 1.1 et seq.. 
 (h) Cost of Arbitration. The cost of
arbitration shall be paid by Landlord and Tenant equally. 
 (i) Default. Tenant’s exercise of the Option shall, at
Landlord’s election, be null and void if Tenant is in Default on the date of Tenant’s notice of exercise or at any time thereafter and prior to commencement of the Extension Period. Tenant’s exercise of the Extension Option shall not
operate to cure any Default by Tenant nor to extinguish or impair any rights or remedies of Landlord arising by virtue of such Default. If the Lease or Tenant’s right to possession of the Premises shall terminate before Tenant shall have
exercised the Extension Option, then immediately upon such termination the Extension Option shall simultaneously terminate and become null and void. 

(j) Time. Time is of the essence of the Extension Option granted hereunder. 

4 EXPANSION OF PREMISES. On the Effective Date the Premises shall be expanded by the
addition thereto of Suite B in the Building containing approximately 3,990 rentable square feet of space for all purposes under the Lease, as reflected in the Table below and as depicted on the space plan attached hereto as Exhibit B
and incorporated herein by reference (the “Space Plan”). 
 5 BASE YEAR. As specified
in the Table below, the Base Year for the purposes calculating Tenant’s Additional Rent under § 2.3 of the Lease as heretofore amended shall be calendar year 2013 from and after the Effective Date. 

6 MONTHLY BASE RENT. The Base Rent for the Premises specified in § 2(a) of the
Lease as heretofore amended shall be the amounts specified as Monthly Base Rent in the Table below for the various periods and spaces set forth in the Table from and after the Effective Date. For the avoidance of doubt and in order to clarify the
parties’ agreement hereunder, the Monthly Base Rent numbers shown in the Table reflect the Base Rent in effect on the original Commencement Date of the Lease as increased by the Base Rent Adjustment as provided in § 2.2 of the Lease. The
parties agree that application of the Base Rent Adjustment has resulted in a Base Rent rate of $1.74 per rentable square foot of space in the Premises, which rate has been in effect since September 1, 2013, subject to further adjustment on the
next Adjustment Date. 

  
 Third Addendum to
Office and Laboratory Lease 
 Bancroft Way, LLC:: Aduro Biotech, Inc. 

page 3 of 6 
 [Suites B, C
& D, 18,211 rsf) 

 7 SUMMARY TABLE. The Table set forth in § 1 of
the Lease as heretofore amended is hereby superseded and replaced in its entirety by the following table, which shall constitute the Table under § 1 of the Lease for all purposes from and after the Effective Date of this Third Addendum: 

 

																			
	 Period
	  	Suite
No.	  	Square
Footage	 	  	Monthly
Base Rent	 	  	Pro Rata
Share	 	 	Base
Year	 
	 June 1, 2014 thru August 31, 2015
	  	C	  	 	8,421	  	  	$	14,652.54	  	  	  
	 37.659
	 % 
	 	  
	 2013
	   

	  	D	  	 	5,800	  	  	$	10,092.00	  	  	 
	  	B	  	 	3,990	  	  	$	6,942.60	  	  	 
	 September 1, 2015 thru August 31, 2016
	  	C	  	 	8,421	  	  	$	14,652.54	  	  	  
	 37.659
	 % 
	 	  
	 2013
	   

	  	D	  	 	5,800	  	  	$	10,092.00	  	  	 
	  	B	  	 	3,990	  	  	$	6,942.60	  	  	 

 8 CONDITION OF PREMISES. Except as otherwise
expressly provided in this ¶ 8 with respect to Landlord’s preparation of the Premises for Tenant’s continued occupancy, Tenant shall accept the Premises, any existing Improvements in the Premises, and the Systems and Equipment serving
the same in an “as is” condition on the Effective Date, and Landlord shall have no obligation to improve, alter, remodel, or otherwise modify the Premises in connection with Tenant’s continued occupancy of the Premises from and after
the Effective Date. 
 8.1 Landlord’s Work. Landlord agrees that all Systems and Equipment serving the Premises shall be
in good working condition on the Effective Date, and Landlord further agrees to complete the following items (and the following items only) as soon as reasonably feasible after the Effective Date, in coordination with Tenant’s Work described
below, at Landlord’s sole cost and expense (collectively “Landlord’s Work”), as shown on the Space Plan: 
 (i)
moving the existing fire panel in Suite B from its current location to a new location of Landlord’s choosing out of the way of Tenant; 

8.2 Tenant’s Work. The facilities, materials, and work to be furnished, installed, and performed in Suite B by Tenant are
referred to as the “Tenant’s Work,” which shall include any and all installations, materials, and work which may be undertaken by or for the account of Tenant other than Landlord’s Work described in ¶ 8.1 above, to prepare,
equip, decorate, and furnish Suite B and/or the Premises for Tenant’s continued occupancy and shall include the connection and/or rewiring of Tenant’s telephone and data lines. Tenant shall not permit any liens to accrue or be filed
against the Building or Development in connection the Tenant’s performance of Tenant’s Work. Tenant shall obtain all necessary permits for Tenant’s Work, which shall be completed in compliance with all applicable Laws and codes and in
accordance with the highest standards of best construction practices. The parties agree that Tenant’s Work, to be completed by Tenant under Landlord’s supervision, as provided in the Lease, at Tenant’s sole cost and expense as soon as
reasonably feasible after the Effective Dave, shall be completed in accordance with ¶¶ 8.2.1 through 8.2.4 below. 
 8.2.1 Plans
& Approval. Tenant shall submit plans for any and all Tenant’s Work to Landlord for approval, which shall not be unreasonably withheld, conditioned, or delayed. Tenant shall comply with all applicable Laws in connection with the
performance of Tenant’s Work and shall be responsible for obtaining any required permits. 
 8.2.2 Cost of Tenant’s Work and
Rent Credit. Notwithstanding anything to the contrary herein, Tenant shall bear the entire cost of Tenant’s Work described in ¶ 8.2 above at Tenant’s sole cost and expense. 

  
 Third Addendum to
Office and Laboratory Lease 
 Bancroft Way, LLC:: Aduro Biotech, Inc. 

page 4 of 6 
 [Suites B, C
& D, 18,211 rsf) 

 8.2.3 Contractor & Vendor Selection. Tenant shall have the right to select
its own contractors and vendors for the performance of Tenant’s Work, subject to Landlord’s reasonable approval, which shall not be unreasonably withheld, conditioned, or delayed. Tenant shall give Landlord sufficient written notice before
the commencement of any work so that Landlord can post notices of non-responsibility with respect to Tenant’s Work. 
 8.2.4
Restoration. Tenant shall have the right to configure its existing office and laboratory space to its own specifications, subject to Landlord’s reasonable approval, which shall not be unreasonably withheld, conditioned, or delayed;
provided, that Tenant shall be required to restore the Premises to their original condition on or before the Expiration Date as the same may be extended hereunder, unless Landlord’s waives the restoration requirement in writing in connection
with granting its consent to any proposed changes. 
 8.3 Notice of Defects. It shall be conclusively presumed that the
Premises including Suite B were in satisfactory condition (except for latent defects) as of the Effective Date, unless within thirty (30) days after the Effective Date Tenant shall give Landlord notice in writing specifying the respects in
which the Premises Suite B were not in satisfactory condition. Nothing in this ¶ 8.7 shall excuse Landlord from its obligation to complete Landlord’s Work 

9 SECURITY DEPOSIT. Tenant’s Security Deposit specified in § 3 of the Lease as heretofore
amended shall be increased in consequence of the parties’ execution and delivery of this Third Addendum to each other from its current level to Ninety-Five Thousand Sixty One Dollars and 42/100 ($95,061.42). Tenant shall pay the
increase in the Security Deposit to Landlord upon Tenant’s execution and delivery of this Third Addendum to Landlord. Tenant shall have the right to deliver up to a maximum of fifty percent (50%) of the Security Deposit to Landlord in the
form of an irrevocable on-demand sight-draft letter of credit in a form reasonably satisfactory to Landlord and drawn on an institution reasonably satisfactory to Landlord. 

10 ACCESS INSPECTION DISCLOSURE. Pursuant to California Civil Code § 1938,
Landlord hereby notifies Tenant that, as of the date of this Third Addendum, the Premises have not undergone inspection by a “Certified Access Specialist” to determine whether the Premises meet all applicable construction-related
accessibility standards under California Civil Code § 55.53, and the Premises have not been determined to meet all applicable construction-related accessibility standards pursuant to Civil Code § 55.53. 

11 NO DISCLOSURE. Tenant agrees that it shall not disclose any of the matters set forth in this
Third Addendum or disseminate or distribute any information concerning the terms, details, or conditions hereof to any person, firm, or entity without obtaining the express written approval of Landlord. 

12 DEFINED TERMS. Terms used herein that are defined in the Lease shall have the meanings therein
defined, unless a different definition is set forth in this Third Addendum. The term Lease as used herein shall be deemed to include the Work Letter Agreement and the First Letter Agreement, each of which may also be referred to separately
herein. In the event of any conflict between the provisions of the Lease, and this Third Addendum, the terms of this Third Addendum shall prevail. 
 13
SURVIVAL. Warranties, representations, agreements, and obligations contained in this Third Addendum shall survive the execution and delivery of this Third Addendum and shall survive any and all performances
in accordance with this Third Addendum. 
 14 COUNTERPARTS. This Third Addendum may be executed in any number of
counterparts, which each severally and all together shall constitute one and the same Third Addendum. 
 15 ATTORNEYS’
FEES. If any party obtains a judgement against any other party or parties by reason of breach of this Third Addendum, reasonable attorneys’ fees and costs as fixed by the court shall be included in such
judgement against the losing party or parties. 
 16 SUCCESSORS. This Third Addendum and the terms and
provisions hereof shall inure to the benefit of and be binding upon the heirs, successors, and assigns of the parties. 
 17
AUTHORITY. Each of the individuals executing this Third Addendum represents and warrants that he or she is authorized to execute this Third Addendum on behalf of the party for whom he or she is executing this
Third Addendum and that by his or her signature such party is legally bound by the terms, covenants, and conditions of this Third Addendum. 

  
 Third Addendum to
Office and Laboratory Lease 
 Bancroft Way, LLC:: Aduro Biotech, Inc. 

page 5 of 6 
 [Suites B, C
& D, 18,211 rsf) 

 18 GOVERNING LAW. This Third Addendum shall be
construed and enforced in accordance with the laws of the State of California. 
 19 CONSENT. This Third
Addendum is subject to, and conditioned upon, any required consent or approval being granted without any fee or charge that is unacceptable to Landlord by Landlord’s mortgagees or ground lessors. If any such consents shall be denied or granted
subject to the payment of unacceptable fees or charges hereunder, the Lease shall remain in full force and effect. If Landlord fails to notify Tenant to the contrary within sixty (60) days after this Third Addendum has been executed and delivered by
both parties, Tenant may assume that such consent has been granted, or that the same is not required. 
 20 CONTINUING
VALIDITY OF LEASE. Except as expressly modified herein, the Lease remains in full force and effect. 

21 EXHIBITS. The following exhibits have been attached to this Third Addendum by the parties prior to their
execution and deliver of the same to each other, which are incorporated herein by reference: 
 Exhibit A — The Lease 

Exhibit B — Space Plan 
 22
WHOLE AGREEMENT. The mutual obligations of the parties as provided herein are the sole consideration for this Third Addendum, and no representations, promises, or inducements have been made by
the parties other than as appear in this Third Addendum, which supersedes any previous negotiations. There have been no representations made by the Landlord or understandings made between the parties other than those set forth in this Third
Addendum. This Third Addendum may not be amended except in writing signed by all the parties. 
 In witness whereof, the parties have
executed this Third Addendum as of the date first above written. 
  

			
	Landlord:	 	Tenant:
		
	 BANCROFT WAY, LLC, a California limited liability company
	 	 ADURO BIOTECH, INC., a Delaware corporation

		
	            By:    /s/ Steven Goldin	 	            By:    /s/ Gregory W. Schafer
		
	                      Steven
Goldin                                	 	                      Gregory W.
Schafer                                
	 [name typed]
	 	[name typed]
		
	             Its:    Managing Member
	 	            Its:    COO

  
 Third Addendum to
Office and Laboratory Lease 
 Bancroft Way, LLC:: Aduro Biotech, Inc. 

page 6 of 6 
 [Suites B, C
& D, 18,211 rsf) 

  
 

 

 BANCROFT WAY, LLC 

Second Addendum to Office Lease 
 THIS
SECOND ADDENDUM TO OFFICE LEASE (the “Second Addendum”) is made and entered into as of May 1, 2013, by and between BANCROFT WAY, LLC, a California limited liability company (“Landlord”) and ADURO BIOTECH, INC.,
a Delaware corporation fka NanoTx Corp. (“Tenant”). 
 Recitals 

A. Landlord and Tenant or its predecessor have heretofore entered into that certain lease dated June 1, 2005 (the “Lease”) for
premises described as Suite C (the “Premises”), initially containing approximately 8,073 rentable square feet, in the building located at 626 Bancroft Way, Berkeley, California (the “Building”), which forms part of the mixed-use
building development commonly known as the 600-630 Bancroft Way Development (the “Development”) with a street address of 600-630 Bancroft Way, Berkeley, California. The square footage of the Development is 48,358. 

B. The Lease has heretofore been amended or assigned by the following instruments: (1) letter agreement dated September 1, 2008 (the
“First Letter Agreement”), under which the Term of the Lease was extended through August 31, 2010; (ii) letter agreement dated February 11, 2010 (the “Second Letter Agreement, under which the Term of the Lease was
extended through August 31, 2012; and (iii) that certain First Addendum to Office Lease dated as of May 12, 2011 (the “First Addendum”), under which the Term of the Lease was extended through August 31, 2014, and the
Premises were expanded by the addition thereto of approximately 5,800 rentable square feet of space known as Suite D in the Building. 
 C.
Tenant was named NanoTx Corp. when it signed the Lease, although it did business as Aduro BioTech. Tenant has changed its corporate name to Aduro BioTech. Tenant has reincorporated in Delaware by merging into a Delaware corporation named Aduro
BioTech, Inc. 
 D. The parties mutually desire to amend the terms of the Lease to extend the Term of the Lease and make certain other
related changes, all on and subject to the terms and conditions hereof. 
 Agreement 

Now, therefore, in consideration of the mutual terms and conditions herein contained and of other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the’ parties agree as follows: 
 1 EFFECT OF
ADDENDUM. Landlord and Tenant agree that, notwithstanding anything contained in the Lease to the contrary, the provisions set forth below will be deemed to be part of the Lease and shall supersede, to the
extent they differ, any contrary provisions hi the Lease. Terms defined in the Lease shall have the same meanings in this Second Addendum, unless a different definition is set forth in this Second Addendum. The term Lease as used herein shall
be deemed to include the First Extension Agreement, the Second Extension Agreement, and the First Addendum, each of which may also be referred to separately herein. A true, complete, and correct copy of the Lease as heretofore amended is attached
hereto as Exhibit A and incorporated herein by reference. 
 2 EFFECTIVE DATE. The
amendments and changes specified in this Second Addendum shall become effective from and after the date of the parties’ execution and delivery of this Second Addendum to each other(the “Effective Date”), or, if later, on the specific
date expressly associated with each change or modification of the Lease specified in this Second Addendum. 
 3 EXTENSION
OF LEASE TERM. The Term of the Lease specified in § 1.2 of the Lease as heretofore amended is hereby extended for an additional period of two (2) years commencing on
September 1, 2014 (the “Extension Term Commencement Date” or “ETCD”), and the Ex lion Date of the Lease is hereby amended accordingly to August 31, 2016. 

  
 Second Addendum to
Office Lease 
 Bancroft Way, LLC:: Aduro Biotech, Inc. fka NanoTx Corp. 

page 1 of 5 
 [Suites C
& D, 14,221 rsf) 

 4 EXPANSION OF PREMISES. On the ETCD
the rentable square footage of Suite C shall increase from its current level of 8,073 rentable square feet of space to 8,421 square feet of rentable space. 

5 SUMMARY TABLE. The Table set forth in § 1 of the Lease as heretofore amended is hereby
superseded and replaced in its entirety by the following table, which shall constitute the Table under § 1 of the Lease for all purposes from and after the Effective Date of this Second Addendum: 

 

																			
	 Period
	  	Suite
No.	  	Square
Footage	 	  	Monthly
Base Rent	 	  	Pro Rata
Share	 	 	Base
Year	 
	 September 1, 2014 thru August 31, 2015
	  	C	  	 	8,421	  	  	$	13,894.65	  	  	 	29.408	% 	 	 	2013	  
		  	D	  	 	5,800	  	  	$	9,570.00	  	  	 
	 September 1, 2015 thru August 31, 2016
	  	C	  	 	8,421	  	  	$	13,894.65	  	  	 	29.408	% 	 	 	2013	  
		  	D	  	 	5,800	  	  	$	9,570.00	  	  	 

 6 EXTENSION TERM BASE RENT. The Base
Rent for the Premises specified in § 2(a) of the Lease as heretofore amended shall be the amounts specified as Monthly Base Rent in the Table above for the various periods and spaces set forth in the Table from and after the ETCD. For the
avoidance of doubt and in order to clarify the parties’ agreement hereunder, the Base Rent numbers shown in the Table able are the Base Rent numbers applicable under the First Addendum as of September 1, 2011 (the “Base Rent
Date”), which Base Rent numbers have increased (and shall continue to increase) on each anniversary of the Commencement Date as provided in § 2.2 of the Lease. The Base Rent under this Second Addendum shall be increased on the ETCD and
each anniversary of the ETCD thereafter as provided in § 2.2 of the Lease, except that from and after the ETCD the Base Rent Date shall be substituted for all purposes hereunder for “Commencement Date” in § 2.2 of the Lease.
Notwithstanding anything to the contrary herein or in the Table, the CPI Escalation Amount to be applied on the ETCD shall be the percentage increase in the CPI from September 1, 2013, through the ETCD. 

7 EXTENSION TERM BASE YEAR. As specified in the Table above, the Base
Year for the purposes calculating Tenant’s Additional Rent under § 2.3 of the Lease as heretofore amended shall be calendar year 2013 from and after the Effective Date. 

8 CONDITION OF PREMISES. Except as otherwise expressly provided in this ¶ 8
with respect to Landlord’s preparation of the Premises for Tenant’s continued occupancy, Tenant shall accept the Premises, any existing Improvements in the Premises, and the Systems and Equipment serving the same in an “as is”
condition on the Effective Date, and Landlord shall have no obligation to improve, alter, remodel, or otherwise modify the Premises in connection with Tenant’s continued occupancy of the Premises from and after the Effective Date. 

8.1 Landlord’s Work. Landlord agrees that all Systems and Equipment serving the Premises shall be in good working condition
on the Effective Date, and Landlord further agrees to complete the following items (and the following items only) as soon as reasonably feasible after the Effective Date at Landlord’s sole cost and expense (collectively “Landlord’s
Work”): 
 (i) revision of the landscaping on the north and west faces of the Building and at the front gate, as shown on the
Site Plan, which work Landlord agrees to use commercially reasonable efforts to complete on or before August 31, 2013; and 

(ii) improvement of the exhaust capacity for the eastern set of bathrooms. 

(iii) removal of the vacuum pump; 

  
 Second Addendum to
Office Lease 
 Bancroft Way, LLC:: Aduro Biotech, Inc. fka NanoTx Corp. 

page 2 of 5 
 [Suites C
& D, 14,221 rsf) 

 8.2 Tenant’s Work. The facilities, materials, and work to be furnished,
installed, and performed in the Premises by Tenant are referred to as the “Tenant’s Work,” which shall include any and all installations, materials, and work which may be undertaken by or for the account of Tenant other than
Landlord’s Work described in ¶ 8.1 above, to prepare, equip, decorate, and furnish the Premises and/or Premises for Tenant’s continued occupancy and shall include the connection and/or rewiring of Tenant’s telephone and data
lines. Tenant shall not permit any liens to accrue or be filed against the Building or Development in connection the Tenant’s performance of Tenant’s Work. Tenant shall obtain all necessary permits for Tenant’s Work, which shall be
completed in compliance with all applicable Laws and codes and in accordance with the highest standards of best construction practices. The parties agree that Tenant’s Work, to be completed by Tenant under Landlord’s supervision, as
provided in the Lease, at Tenant’s sole cost and expense as soon as reasonably feasible after the Effective Dave, shall include the following items and the following items only: 

(a) reconfiguration the existing Premises to create areas designated A, D, E, F, & G as shown on the site plan attached hereto as
Exhibit B and incorporated herein by reference (the “Site Plan”); 
 (b) repair of the HVAC serving the main
conference room — apply up to $3K in TI’s for upgraded compressor. 
 (c) remodeling of kitchenette; 

(d) installation of light tubes for Area A shown on the Site Plan; 

(e) installation of carpet for Areas A, B, C, D, E, F, & G as shown on the Site Plan; 

(f) installation of a keycard access system; 

(g) update Bldg. 3 external paint accent colors to match Bldg. 2 

(j) addition of an office for Area G, as shown on the Site Plan. 

8.2.1 Plans & Approval. Tenant shall submit plans for any and all Tenant’s Work to Landlord for approval, which
shall not be unreasonably withheld, conditioned, or delayed. Tenant shall comply with all applicable Laws in connection with the performance of Tenant’s Work and shall be responsible for obtaining any required permits. 

8.2.2 Cost of Tenant’s Work and Rent Credit. Notwithstanding anything to the contrary herein, Tenant shall bear the entire
cost of Tenant’s Work described in ¶ 8.2 above at Tenant’s sole cost and expense. In consideration of Tenant’s agreement to bear the cost of Tenant’s Work as provided in this ¶ 8.2, Landlord agrees to provide a credit
to Tenant against the Base Rent first due after the ETCD in the amount of Thirty Thousand Dollars ($30,000.00) (the “Base Rent Credit”). 

8.2.3 Contractor & Vendor Selection. Tenant shall have the right to select its own contractors and vendors for the
performance of Tenant’s Work, subject to Landlord’s reasonable approval, which shall not be unreasonably withheld, conditioned, or delayed. Tenant shall give Landlord sufficient written notice before the commencement of any work so that
Landlord can post notices of non-responsibility with respect to Tenant’s Work. 
 8.2.4 Restoration. Tenant shall have the
right to configure its existing office and laboratory space to its own specifications, subject to Landlord’s reasonable approval, which shall not be unreasonably withheld, conditioned, or delayed; provided, that Tenant shall be required to
restore the Premises to their original condition on or before the Expiration Date as the same may be extended hereunder, unless Landlord’s waives the restoration requirement in writing in connection with granting its consent to any proposed
changes. 

  
 Second Addendum to
Office Lease 
 Bancroft Way, LLC:: Aduro Biotech, Inc. fka NanoTx Corp. 

page 3 of 5 
 [Suites C
& D, 14,221 rsf) 

 8.3 Notice of Defects. It shall be conclusively presumed that the Premises were in
satisfactory condition (except for latent defects) as of the Effective Date, unless within thirty (30) days after the Effective Date Tenant shall give Landlord notice in writing specifying the respects in which the Premises was not in
satisfactory condition. Nothing in this ¶ 8.7 shall excuse Landlord from its obligation to complete Landlord’s Work. 
 8.4
Adjustment of Square Footage. Landlord and Tenant agree that it is not certain as of the date of this Second Addendum whether Landlord’s Work and/or Tenant’s Work described in this ¶ 8 et seq. will change the square
footage of the Premises stated in the Table above. Landlord and Tenant agree to re-measure the Premises at the conclusion of all such work and, if the square footage shown in the Table has changed, to execute
and deliver to each other a suitable amendment to the Lease expressing such change in the square footage and related adjustments. 
 9
SECURITY DEPOSIT. Tenant’s Security Deposit specified in § 3 of the Lease as heretofore amended shall remain unchanged in consequence of the parties’ execution and delivery of
this Second Addendum to each other. 
 10 NO DISCLOSURE. Tenant agrees that it shall not disclose
any of the matters set forth in this Second Addendum or disseminate or distribute any information concerning the terms, details, or conditions hereof to any person, firm, or entity without obtaining the express written approval of Landlord. 

11 DEFINED TERMS. Terms used herein that are defined in the Lease shall have the meanings therein
defined, unless a different definition is set forth in this Second Addendum. The term Lease as used herein shall be deemed to include the Work Letter Agreement and the First Letter Agreement, each of which may also be referred to separately
herein. In the event of any conflict between the provisions of the Lease, and this Second Addendum, the terms of this Second Addendum shall prevail. 

12 SURVIVAL. Warranties, representations, agreements, and obligations contained in this Second Addendum shall
survive the execution and delivery of this Second Addendum and shall survive any and all performances in accordance with this Second Addendum. 
 13
COUNTERPARTS. This Second Addendum may be executed in any number of counterparts, which each severally and all together shall constitute one and the same Second Addendum. 

14 ATTORNEYS’ FEES. If any party obtains a judgement against any other party or parties by
reason of breach of this Second Addendum, reasonable attorneys’ fees and costs as fixed by the court shall be included in such judgement against the losing party or parties. 

15 SUCCESSORS. This Second Addendum and the terms and provisions hereof shall inure to the benefit of and be
binding upon the heirs, successors, and assigns of the parties. 
 16 AUTHORITY. Each of the individuals
executing this Second Addendum represents and warrants that he or she is authorized to execute this Second Addendum on behalf of the party for whom he or she is executing this Second Addendum and that by his or her signature such party is legally
bound by the terms, covenants, and conditions of this Second Addendum. 
 17 GOVERNING LAW. This
Second Addendum shall be construed and enforced in accordance with the laws of the State of California. 
 18
CONSENT. This Second Addendum is subject to, and conditioned upon, any required consent or approval being granted without any fee or charge that is unacceptable to Landlord by Landlord’s mortgagees or
ground lessors. If any such consents shall be denied or granted subject to the payment of unacceptable fees or charges hereunder, the Lease shall remain in full force and effect. If Landlord fails to notify Tenant to the contrary within sixty
(60) days after this Second Addendum has been executed and delivered by both parties, Tenant may assume that such consent has been granted, or that the same is not required. 

19 CONTINUING VALIDITY OF LEASE. Except as expressly modified herein,
the Lease remains in full force and effect. 

  
 Second Addendum to
Office Lease 
 Bancroft Way, LLC:: Aduro Biotech, Inc. fka NanoTx Corp. 

page 4 of 5 
 [Suites C
& D, 14,221 rsf) 

 20 EXHIBITS. The following exhibits have been attached to this Second
Addendum by the parties prior to their execution and deliver of the same to each other, which are incorporated herein by reference: 

Exhibit A — The Lease 

Exhibit B — Site Plan 
 21
WHOLE AGREEMENT. The mutual obligations of the parties as provided herein are the sole consideration for this Second Addendum, and no representations, promises, or inducements have been made by
the parties other than as appear in this Second Addendum, which supersedes any previous negotiations. There have been no representations made by the Landlord or understandings made between the parties other than those set forth in this Second
Addendum. This Second Addendum may not be amended except in writing signed by all the parties. 
 In witness whereof, the parties have
executed this Second Addendum as of the date first above written. 
  

			
	Landlord:	  	Tenant:
		
	 BANCROFT WAY, LLC, a California limited liability company
	  	 ADURO BIOTECH, INC., a Delaware corporation fka NanoTx Corp.

		
	            By:    /s/ Steven Goldin	  	            By:    /s/ Stephen T. Isaacs
		
	                      Steven
Goldin                                	  	                      Stephen T.
Isaacs                                
	 [name typed]
	  	[name typed]
		
	             Its:    Managing Member
	  	            Its:    Chairman & CEO

  
 Second Addendum to
Office Lease 
 Bancroft Way, LLC:: Aduro Biotech, Inc. fka NanoTx Corp. 

page 5 of 5 
 [Suites C
& D, 14,221 rsf) 

  
 

 

 BANCROFT WAY, LLC 

First Addendum to Office Lease 
 THIS FIRST
ADDENDUM TO OFFICE LEASE (the “First Addendum”) is made and entered into as of May 12, 2011, by and between BANCROFT WAY, LLC, a California limited liability company (“Landlord”) and ADURO BIOTECH, INC., a
California corporation fka NanoTx Corp. (“Tenant”). 
 Recitals 

A. Landlord and Tenant or its predecessor have heretofore entered into that certain lease dated June 1, 2005 (the “Lease”) for
premises described as Suite 3C (the “Premises”), initially containing approximately 8,073 rentable square feet, in the building located at 626 Bancroft Way, Berkeley, California (the “Building”), which forms part of the mixed-use
building development commonly known as the 600-630 Bancroft Way Development (the “Development”) with a street address of 600-630 Bancroft Way, Berkeley, California. The square footage of the Development is 48,358. 

B. The Lease has heretofore been amended or assigned by instruments dated September 1, 2008, and February 11, 2010 (the
“Extension Agreements”) under which the Term of the Lease was extended through August 31, 2012. 
 C. Tenant was named NanoTx
Corp. when it signed the Lease, although it did business as Aduro BioTech. Tenant has changed its corporate name to Aduro BioTech. Tenant intends to reincorporate in Delaware by merging into a Delaware corporation named Aduro BioTech, Inc. 

D. The parties mutually desire to amend the terms of the Lease to extend the Term, expand the Premises, and make certain other related
changes, all on and subject to the terms and conditions hereof. 
 Agreement 

Now , therefore , in consideration of the mutual terms and conditions herein contained and of other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: 
 1 EFFECT OF
ADDENDUM. Landlord and Tenant agree that notwithstanding anything contained in the Lease to the contrary, the provisions set forth below will be deemed to be part of the Lease and shall supersede, to the
extent they differ, any contrary provisions in the Lease. Terms defined in the Lease shall have the same meanings in this First Addendum, unless a different definition is set forth in this First Addendum. The term Lease as used herein shall
be deemed to include the Extension Agreements, each of which may also be referred to separately herein. A true, complete, and correct copy of the Lease as heretofore amended is attached hereto as Exhibit A and incorporated herein
by reference. 
 2 EFFECTIVE DATE. The amendments and changes specified in this First Addendum
shall become effective on June 1, 2011 (the “Effective Date”). Notwithstanding the foregoing, this First Addendum shall constitute the fully-binding agreement and contract of the parties from and after the date of the
parties’ execution and delivery of this First Addendum to each other. 
 3 CORPORATE CHANGE OF
NAME. Upon the effectiveness of the merger described as intended under Recital C above, Aduro BioTech, Inc., a Delaware corporation, will automatically become the Tenant under the Lease. Tenant agrees to give
to Landlord written notice of any such change in name within thirty (30) days after the completion of the proposed merger. 
 4
EXTENSION OF LEASE TERM. The Term of the Lease specified in § 1.2 of the Lease as heretofore amended is hereby extended for an additional period of two
(2) years commencing on September 1, 2012, and the Expiration Date of the Lease is hereby amended accordingly to August 31, 2014. 

  
 First Addendum to
Office Lease 
 Bancroft Way, LLC:: Aduro BioTech fka NanoTx Corp. 

					
			page 1 of 7		[Suites 3C & D, 13,873 rsf]

 4.1 Option to Renew. Tenant is hereby granted three (3) successive options to
extend (collectively the “Extension Options”) the Term of the Lease for three (3) additional consecutive periods of two (2) years each (collectively the “Extension Periods”). The first Extension Period term shall begin
the first day following the Expiration Date and shall take effect on the same terms and conditions in effect under the Lease immediately prior to the first Extension Period, except that (i) Tenant shall have no right to extend other than any
remaining Extension Options and (ii) monthly Base Rent shall be the rate which is Fair Market Value (as defined below). The Fair Market Value shall be the effective rent (face rate less free rent) being charged for comparable space in
comparable buildings in the vicinity of the Building leased on comparable terms and shall be limited the rates charges in such comparable transactions for tenants renewing or extending their leases. 

(a) Exercise of Options. The Extension Options may be exercised only by (i) delivering in person to Landlord’s
Building Manager in the Building Office written notice of Tenant’s irrevocable election to exercise no earlier than ten (10) months and no later than six (6) months prior to the commencement of the first, second, or third Extension
Period, as the case may be, and (ii) collecting and retaining in exchange for such notice of exercise an original written receipt therefor signed and dated by Landlord’s Building Manager. Tenant’s exercise of its Extension Options
shall not be effective or valid if there is any deviation in the timing or manner of exercise prescribed herein. 
 (b) Nullification of
Exercise. Notwithstanding anything to the contrary herein, Landlord shall have the right in its sole and absolute discretion to nullify Tenant’s exercise of any of its Extension Options granted hereunder upon written notice within
thirty (30) days after the date of Tenant’s exercise of its Extension Option for such Extension Period if the Building or Development is selected by the LBNL as the site for development of a new campus. If Landlord exercises its option
nullification right hereunder, Landlord shall pay to Tenant (i) a “Nullification Fee” in the amount of Eighty Thousand Dollars ($80,000) and (ii) the reasonable costs incurred by Tenant in moving to a comparable facility
of Tenant’s choice in the San Francisco Bay Area. The Nullification Fee, if any, shall be payable by Landlord in full on or before the Expiration Date of the then-current initial Term or Extension Period, as the case may be. 

(c) Failure to Exercise. If Tenant shall fail validly and timely to exercise any of the Options herein granted, said Options
shall terminate and shall be null and void and of no further force and effect. 
 (d) Fair Market Value. Provided that Tenant
has validly exercised its Options when and as required hereunder, not less than one hundred and eighty (180) days prior to the commencement of the first, second, or third Extension Period, as the case may be, Landlord shall provide written
notice to Tenant of its determination of the Fair Market Value. Within ten (10) days after receiving such determination (“Tenant’s Review Period”), Tenant shall irrevocably elect, in writing, to do one of the following:
(i) accept Landlord’s determination; or (ii) object to Landlord’s determination and with such objection set forth in writing Tenant’s determination of the Fair Market Value. If Tenant so objects, Landlord and Tenant shall
attempt in good faith to agree upon such Fair Market Value using their best good-faith efforts. If Landlord and Tenant fail to reach agreement within fifteen (15) days following Tenant’s Review Period (the “Outside Agreement
Date”), then each party’s determination shall be submitted to arbitration in accordance with the then-current rules and procedures of the American Arbitration Association, but subject to the instructions set forth in this § 3.1 et
seq.. If Tenant objects to Landlord’s determination of Fair Market Value, Tenant shall pay Rent at the Fair Market Value determined by Landlord until the matter is resolved by binding arbitration as provided below subject to retroactive
adjustment after the matter is so resolved. If Tenant fails so to accept or object to Landlord’s determination of Fair Market Value in writing within Tenant’s Review Period, Tenant shall conclusively be deemed to have approved of the Fair

  
 First Addendum to
Office Lease 
 Bancroft Way, LLC:: Aduro BioTech fka NanoTx Corp. 

					
			page 2 of 7		[Suites 3C & D, 13,873 rsf]

 Market Value as determined by Landlord. The determination of the arbitrators shall be limited
solely to the issue of whether Landlord’s or Tenant’s submitted Fair Market Value for the Premises is the more accurate as determined by the arbitrators, taking into account the requirements of this § 3.1 et seq. 

(e) Appointment of Arbitrators. Not later than fifteen (15) days following the Outside Agreement Date, Landlord and Tenant
shall each appoint one arbitrator who shall by profession be a real estate broker who shall have been active over the ten-year period ending on the date of such appointment in the leasing of commercial properties within Berkeley, California. The
determination of the arbitrators shall be limited solely to the issue of whether Landlord’s or Tenant’s submitted Fair Market Value for the Premises is the more accurate as determined by the arbitrators, taking into account the
requirements of this § 3.1 et seq. 
 (f) Appointment of Third Arbitrator. The two (2) arbitrators so
appointed shall within fifteen (15) days of the date of the appointment of the last-appointed arbitrator agree upon and appoint a third arbitrator, who shall be qualified under the same criteria as set forth hereinabove for qualification of the
initial two arbitrators. 
 (g) Arbitrators’ Decision. The three (3) arbitrators shall, within thirty (30) days
of the appointment of the third arbitrator, reach a decision as to whether the parties shall use Landlord’s or Tenant’s submitted Fair Market Value, and shall notify Landlord and Tenant thereof. The decision of the majority of the three
(3) arbitrators shall be binding upon Landlord and Tenant. The arbitrators shall not be permitted to set Fair Market Value to any level other than either Landlord’s or Tenant’s submitted Fair Market Value. 

(h) Failure to Appoint. If either Landlord or Tenant fails to appoint an arbitrator within fifteen (15) days after the
Outside Agreement Date, the arbitrator timely appointed by one of the parties shall reach a decision, notify Landlord and Tenant thereof, and such arbitrator’s decision shall be binding upon Landlord and Tenant. If the two (2) arbitrators
fail to agree upon and appoint a third arbitrator, both arbitrators shall be dismissed and the matter to be decided shall be forthwith submitted to arbitration under the Commercial Arbitration Rules of the American Arbitration Association then in
effect, but subject to the instructions set forth in this § 3.1 et seq.. 
 (i) Cost of Arbitration. The cost of
arbitration shall be paid by Landlord and Tenant equally. 
 (j) Default. Tenant’s exercise of the Options shall, at
Landlord’s election, be null and void if Tenant is in Default on the date of Tenant’s notice of exercise or at any time thereafter and prior to commencement of the relevant Extension Period, Tenant’s exercise of the Extension Options
shall not operate to cure any Default by Tenant nor to extinguish or impair any rights or remedies of Landlord arising by virtue of such Default. If the Lease or Tenant’s right to possession of the Premises shall terminate before Tenant shall
have exercised the first Extension Option, then immediately upon such termination all the Extension Options shall simultaneously terminate and become null and void; and if the Lease or Tenant’s right to possession of the Premises shall
terminate before Tenant shall have exercised the second or third Extension Option, then immediately upon such termination the second and third Extension Options shall simultaneously terminate and become null and void. 

(k) Time. Time is of the essence of the Extension Options granted hereunder. 

  
 First Addendum to
Office Lease 
 Bancroft Way, LLC:: Aduro BioTech fka NanoTx Corp. 

					
			page 3 of 7		[Suites 3C & D, 13,873 rsf]

 5 SUMMARY TABLE. The Table set forth in § 1 of
the Lease as heretofore amended is hereby superseded and replaced in its entirety by the following table, which shall constitute the Table under § 1 of the Lease for all purposes from and after the Effective Date of this First Addendum: 

 

																			
	 Period
	  	Suite
No.	  	Square
Footage	 	  	Monthly
Base Rent	 	  	Pro Rata
Share	 	 	Base
Year	 
	 June 1, 2011 thru August 31, 2012
	  	3C	  	 	8,073	  	  	$	13,320.45	  	  	 	28.688	% 	 	 	2011	  
	  	D	  	 	5,800	  	  	$	9,570.00	  	  	 
	 September 1, 2012 thru August 31, 2014
	  	3C	  	 	8,073	  	  	$	13,320.45	  	  	 	28.688	% 	 	 	2011	  
	  	D	  	 	5,800	  	  	$	9,570.00	  	  	 

 6 EXTENSION TERM BASE RENT. The Base
Rent for the Premises specified in § 2(a) of the Lease as heretofore amended shall be the amounts specified as Monthly Base Rent in the Table above for the various periods and spaces set forth in the Table from and after the Effective Date. The
Base Rent shall be increased on each anniversary of the Effective Date, which term shall be substituted for all purposes hereunder for “Commencement Date” in § 2.2 of the Lease. 

7 EXTENSION TERM BASE YEAR. As specified in the Table above, the Base
Year for the purposes calculating Tenant’s Additional Rent under § 2.3 of the Lease as heretofore amended shall be calendar year 2011 from and after the Effective Date. 

8 EXPANSION OF PREMISES. Upon the Effective Date the Premises shall be expanded by
the addition thereto of approximately 5,800 rentable square feet of space known as Suite Din the Building (“Suite D” or the “Expansion Space”) for all purposes under the Lease. All references in the Lease to the
“Premises” shall refer to Premises as so augmented by the addition of Suite D from and after the Effective Date. The floor plan and location of Suite D is shown on the space plan attached hereto as Exhibit B and incorporated
herein by reference (the “Space Plan”). From and after Effective Date, Suite D shall become part of the Premises pursuant to the basic terms specified in the Table above regarding Term, Base Rent, Tenant’s Pro Rata Share of Increased
CAM Charges, Increased Taxes, Increased Insurance Costs, and the Base Year for the purposes of calculating Additional Rentable payable with respect to Suite D. 

8.1 Contingency. Notwithstanding anything to the contrary herein, Tenant understands and acknowledges that the term of the
existing lease of the Expansion Space will not expire on its terms until June 30, 2011. Landlord believes that the existing tenant in the Expansion Space will vacate on or before May 31, 2011; however, Landlord will incur no liability to
Tenant if the existing tenant fails so to vacate, and in any such case the addition of the Expansion Space shall be delay day for day until such time as the existing tenant vacates the Expansion Space. 

8.2 Early Access. Landlord will (subject to the lease with the existing tenant) allow Tenant full access to the Expansion Space
from and after the date of the parties’ execution and delivery of this First Addendum to each other and will continue to permit Tenant to use the conference room in accordance with the agreement between Tenant and the existing tenant in the
Expansion Space. 
 9 CONDITION OF PREMISES. Except as otherwise expressly
provided in this ¶ 8 with respect to Landlord’s preparation of the Expansion Space for Tenant’s occupancy, Tenant shall accept the Expansion Space, any existing Improvements in the Expansion Space, and the Systems and Equipment
serving the same in an “as is” condition on the Effective Date, and Landlord shall have no obligation to improve, alter, remodel, or otherwise modify the Expansion Space in connection with Tenant’s continued occupancy of the Premises
as expanded by the Expansion Space from and after the Effective Date. Landlord agrees to deliver the Expansion Space to Tenant broom clean with all Systems and Equipment in good working condition and to perform the following preparatory work to be
completed on or before the Effective Date (collectively “Landlord’s Work”): 

  
 First Addendum to
Office Lease 
 Bancroft Way, LLC:: Aduro BioTech fka NanoTx Corp. 

					
		  	page 4 of 7	  	[Suites 3C & D, 13,873 rsf]

 (i) application of fresh Building-standard paint; 

(ii) professional cleaning of all carpeted surfaces; 

(iii) cleaning of all lights and fixtures and installation of updated bulbs; and 

(iv) cleaning of all ceiling tiles and removal of all stains. 

The cost of Landlord’s Work shall not be deducted from the Improvement Allowance provided in ¶ 8.3 below. 

9.2 Tenant’s Preparation. The facilities, materials, and work to be furnished, installed, and performed in the Expansion
Space by Tenant are referred to as the “Work,” which shall include any and all other installations, materials, and work which may be undertaken by or for the account of Tenant to prepare, equip, decorate, and furnish the Premises and / or
Expansion Space for Tenant’s occupancy and shall include the connection and / or rewiring of Tenant’s telephone and data lines. Tenant shall not permit any liens to accrue or be filed against the Building or Development. 

9.3 Plans & Approval. Tenant shall submit plans for any and all Tenant’s Work to Landlord for approval, which shall
not be unreasonably withheld, conditioned, or delayed. Tenant shall comply with all applicable Laws in connection with the performance of Tenant’s Work and shall be responsible for obtaining any required permits. 

9.4 Improvement Allowance. Landlord agrees to provide for Tenant’s use a sum equal to Sixty Thousand Dollars
($60,000) to be applied to the cost of Tenant’s Work or to other costs to Tenant under the Lease. Tenant may cause bills from approved contractors and vendors to be submitted directly to Landlord for payment up to the maximum amount of the
Improvement Allowance. If Tenant elects to apply the Improvement Allowance or any portion thereof against rentals owing under the Lease, a maximum of one (1) month’s rental obligation may be applied immediately, and the remainder of the
amount to be applied shall be amortized over the remainder of the initial renewal term after the Effective Date. 
 9.5
Contractor & Vendor Selection. Tenant shall have the right to select its own contractors and vendors for the performance of Tenant’s Work, subject to Landlord’s reasonable approval, which shall not be unreasonably
withheld, conditioned, or delayed. Tenant shall give Landlord sufficient written notice before the commencement of any work so that Landlord can post notices of non-responsibility with respect to Tenant’s Work. 

9.6 Restoration. Tenant shall have the right to configure its existing office and laboratory space to its own specifications,
subject to Landlord’s reasonable approval, which shall not be unreasonably withheld, conditioned, or delayed; provided, that Tenant shall be required to restore the Premises to their original condition on or before the Expiration Date as the
same may be extended hereunder, unless Landlord’s waives the restoration requirement in writing in connection with granting its consent to any proposed changes. 

9.7 Notice of Defects. It shall be conclusively presumed upon Tenant’s taking actual possession of the Expansion Space that
the same were in satisfactory condition (except for latent defects) as of the date of such taking of possession, unless within thirty (30) days after the Effective Date Tenant shall give Landlord notice in writing specifying the respects in
which the Expansion Space was not in satisfactory condition. Nothing in this ¶ 8.7 shall excuse Landlord from its obligation to complete Landlord’s Work. 

10 Incubator Tenants. Landlord and Tenant agree to work together in good faith to accommodate any “incubator” tenants that Landlord
may suggest to Tenant; provided, the parties understand that no enforceable or legal obligation is created under this ¶ 9. If Tenant elects to accommodate any incubator tenant proposed by Landlord, the parties will enter into a separate
agreement to memorialize their agreement with respect to any such arrangement, which will include a flat rate to include utilities, the location for the subtenant, a separate entrance, insurance, and alarm considerations. 

  
 First Addendum to
Office Lease 
 Bancroft Way, LLC:: Aduro BioTech fka NanoTx Corp. 

					
			page 5 of 7		[Suites 3C & D, 13,873 rsf]

 11 External Property Upgrades. Tenant has requested the following external property upgrades in
connection with the extension of the Term provided for hereunder (collectively the “External Improvements”): 
 (i) removal of the
ramp in from of the entrance after SEEO’s HVAC unit is removed; 
 (ii) landscaping of the existing flower beds; and 

(iii) repainting of the orange railings, if the Landlord’s Board approves of such a change. 

Landlord agrees to use commercially reasonable efforts to complete the External Upgrades within eighteen (18) months after the Effective Date; provided,
Landlord shall incur no liability to Tenant hereunder if Landlord fails to complete any such External Upgrades for any reason. 
 12
SECURITY DEPOSIT. Tenant’s Security Deposit specified in § 3 of the Lease as heretofore amended shall be increased in consequence of the parties’ execution and delivery of this
First Addendum to each other from its current level to Forty-Seven Thousand Seven Hundred Eighty Dollars and Ninety Cents ($45,780.90). Tenant shall pay the increase in the Security Deposit to Landlord upon Tenant’s execution and
delivery of this First Addendum to Landlord. 
 13 NO DISCLOSURE. Tenant agrees that it
shall not disclose any of the matters set forth in this First Addendum or disseminate or distribute any information concerning the terms, details, or conditions hereof to any person, firm, or entity without obtaining the express written approval of
Landlord. 
 14 DEFINED TERMS. Terms used herein that are defined in the Lease shall have the
meanings therein defined, unless a different definition is set forth in this First Addendum. The term Lease as used herein shall be deemed to include the Work Letter Agreement and the Extension Agreements, each of which may also be referred
to separately herein. In the event of any conflict between the provisions of the Lease, and this First Addendum, the terms of this First Addendum shall prevail. 

15 SURVIVAL. Warranties, representations, agreements, and obligations contained in this First Addendum shall
survive the execution and delivery of this First Addendum and shall survive any and all performances in accordance with this First Addendum. 
 16
COUNTERPARTS. This First Addendum may be executed in any number of counterparts, which each severally and all together shall constitute one and the same First Addendum. 

17 ATTORNEYS’ FEES. If any party obtains a judgement against any other party or parties by
reason of breach of this First Addendum, reasonable attorneys’ fees and costs as fixed by the court shall be included in such judgement against the losing party or parties. 

18 SUCCESSORS. This First Addendum and the terms and provisions hereof shall inure to the benefit of and be
binding upon the heirs, successors, and assigns of the parties. 
 19 AUTHORITY. Each of the individuals
executing this First Addendum represents and warrants that he or she is authorized to execute this First Addendum on behalf of the party for whom he or she is executing this First Addendum and that by his or her signature such party is legally bound
by the terms, covenants, and conditions of this First Addendum. 
 20 GOVERNING LAW. This First
Addendum shall be construed and enforced in accordance with the laws of the State of California. 
 21 CONSENT.
This First Addendum is subject to, and conditioned upon, any required consent or approval being granted without any fee or charge that is unacceptable to Landlord by Landlord’s mortgagees or ground lessors. If any such consents shall be denied
or granted subject to the payment of unacceptable fees or charges hereunder, the Lease shall remain in full force and effect. If Landlord fails to notify Tenant to the contrary within sixty (60) days after this First Addendum has been executed
and delivered by both parties, Tenant may assume that such consent has been granted, or that the same is not required. 

  
 First Addendum to
Office Lease 
 Bancroft Way, LLC:: Aduro BioTech fka NanoTx Corp. 

					
			page 6 of 7		[Suites 3C & D, 13,873 rsf]

 22 CONTINUING VALIDITY OF
LEASE. Except as expressly modified herein, the Lease remains in full force and effect. 
 23
EXHIBITS. The following exhibits have been attached to this First Addendum by the parties prior to their execution and deliver of the same to each other, which are incorporated herein by reference: 

Exhibit A — The Lease 

Exhibit B — Site Plan 
 24.
WHOLE AGREEMENT. The mutual obligations of the parties as provided herein are the sole consideration for this First Addendum, and no representations, promises or inducements have been made by the
parties other than as appear in this First Addendum, which supersedes any previous negotiations. There have been no representations made by the Landlord or understandings made between the parties other than those set forth in this First Addendum.
This First Addendum may not be amended except in writing signed by all the parties. 
 In witness whereof, the parties have executed this
First Addendum as of the date first above written. 
  

			
	 Landlord:
  

BANCROFT WAY, LLC, a California limited
 liability
company
  
 By:   /s/
Steven Goldin
  

         Steven
Goldin            

            [name typed]

 
 Its:   Managing Member
		 Tenant:
  

ADURO BIOTECH, INC., a Delaware corporation fka

NanoTx Corp.
  

By:   /s/ Stephen. T Isaacs

 

         Stephen T.
Isaacs            

            [name typed]

 
 Its:   Chairman &
CEO

			  

            /s/ Dirk Brockstedt

Dirk Brockstedt

  
 First Addendum to
Office Lease 
 Bancroft Way, LLC:: Aduro BioTech fka NanoTx Corp. 

					
			page 7 of 7		[Suites 3C & D, 13,873 rsf]

 600-630 BANCROFT WAY 

Commercial Office Lease 
 THIS COMMERCIAL
OFFICE LEASE (the “Lease”) is entered into as of June 1, 2005 by and between BANCROFT WAY, LLC, a California limited liability company (“Landlord”) and ONCOLOGIC, INC., a California corporation (“Tenant”).

 1 BASICLEASETERMS. Landlord leases to Tenant, and Tenant rents and hires from Landlord, the Premises
described in § 1.1 below, for the rents hereinafter reserved, for the term stated in § 1.1.3 below, and upon and subject to the terms, conditions (including limitations, restrictions, and reservations), and covenants hereinafter provided.
Each party hereby expressly covenants and agrees to observe and perform all of the conditions and covenants herein contained on its part to be observed and performed. The parties agree that the following table (the “Table”) sets forth in
summary form the basic terms of this Lease, as all of such terms as defined below: 
  

																			
	 Period
	  	Suite
No.	  	Square
Footage	 	  	Monthly
Base Rent	 	  	Pro Rata
Share	 	 	Base
Year	 
	 September l, 2005 to August 31, 2006
	  	3C	  	 	8,073	  	  	$	10,091.25	  	  	 	16.694	% 	 	 	2005	  
	 September 1, 2006 to August 31, 2007
	  	3C	  	 	8,073	  	  	$	10,091.25	  	  	 	16.694	% 	 	 	2005	  
	 September 1, 2007 to August 31, 2008
	  	3C	  	 	8,073	  	  	$	10,091.25	  	  	 	16.694	% 	 	 	2005	  

 In the event of any conflict between the terms contained in the Table and the terms contained in subsequent sections of the
Lease, the terms of the Table shall control, subject to any adjustments specifically provided for in any other provisions of the Lease. 

1.1 Premises. The Premises leased to Tenant (the “Premises”) are a portion of the first (1st) floor of the
Building described in § 1.1.1 below and are commonly known as Suite 3C, containing approximately 8,073 rentable square feet of space, as shown on the floor plan annexed hereto as Exhibit B. The Premises also include all fixtures
and equipment which are attached thereto, except items not deemed to be included therein and which are removable by Tenant as provided in § 19 below. Landlord and Tenant agree that the square footage of the Premises, for all purposes under this
Lease, is as specified in the Table. Tenant acknowledges that it has had an opportunity to verify the numbers stated in the Table relating to the measurements of the Premises prior to the Commencement Date of this Lease. 

1.1.1 Building. The Premises are located in the building known by the street address 626 Bancroft Way (the “Building”) in the
City of Berkeley, County of Alameda, State of California. The Building is more particularly described and depicted in Exhibit A which is attached hereto. Landlord and Tenant agree that the square footage of the Building, for all purposes
under this Lease, is 24,295. Tenant acknowledges that it has had an opportunity to verify the measurement of the Building prior to the Commencement Date of this Lease. 

1.1.2 Development. The Building is located in and forms part of the real property commonly known as the 600-630 Bancroft Way
Development, with a street address of 626 Bancroft Way, Berkeley, California (the “Development”), which comprises three different buildings and constitutes a single parcel on the assessment roll of the Alameda County Tax Assessor. For the
purposes of this Lease, the Development shall mean the Building and any common or public areas or facilities, easements, corridors, lobbies, sidewalks, loading areas, driveways, landscaped areas, skywalk, parking garages and lots, and any and
all other structures or facilities operated or maintained in connection with or for the benefit of the Building, and all parcels or tracts of land on which all or any portion of the 

  
 626 Bancroft Way
Office Lease 
 Bancroft Way, LLC:: Oncologic, Inc. 

page 1 of 23 
 Suite 3C
(8,073 rsf) 

 
Building or any of the other foregoing items are located, and any fixtures, machinery, equipment, apparatus, Systems and Equipment (as defined in § 5.5 below), furniture, and other personal
property located thereon or therein and used in connection therewith, whether title is held by Landlord or its affiliates. Landlord and Tenant agree that the square footage of the Development, for all purposes under this Lease, is 48,358. Tenant
acknowledges that it has had an opportunity to verify the measurement of the Development prior to the Commencement Date of this Lease. 

1.1.3 Parking. Tenant is entitled to sixteen (16) unreserved parking spaces in the parking lot of 600- 630 Bancroft Way. If it is
necessary at any time to reserve parking spaces or hire a guard to monitor parking, Landlord may, at its option, do so and pass through to Tenant both reasonable administrative and direct labor expenses for the guard or monitor based on
Tenant’s Pro Rata Share as defined in § 2.3 below. Notwithstanding the foregoing, Tenant may use additional spaces as available so long as they are not required for new tenants in the Property 

1.2 Term. The term (the “Term”) for which the Premises are hereby leased shall commence on the “Commencement Date,”
which shall be September 1, 2005, or, if earlier, the day on which the Premises are ready for occupancy (as defined in § 5.2 below) and shall end on August 31, 2008 (the “Expiration Date”) or any earlier date upon which the
Term may expire or be cancelled or terminated pursuant to any of the conditions or covenants of this Lease or pursuant to law. Promptly following the Commencement Date the parties hereto shall, if required by Landlord, enter into a supplementary
agreement fixing the dates of the Commencement Date and the Expiration Date in the form which is attached hereto as Exhibit C and incorporated herein by reference. 

1.2.1 Delay in Possession. If Landlord is unable for any reason to deliver possession of the Premises to Tenant at the target
commencement dated stated in the Table above, or if Landlord’s Work pursuant to § 5 below and / or any Work Letter Agreement is not substantially completed on or before such target commencement date, Landlord shall not be liable for any
damage caused thereby, nor shall this Lease be void or voidable, but Tenant shall not be liable for any Rent until possession is delivered and the Commencement Date occurs as provided in § 1.2 above. In the event of any such delay in the
occurrence of the Commencement Date, the Expiration Date shall be similarly extended by one (1) day for each such day of delay in the Commencement Date, so that the duration of the Term shall remain the same as that stated in the Table despite
the delay in the Commencement Date. Tenant may at its option terminate this Lease if the Commencement Date does not occur within sixty (60) days of the target commencement date stated in the Table above. 

1.2.2 Options to Renew. Tenant is hereby granted one (1) option to extend (the “Extension Option”) the Term of the Lease
for one (1) additional period of two (2) Lease Years (collectively the “Extension Period”). The Extension Period term shall begin the first day following the Expiration Date and shall take effect on the same terms and conditions
in effect under the Lease immediately prior to the Extension Period, except that monthly Base Rent shall be the rate which is Fair Market Value (as defined below), except that (i) Tenant shall have no further right to extend and
(ii) monthly Base Rent shall be the rate which is Fair Market Value (as defined below). The Fair Market Value shall be the effective rent (face rate less free rent) being charged for comparable space in comparable buildings in the vicinity of
the Building leased on comparable terms. 
 (a) Exercise of Option. The Extension Options may be exercised only by giving Landlord
written notice of Tenant’s irrevocable election to exercise no earlier than ten (10) months and no later than six (6) months prior to the commencement of the Extension Period. 

  
 626 Bancroft Way
Office Lease 
 Bancroft Way, LLC:: Oncologic, Inc. 

page 2 of 23 
 Suite 3C
(8,073 rsf) 

 (b) Failure to Exercise. If Tenant shall fail validly and timely to exercise either of
the options herein granted, said option shall terminate and shall be null and void and of no further force and effect. 
 (c)
Determination of Fair Market Value. Not less than one hundred and fifty (150) days prior to the commencement of the Extension Term, Landlord shall provide written notice to Tenant of its determination of the Fair Market Value. Within ten
(10) days after receiving such determination (“Tenant’s Review Period”), Tenant shall irrevocably elect, in writing, to do one of the following: (i) accept Landlord’s determination; or (ii) object to
Landlord’s determination and with such objection set forth in writing Tenant’s determination of the Fair Market Value. If Tenant so objects, Landlord and Tenant shall attempt in good faith to agree upon such Fair Market Value using their
best good faith efforts. If Landlord and Tenant fail to reach agreement within fifteen (15) days following Tenant’s Review Period (the “Outside Agreement Date”), then each party’s determination shall be submitted to
arbitration in accordance with § 25 below, but subject to the instructions set forth in this § 25 et seq. If Tenant objects to Landlord’s determination of Fair Market Value, Tenant shall pay Rent at the Fair Market Value
determined by Landlord until the matter is resolved by binding arbitration as provided below subject to retroactive adjustment after the matter is so resolved. If Tenant fails so to accept or object to Landlord’s determination of Fair Market
Value in writing within Tenant’s Review Period, Tenant shall conclusively be deemed to have approved of the Fair Market Value as determined by Landlord. The determination of the arbitrators shall be limited solely to the issue of whether
Landlord’s or Tenant’s submitted Fair Market Value for the Premises is the more accurate as determined by the arbitrators, taking into account the requirements of this § 25 et seq. 

(d) Default. Tenant’s exercise of the Options shall, at Landlord’s election, be null and void if Tenant is in Default on the
date of Tenant’s notice of exercise or at any time thereafter and prior to commencement of the Extension Period. Tenant’s exercise of the Extension Option shall not operate to cure any Default by Tenant nor to extinguish or impair any
rights or remedies of Landlord arising by virtue of such Default. 
 (e) Time. Time is of the essence of the Extension Option granted
hereunder. 
 2 Rent. The “Rent” reserved under this Lease, for the Term thereof, shall consist of the following: 

(a) “Base Rent” as shown in the Table per month, which shall be payable in advance on the first day of each and every calendar month
during the Term of this Lease, except that Tenant shall pay the first month’s Base Rent due under the Lease upon the execution and delivery of this Lease by Tenant; and 

(b) “Additional Rent” consisting of any and all other sums of money as shall become payable by Tenant to Landlord hereunder; and
Landlord shall have the same remedies for default in the payment of Additional Rent as for a default in payment of Base Rent. 
 2.2 Base
Rent Adjustment. If the CPI on any anniversary of the Commencement Date shall be greater than the CPI for the Commencement Date, monthly Base Rent commencing on each anniversary of the Commencement Date shall be adjusted by adding an
amount (the “CPI Escalation Amount”) equal to the product obtained by multiplying the monthly Base Rent by the percentage increase in the CPI from the Commencement Date through the relevant anniversary of the Commencement Date, provided
that in no event shall the new rent be less than that charged for the prior twelve-month period. “CPI” shall mean the Consumer Price Index for All Urban Consumers, All Items, San Francisco-Oakland-San José, California (Base year
1982-1984=100) published by the United States Department of Labor, Bureau of 

  
 626 Bancroft Way
Office Lease 
 Bancroft Way, LLC:: Oncologic, Inc. 

page 3 of 23 
 Suite 3C
(8,073 rsf) 

 
Labor Statistics. If the CPI becomes unavailable to the public because publication is discontinued, or otherwise, Landlord shall substitute therefor a comparable index based upon changes in the
cost of living or purchasing power of the consumer dollar published by a governmental agency, major bank, other financial institution, university, or recognized financial publisher. If the CPI is available on a monthly (or alternating monthly)
basis, the CPI for the months in which (or immediately preceding, as the case may be) the Commencement Date and Adjustment Date respectively occur shall be used. 

2.3 Additional Rent. In addition to the Base Rent and all other payments due under this Lease, Tenant shall pay to Landlord, in the
manner set forth herein, as Additional Rent, the following amounts (collectively the “Rental Adjustment”): 
 (a) Increased CAM
Charges. An amount equal to Tenant’s Pro Rata Share of the increase, if any, in total CAM Charges during each Adjustment Period over the amount of “Base CAM Charges,” which shall mean the total of CAM Charges paid or incurred, by
Landlord during the Base Year, which charges shall not exceed $.10 per square foot per month over the term of the Lease. “CAM Charges” means all expenses, costs, and amounts (other than Real Estate Taxes) of every kind and nature which
Landlord shall pay during any Adjustment Period of which any portion occurs during the Terra, because of or in connection with the ownership, management, repair, maintenance, restoration, and / or operation of the common areas of the Development,
including 
 (i) groundskeeping, landscaping, parking lot maintenance, and janitorial services for the common areas of the
Development, including amortization of capital expenses (including financing costs) incurred by Landlord after the Commencement Date in order to (A) comply with Laws, (B) reduce CAM Charges or Utilities, or (c) upgrade the utility,
efficiency, or capacity of ally utility or telecommunication systems serving tenants of the Property; and 
 (ii) operation, repair,
and maintenance of all Systems and Equipment and components thereof (including replacement of components); janitorial service; alarm and security service; window cleaning; trash removal; elevator maintenance; cleaning of walks, parking facilities,
and building walls; removal of ice; replacement of wall and floor coverings, ceiling tiles, and fixtures in lobbies, corridors, restrooms and other common or public areas or facilities; maintenance and repair of the roof and exterior fabric of the
Building, including replacement of glazing as needed; maintenance and replacement of shrubs, trees, grass, sod, and other landscaped items, irrigation systems, drainage facilities, fences, curbs, and walkways; and repaving and restriping parking
facilities. 
 (b) Increased Taxes. An amount equal to Tenant’s Pro Rata Share of the increase, if any, in total Real Estate
Taxes paid or incurred by Landlord during each Adjustment Period which exceeds the amount of “Base Real Estate Taxes,” which shall mean the total of Real Estate Taxes paid or incurred by Landlord during the Base Year. “Real Estate
Taxes” means any and all ad valorem real property taxes and any form of assessment, levy, charge, or other imposition as shown on Landlord’s tax statement from the County Assessor which Landlord shall pay during any Adjustment
Period because of or in connection with the ownership, leasing, or operation of the Development, together with reasonable legal and other professional fees, costs, and disbursements incurred in connection with proceedings to contest, determine or
reduce Real Estate Taxes. 
 (c) Increased Insurance Costs. An amount equal to Tenant’s Pro Rata Share of the increase,
if any, in total Insurance Costs paid or incurred by Landlord during each Adjustment Period which exceeds the amount of “Lease Insurance Costs,” which shall mean the total of Insurance 

  
 626 Bancroft Way
Office Lease 
 Bancroft Way, LLC:: Oncologic, Inc. 

page 4 of 23 
 Suite 3C
(8,073 rsf) 

 
Cost paid or incurred by Landlord during the Base Year. “Insurance Costs” means all insurance premiums for any insurance policies covering the Development deemed necessary or desirable
by Landlord as determined by Landlord in accordance with the reasonable practice of prudent landlords in the vicinity of the Development (including public liability, property damage, earthquake if commercially reasonable, and fire and extended
coverage insurance for the full replacement cost of the Building and any other structure of the Development as required by Landlord or its lenders for the Development). 

As used herein, “Adjustment Period” means each calendar year of which any portion occurs during the Term, excluding the Base Year and
beginning with the Adjustment Date (January 1st) that occurs in the first calendar year immediately following the Base Year; and “Tenant’s Pro Rata Share” means the percentage
labeled as such in the Table in § 1 above, calculated by dividing the agreed rentable area of the Premises (numerator) by the agreed rentable area of the Development (denominator) and expressing the resulting quotient as a percentage.
Tenant’s Pro Rata Share shall be increased during the Term in proportion to any increase in the area of the Premises in accordance with the formula stated herein. 

2.3.2 Exclusions from CAM Charges. Notwithstanding anything to the contrary in this § 2.3 et seq., Cam Charges shall
not include (A) depreciation, interest, and amortization on any mortgage or deed of trust or other debt costs or ground lease payments, if any; (B) legal fees in connection with leasing, tenant disputes, or enforcement of leases;
(C) real estate brokers’ leasing commissions; (D) improvements or alterations to tenant spaces; (E) the cost of providing any utility or service directly to, and reimbursed or paid directly by, any tenant; (F) any costs
expressly excluded from CAM Charges elsewhere in this Lease; (G) costs of arty items to the extent Landlord receives reimbursement from insurance proceeds or from a third party (such proceeds to be deducted from CAM Charges in the year in which
received); (H) capital expenditures, except those expressly permitted above; provided, all such permitted capital expenditures (together with reasonable financing charges) shall be amortized for purposes of this Lease over the shorter of
(x) their useful lives, (y) the period during which the reasonably estimated savings in Operating Expenses equals the expenditures, or (z) three (3) years. 

2.3.3 Manner of Payment. To provide for current payments of the Rental Adjustment, Tenant shall pay as Additional Rent during each
Adjustment Period an amount equal to Landlord’s estimate of the Rental Adjustment which will be payable by Tenant for such Adjustment Period. Such payments shall be made in monthly installments, commencing on the first day of the month
following the month in which Landlord notifies Tenant of the amount it is to pay hereunder and continuing until the first day of the month following the month in which Landlord gives Tenant a new notice of the estimated Rental Adjustment. It is the
intention hereunder to estimate from time to time the amount of Tenant’s Rental Adjustment for each Adjustment Period and then to effect a reconciliation in the following year based on the actual expenses incurred for the preceding Adjustment
Period, as provided in § 2.3.4 below. 
 2.3.4 Reconciliation. On or before the first day of April of each year after the first
Adjustment Period (or as soon thereafter as is practical), Landlord shall deliver to Tenant a statement (the “Statement”) setting forth the Rental Adjustment for the preceding year. If the actual Rental Adjustment for the preceding
Adjustment Period exceeds the total of the estimated monthly payments made by Tenant for such Adjustment Period, Tenant shall pay Landlord the amount of the deficiency within ten (10) days of the receipt of the Statement. If such total of
estimated payments made exceeds the actual Rental Adjustment for such Adjustment Period, then Tenant shall receive a credit for the difference against payments of Rent next due. If the credit is due from Landlord on the Expiration Date, Landlord
shall pay Tenant the amount of the credit, less any Rent then due. The obligations of Tenant and Landlord to make payments required under this § 2.3.4 shall survive the expiration or earlier termination of the Term of this Lease. Upon request,
tenant may review insurance premiums, policies, and tax bills within thirty (30) days of the Statement. 

  
 626 Bancroft Way
Office Lease 
 Bancroft Way, LLC:: Oncologic, Inc. 

page 5 of 23 
 Suite 3C
(8,073 rsf) 

 2.3.5 Proration of Rental Adjustment. If the Term does not commence on January 1 or
does not end on December 31, Tenant’s obligations to pay estimated and actual amounts towards Real Estate Taxes, CAM Charges, and Insurance Costs for such first or final calendar year shall be prorated to reflect the portion of such
year(s) included in the Term. Such proration shall be made by multiplying the total estimated or actual (as the case may be) Real Estate Taxes, CAM Charges, and / or Insurance Costs (as the case may be) for such calendar year(s), as well as the Base
Real Estate Taxes, Base CAM Charges, and / or Base Insurance Costs (as the case may be), by a fraction, the numerator of which shall be the number of days of the Term during such calendar year, and the denominator of which shall be three hundred
sixty-five (365). 
 2.3.6 Gross-up. If the Building is less than ninety-five percent (95%) occupied during the Base Year or any
Adjustment Period, then CAM Charges, Insurance Costs, and Real Estate Taxes for such Base Year or Adjustment Period (as the case maybe) shall be “grossed up” to that amount of CAM Charges, Insurance Costs, and Real Estate Taxes that, using
reasonable projections, would normally have been incurred during such Base Year or Adjustment Period (as the case may be) if the Building had been ninety-five percent (95%) occupied during such Base Year or Adjustment Period (as the case may
be), as determined in accordance with sound accounting and management practices, consistently applied. Only those component elements or items of expense of CAM Charges, Insurance Costs, and Real Estate Taxes that are affected by variations in
occupancy levels shall be grossed up. 
 2.4 Payment of Rent. Tenant shall pay the Base Rent and Additional Rent promptly when due,
without demand therefor and without any abatement, deduction, or setoff whatsoever, except as may be expressly provided in this Lease. Tenant shall pay the Rent to Landlord, in lawful money of the United States of America, at Landlord’s office
at the Building or at such other place, or to such agent and at such place, as Landlord may designate by notice to Tenant. If the Commencement Date occurs on a day other than the first day of a calendar month, the Base Rent for such calendar month
shall be prorated, and the balance of the first month’s Base Rent theretofore paid shall be credited against the next monthly installment of Base Rent. 

2.5 Late Charges. Tenant acknowledges that the late payment of any monthly Rent will cause Landlord to lose the use of that money and
incur costs and expenses not contemplated under this Lease, including administrative and collection costs and processing and account expenses, the exact amount of which it is difficult to ascertain. Therefore, if any such installment is not received
by Landlord within ten (10) days from the date it is due, Tenant shall pay Landlord a late charge equal to five percent (5%) of such installment. Landlord and Tenant agree that this late charge represents a reasonable estimate of such
costs and expenses and is fair compensation to Landlord for the loss suffered from such nonpayment by Tenant. In addition, any check returned by the bank for any reason will be considered late and will be subject to all late charges plus a Twenty
Dollar ($20.00) fee. After two such occasions in any twelve (12) month period, Landlord will have the right to require payment by a cashier’s check or money order. Acceptance of any late charge shall not constitute a waiver of
Tenant’s default with respect to such nonpayment by Tenant nor prevent Landlord from exercising any other rights or remedies available to Landlord under this Lease or at law. 

3 SECURITY DEPOSIT. Tenant shall deposit with Landlord the amount of Twenty Thousand One Hundred
Eighty-Two Dollars and Fifty Cents ($20,132.50) (the “Security Deposit”) upon Tenant’s execution and submission of this Lease. The Security Deposit shall serve as security for the prompt, full, and faithful performance by Tenant
of the terms and provisions of this Lease. Landlord shall not be required to keep the Security Deposit separate from Landlord’s general funds or pay interest on the Security Deposit. 

  
 626 Bancroft Way
Office Lease 
 Bancroft Way, LLC:: Oncologic, Inc. 

page 6 of 23 
 Suite 3C
(8,073 rsf) 

 3.1 Application of Deposit. In the event that Tenant is in Default hereunder and fails to
cure within any applicable time permitted under this Lease, or in the event that Tenant owes any amounts to Landlord upon the expiration of this Lease, Landlord may use or apply the whole or any part of the Security Deposit for the payment of
Tenant’s obligations hereunder. The use or application of the Security Deposit or any portion thereof shall not prevent Landlord from exercising any other right or remedy provided hereunder or under any Law and shall not be construed as
liquidated damages. 
 3.2 Restoration of Full Deposit. In the event the Security Deposit is reduced by such use or application,
Tenant shall deposit with Landlord, within ten (10) days after written notice, an amount sufficient to restore the full amount of the Security Deposit. If the Premises shall be expanded at any time, or if the Term shall be extended at any
increased rate of Rent, the Security Deposit shall thereupon be proportionately increased. 
 3.3 Disposition of Security Deposit.
After the Expiration Date or any earlier termination of the Lease, any remaining portion of the Security Deposit shall be returned to Tenant in accordance with the provisions of § 1950.7 of the California Civil Code. 

4 USE. The Premises are to be used for general office space, oncological laboratory testing and analysis, including
organic and inorganic chemistry, biochemistry, animal testing, and radioactive syntheis and testing and related uses, and for no other purpose without prior written consent of Landlord. 

4.1 Prohibited Uses. Tenant shall not use any portion of the Premises for purposes other than those specified hereinabove, and no use
shall be made or permitted to be made upon the Premises, nor acts done, which will increase the existing rate of insurance upon the property, or cause cancellation of insurance policies covering said property. Tenant shall not conduct or permit any
sale by auction on the Premises. Tenant shall not use, release or store or permit the usage, release, or storage of restricted by Department of Health Services, California Water Quality Control Board, Environmental Protection Agency, or any other
governmental agency or entity, and Tenant shall comply with all environmental laws, regulations, rules and requirements applicable to the Premises. Tenant shall indemnify, defend and hold Landlord harmless from and against any claims, judgements,
demands, liabilities, costs and expenses (including reasonable attorney’s fees) arising from Tenant’s breach of the above covenants. Tenant shall not commit any waste upon the Premises or any nuisance or act which may disturb the quiet
enjoyment of any tenant in the Building. 
 5 CONDITION OF PREMISES. Except as otherwise
expressly provided in any “Work Letter Agreement” which may be executed by Landlord and Tenant concurrently with their execution of this Lease and attached hereto as Exhibit D, Tenant shall accept the Premises (and the Systems and
Equipment serving the same) in an “as is” condition on the date the Term commences, and Landlord shall have no obligation to improve, alter, remodel, or otherwise modify the Premises prior to Tenant’s occupancy. Notwithstanding the
foregoing, HVAC units, fume hoods, building wiring and plumbing, and lighting shall all be in working condition. 
 5.1 Landlord’s
Preparation. Landlord shall use reasonable diligence in completing and preparing the Premises for Tenant’s occupancy in the manner and subject to the terms, conditions, and covenants set forth on or before the Commencement Date specified in
the Table, The facilities, materials, and work to be furnished, installed, and performed in the Premises by Landlord hereunder are referred to as the “Work.” Any and all other such other installations, materials, and work which may be
undertaken by or for the account of Tenant to prepare, equip, decorate, and furnish the Premises for Tenant’s occupancy are referred to as the “Tenant’s Work.” 

5.1.1 Landlord’s Work. The parties agree that Landlord’s entire obligation as to the Work shall be at Landlord’s sole
cost and expense (i) to enclose the perimeter of the Premises so as to separately demise them from any other premises in the Building and (ii) to adjust the location of three (3) doors in the Premises as agreed by the parties. 

  
 626 Bancroft Way
Office Lease 
 Bancroft Way, LLC:: Oncologic, Inc. 

page 7 of 23 
 Suite 3C
(8,073 rsf) 

 5.1.2 Tenant’s Improvement Allowance. In addition to Landlord’s performance of
the Work specified in § 5.1.1 above, Landlord agrees to make available to Tenant an improvement allowance in the amount of Ten Thousand Dollars ($10,000.00) (the “Allowance”) to be utilized by Tenant to pay the cost of any
Tenant’s Work that Tenant may elect to complete in the Premises in connection with its preparations for the occupancy of the Premises. Landlord agrees to reimburse Tenant for the cost of the Tenant’s Work, up to the maximum amount of the
Allowance, promptly after receipt from Tenant of invoices, paid receipts, and such other documentation as Landlord may reasonably require in connection with Tenant’s completion of Tenant’s Work. Tenant agrees that the Allowance shall be
repaid to Landlord as Additional Rent in monthly installments of Thirty Dollars and Eighty Eight cents ($30.88) per month for each increment of One Thousand Dollars ($1,000) or part thereof that Tenant elects to draw of the available
Supplementary Allowance as provided herein, which increase assumes an amortization period of three (3) years Tenant agrees promptly to execute and deliver to Landlord an amendment to the Lease to reflect the increase in the Rent thereunder
which results from the utilization of the Allowance described herein as soon as the amount of such increase is liquidated and as soon as such amendment is presented to Tenant for execution. The increase shall be deemed an item of Additional Rent
under § 2.3 above. Tenant agrees that the unamortized portion of the Supplementary Allowance shall be immediately due and payable to Landlord if Tenant defaults under the Lease or if the Lease terminates for any reason prior to the Expiration
Date specified in the Table in the Lease. 
 5.2 Readiness for Occupancy. The Premises shall be deemed ready for occupancy on the
earliest date on which all of the following conditions (the “Occupancy Conditions”) have first been met: 
 (a) Substantial
Completion of Work. The Work has been substantially completed; and it shall be so deemed notwithstanding the fact that minor or insubstantial details of construction, mechanical adjustment, or decoration remain to be performed, the noncompletion
of which does not materially interfere with Tenant’s beneficial use of the Premises for their intended purposes; 
 (b) Access and
Services. Reasonable means of access and facilities necessary to Tenant’s use and occupancy of the Premises, including corridors, elevators, stairways, heating, ventilating, air-conditioning, sanitary, water, and electrical facilities (but
exclusive of parking facilities) have been installed and are in reasonably good operating order and available to Tenant; and 

(c) Certificate of Occupancy or Completion. A certificate of occupancy, certificate of completion, final inspection card, or similar
required governmental approval (temporary or final) has been issued by the City of Berkeley permitting use of the Premises for office and laboratory purposes. 

5.2.2 Tenant Delays. If the occurrence of any of the Occupancy Conditions and Landlord’s preparation of the Premises for occupancy
shall be delayed owing to either (a) any act, omission, or failure of Tenant or any of its employees, agents, or contractors which shall continue after Landlord shall have given Tenant reasonable notice that such act, omission, or failure would
result in delay, and such delay shall have been unavoidable by Landlord in the exercise of reasonable diligence and prudence; or (b) the nature of any items of additional work or change orders that Landlord undertakes to perform for the account
of Tenant (including any delays incurred by Landlord, after making reasonable efforts, in procuring any materials, equipment, or fixtures of a kind or nature 

  
 626 Bancroft Way
Office Lease 
 Bancroft Way, LLC:: Oncologic, Inc. 

page 8 of 23 
 Suite 3C
(8,073 rsf) 

 
not used by Landlord as part of its standard construction) (collectively “Tenant Delays”), then the Premises shall be deemed ready for occupancy on the date when they would have been
ready but for such Tenant Delays. 
 5.3 Early Entry. During any period that Tenant shall be permitted to enter the Premises prior to
the Commencement Date other than to occupy the same (e.g., to perform alterations or improvements), Tenant shall comply with all terms and provisions of this Lease, except those provisions requiring the payment of Rent. Landlord shall permit
early entry, provided the Premises are legally available and Landlord has completed any Work required under this Lease. 
 5.4 Notice of
Defects. It shall be conclusively presumed upon Tenant’s taking actual possession of the Premises that the same were in satisfactory condition (except for latent defects) as of the date of such taking of possession, unless within thirty
(30) days after the Commencement Date Tenant shall give Landlord notice in writing specifying the respects in which the Premises were not in satisfactory condition. 

5.5 Systems and Equipment. As used in this Lease, “Systems and Equipment” means collectively any existing plant, machinery,
transformers, duct work, fume hoods, intrabuilding network cables and wires that transmit voice, data, and other telecommunications signals (“INC”), and other equipment, facilities, and systems designed to supply water, heat, ventilation,
air conditioning and humidity or any other services or utilities, or comprising or serving as any component or portion of the electrical, gas, steam, plumbing, sprinkler, communications, alarm, security, or fire/life/safety systems or equipment, or
any other mechanical, electrical, electronic, computer, or other systems or equipment for the Building. 
 6 ASSIGNMENT AND
SUBLETTING. Tenant agrees that it shall not assign, sublet, mortgage, hypothecate, or encumber this Lease, nor permit or allow the Premises or any part thereof to be used or occupied by others, without the prior
written consent of Landlord in each instance, which consent shall not unreasonably be witheld. The actions described in the foregoing sentence are referred to collectively herein as “Transfers.” Tenant shall give Landlord written notice of
its intent to effectuate any Transfer not less than thirty (30) days prior to the date of any such proposed Transfer. If the Premises or any part thereof be sublet or occupied by anybody other than Tenant, Landlord may, after default by Tenant,
collect rent from the subtenant or occupant and apply the net amount collected to the Rent herein reserved; but no Transfer, occupancy, or collection shall be deemed a waiver of the provisions hereof, the acceptance of the subtenant or occupant as
tenant or a release of Tenant from the further performance hereunder by Tenant. The consent by Landlord to a Transfer shall not relieve Tenant from obtaining the Landlord’s express written consent to any further Transfer. In no event shall any
permitted sublessee assign or encumber its sublease or further sublet all or any portion of its sublet space, or otherwise suffer or permit the sublet space or any part thereof to be used or occupied by others, without Landlord’s prior written
consent in each instance. Tenant shall pay as Additional Rent Landlord’s reasonable costs incurred in the review of any request to sublease or assign the Premises or any portion thereof, including the costs of Landlord’s attorneys’
fees incurred in reviewing and documenting the proposed transaction. 
 6.1 Landlord’s Recapture Right. Tenant’s transfer
notice shall be deemed an offer from Tenant to Landlord whereby Landlord (or Landlord’s designee) may, at its option, terminate this Lease as to all or the affected portion or the Premises (as the case may be) as of the effective date of the
proposed Transfer. Landlord may exercise its recapture right by notice to Tenant at any time within thirty (30) days after Landlord’s receipt of Tenant’s Transfer Notice; and during such thirty-day period Tenant shall not assign this
Lease nor sublet such space to any person. Notwithstanding the foregoing, Landlord shall not terminate this Lease if Landlord has approved a sublease. 

6.1.1 Date of Termination. If Landlord exercises its option to terminate this Lease as provided in § 6.1 above, this Lease shall
end and expire on the date that such Transfer was to be effective or commence, as the case may be, and the Base Rent and Additional Rent shall be paid and apportioned to such date. 

  
 626 Bancroft Way
Office Lease 
 Bancroft Way, LLC:: Oncologic, Inc. 

page 9 of 23 
 Suite 3C
(8,073 rsf) 

 6.2 Transfer Premium. If Landlord shall give its consent to any assignment of this Lease
or to any sublease, Tenant shall in consideration therefor pay to Landlord, as Additional Rent, the following amounts (collectively the “Transfer Premium”): 

(a) in the case of an assignment, an amount equal to fifty percent (50%) of all sums and other considerations paid to Tenant by the
assignee for or by reason of such assignment, but excluding the following: (1) the brokerage commission or finder’s fee paid by Tenant in connection with the assignment; (2) reasonable legal fees and reimbursements; and
(3) reasonable amounts paid by Tenant for tenant improvements constructed for the assignee; and 
 (b) in the case of a sublease, fifty
percent (50%) of any rents, additional charge, or other consideration payable under the sublease to Tenant by the subtenant which is in excess of the Base Rent and Additional Rent accruing during the term of the sublease in respect of the
subleased space (at the rate per square foot payable by Tenant hereunder) pursuant to the terms hereof, but excluding the following: (1) the brokerage commission or finder’s fee paid by Tenant in connection with the sublease;
(2) reasonable legal fees and disbursements; and (3) reasonable amounts paid by Tenant for tenant improvements constructed for the subtenant. 

The sums payable as the Transfer Premium under this § 6.2 shall be paid to Landlord as and when payable by the subtenant or assignee to
Tenant. 
 7 COMPLIANCE WITH LAWS. Tenant shall use the Premises in compliance with all
applicable federal, state, county, and local governmental anti municipal laws, statutes, ordinances, rules, regulations, codes, decrees, orders, and other such requirements, and decisions by courts in cases where such decisions are considered
binding precedents in the State of California (the “State”), and decisions of federal courts applying the laws of the State (collectively “Laws”). Tenant shall, at its sole cost and expense, promptly comply with each and all of
such Laws, and also with the requirements of any board of fire underwriters or other similar body now or hereafter constituted to deal with the condition, use, or occupancy of the Premises, except in the case of required structural changes not
triggered by Tenant’s change in use of the Premises or Tenant’s alterations, additions, or improvements therein. Tenant shall comply with all applicable Laws regarding the physical condition of the Premises, but only to the extent that the
applicable Laws pertain to the particular manner in which Tenant uses the Premises or the particular use to which Tenant puts the Premises, if different from that permitted under § 4 of this Lease. Tenant shall also comply with all applicable
Laws which do not relate to the physical condition of the Premises and with which only the occupant can comply, such as laws governing maximum occupancy, workplace smoking, VDT regulations, and illegal business operations, such as gambling. The
judgement of any court of competent jurisdiction or the admission of Tenant in any judicial action, regardless of whether Landlord is a party thereto, that Tenant has violated any of such Laws shall be conclusive of that fact as between Landlord and
Tenant 
 7.1 Code Costs. Notwithstanding anything to the contrary in this § 7, if the requirement of any public authority
obligates either Landlord or Tenant to expend money in order to bring the Premises and/or any area of the Building into compliance with Laws as a result of (1) Tenant’s particular use or alteration of the Premises other than as shown on
Exhibit A which assumes a use of office and standard laboratory use; (2) Tenant’s change in the use of the Premises; (3) the manner of conduct of Tenant’s business or operation of its installations, equipment, or other property
therein; (4) any cause or condition created by or at the instance of Tenant, other than by Landlord’s performance of any work for or on behalf of Tenant; or (5) breach of any of Tenant’s obligations hereunder, then Tenant shall
bear all costs (“Code Costs”) of bringing the Premises and/or building into compliance with Laws, whether such Code Costs are related to structural or nonstructural elements of the Premises or Building. 

  
 626 Bancroft Way
Office Lease 
 Bancroft Way, LLC:: Oncologic, Inc. 

page 10 of 23 
 Suite 3C
(8,073 rsf) 

 8 HAZARDOUS MATERIALS. Tenant shall not cause or permit to
occur (I) any violation of applicable Laws now or hereafter enacted or issued, related to environmental conditions on, under, or about the Premises arising from Tenant’s leasehold interest in or use or occupancy of the Premises including,
soil and groundwater conditions and (ii) the use, generation, release, manufacture, refining, production, processing, storage, or disposal of any Hazardous Materials on, under, or about the Premises or the Building or the transportation to or
from the Premises or the Building of any Hazardous Materials, except de minimis amounts of Hazardous Materials that are commonly used in office products or are present in ordinary cleaning supplies. All such office products and cleaning supplies
will be used and stored in a manner that complies with all Laws. Tenant shall at its own expense make all submissions to, provide all information required by, and comply with all requirements of all governmental authorities under Laws relating to
Hazardous Materials. Should any governmental entity having jurisdiction over the Premises demand that a remediation plan be prepared or that remediation be undertaken because of any deposit, spill, discharge, or other release of Hazardous Materials
that occurs during the Term of this Lease at or from the Premises which arises at any time from Tenant’s use or occupancy of the Premises or from acts or omissions of Tenant, its agents, employees, representatives, or invitees, then Tenant
shall, at its own expense, prepare and submit the required plans. Tenant shall indemnify, defend, protect, and hold Landlord, its partners, officers, directors, beneficiaries, shareholders, agents, employees, and lenders harmless from all fines,
suits, procedures, claims, liabilities, and actions of every kind, and all costs associated therewith (including investigation costs and attorneys’ and consultants’ fees) arising out of or in any way connected with any deposit, spill,
discharge, or other release of Hazardous Materials that occurs during the Term of this Lease, at or from the Premises which arises at any time from Tenant’s use or occupancy of the Premises or from Tenant’s failure to provide all
information, make all submissions, and take all steps requires by any governmental authorities having jurisdiction over the Premises. Tenant’s obligations and the indemnity hereunder shall survive the expiration or earlier termination of this
Lease. The term Hazardous Materials as used herein shall include any chemical, substance, or material which has been or is hereafter determined by any federal, state, or local governmental agency to be capable of posing a risk of injury to
health or safety including petroleum, asbestos, polychlorinated biphenyls, radioactive materials, and radon gas. 
 8.1 Permitted
Hazardous Materials. Notwithstanding anything to the contrary herein, Landlord agrees that Tenant shall be permitted to conduct industry-standard procedures for oncological testing and analysis in the Premises, including standard tests requiring
the use of radioactive materials, provided, however, that the use and storage complies with all laws . Prior to the use of any Hazardous Material in the Premises and at such times as Landlord may reasonably request, Tenant shall provide Landlord
with a written list identifying any Hazardous Material proposed or then used, stored, or maintained upon the Premises, the use and approximate quantity of each such material, a copy of any material safety data sheet (“MSDS”) issued by the
manufacturer thereof, written information concerning the removal, transportation, and disposal of the same, and such other information as Landlord may reasonably require or as may be required by law. Tenant agrees unconditionally to indemnify,
defend, protect, and hold Landlord harmless against any claims, liabilities, demands, losses, damages, consequential damages, and the like, including reasonable attorneys’ fees and court costs (collectively “Claims”) that may be
maintained, claimed, or asserted against Landlord as a result of Tenant’s use of or the presence of Hazardous Materials introduced by Tenant in the Premises. 

8.2 Cleanup. If any Hazardous Material is released, discharged, or disposed of by Tenant or any other occupant of the Premises, or their
employees, agents, or contractors, on or about the Development in violation of the foregoing provisions, Tenant shall immediately, properly, and in compliance with applicable Laws clean up and remove the Hazardous Material from the Development and
any other affected property and clean or replace any affected personal property (whether or not owned by Landlord), at Tenant’s expense. Such clean up and removal work shall be subject to Landlord’s prior written approval (except in
emergencies), and shall include any testing, investigation, and the preparation and implementation of any remedial action plan required by any governmental body having jurisdiction or 

  
 626 Bancroft Way
Office Lease 
 Bancroft Way, LLC:: Oncologic, Inc. 

page 11 of 23 
 Suite 3C
(8,073 rsf) 

 
reasonably required by Landlord. If Tenant shall fail to comply with the provisions of this § 8.2 within five (5) days after written notice by Landlord, or such shorter time as may be
required by Laws or in order to minimize any hazard to persons or property, Landlord may (but shall not be obligated to) arrange for such compliance directly or as Tenant’s agent through contractors or other parties selected by Landlord, at
Tenant’s expense (without limiting Landlord’s other remedies under this Lease or applicable Laws). 
 9 MAINTENANCE
REPAIRS, ALTERATIONS. After completion of Landlord’s Work, if any, pursuant to § 5.1 above, Tenant shall, at his own expense and at all times, maintain the Premises in good and safe
condition, including window glass and the Systems and Equipment serving the Premises and shall surrender the same at termination hereof in as good condition as received, normal wear and tear excepted. Tenant shall be responsible for all repairs
required, excepting only the roof, skylights, exterior walls, and structural foundations, which shall be maintained by Landlord. Landlord shall maintain in good condition the common areas of the property, such as sidewalks, driveways, lawns, and
shrubbery. Landlord shall be responsible for electrical and plumbing supplied by Landlord and embedded in floor or side walls and not accessible from the Premises. No improvement or alteration of the Premises shall be made without the prior written
consent of the Landlord. Prior to the commencement of any substantial repair, improvement, or alteration, Tenant shall give Landlord at least five (5) days’ written notice in order that Landlord may post appropriate notices of
nonresponsibility to avoid any liability for liens for any such work of improvement on the Premises. If Tenant requests that Landlord perform any maintenance or repair work in the Premises the responsibility for which is allocated to Tenant under
this Lease, Landlord may agree to perform such maintenance or repair at Landlord’s sole discretion. If Landlord agrees to perform such maintenance or repair work, Tenant shall pay, as Additional Rent, Landlord’s standard charges for such
maintenance or repair work within twenty (20) days after receipt of Landlord’s invoice therefor. Landlord’s standard maintenance and repair charges shall be subject to adjustment from time to time in Landlord’s sole discretion,
and all invoices for such maintenance or repair charges shall include a service charge in the amount of fifteen percent (15%) of the invoiced cost or any such maintenance or repair work performed by Landlord at Tenant’s request. 

9.1 Restoration of Premises. At or before the Expiration Date or the date of any earlier termination of this Lease, or as promptly as
practicable using Tenant’s best efforts after such an earlier termination date, Tenant, at its expense, shall do all of the following: 
  

	 	(a)	surrender possession of the Premises in the condition required under § 9 above, ordinary wear and tear excepted; 

  

	 	(b)	surrender all keys, any key cards, and any parking stickers or cards to Landlord and give Landlord in writing the combinations of any locks or vaults then remaining in the Premises; 

 

	 	(c)	remove from the Premises all of Tenant’s Property, including any data wiring and cabling that Tenant has installed, except such items thereof as Tenant shall have expressly agreed in writing with Landlord were to
remain and to become the property of Landlord; and 

  

	 	(d)	fully repair any damage to the Premises or the Development resulting from such removal. 

Tenant’s obligations herein shall survive the expiration or earlier termination of the Lease, unless expressly provided to the contrary
herein. All improvements and other items in or upon the Premises 

  
 626 Bancroft Way
Office Lease 
 Bancroft Way, LLC:: Oncologic, Inc. 

page 12 of 23 
 Suite 3C
(8,073 rsf) 

 
(except Tenant’s Property), whether installed by Tenant or Landlord, shall be Landlord’s property and shall remain upon the Premises, all without compensation, setoff, allowance, or
credit to Tenant; provided, however, that if prior to such expiration or earlier termination Landlord so directs by notice, Tenant shall promptly remove such of the improvements in the Premises as are designated in such notice and shall restore the
Premises to their condition prior to the installation of such Improvements. Notwithstanding the foregoing, Landlord shall not require removal of customary office improvements installed pursuant to the Work Letter Agreement, if any (except as
expressly provided to the contrary therein), or installed by Tenant with Landlord’s written approval (except as expressly required by Landlord in connection with granting such approval), nor shall the removal of the cold room and restoration of
that space be required. 
 9.1.1 Restoration of Fixtures. If any of Tenant’s alterations or changes to the Premises permitted
under § 9 above shall involve the removal of any fixtures, equipment, or other property in the Premises which are not Tenant’s Property, such fixtures, equipment, or other property shall be promptly replaced, at Tenant’s expense, with
new fixtures, equipment, or other property (as the case may be) of like utility and at least equal value, unless Landlord shall otherwise expressly consent in writing; and Tenant shall, store and preserve, at Tenant’s sole cost and expense, any
such fixtures, equipment or property so removed and shall return same to Landlord upon the expiration or sooner termination of this Lease. 

9.2 HVAC Maintenance Contract Costs. Notwithstanding anything to the contrary herein, Tenant shall bear the cost, up to a maximum of
Five Hundred Dollars ($500.00) per HVAC compressor unit serving the Premises per annum, of the annual HVAC maintenance contract for the maintenance of the HVAC serving the Premises, which costs shall be payable in addition to and not as part of
Tenant’s Pro Rata Share of CAM Charges payable under § 2.3 above. Such costs shall be payable upon demand to Landlord as Additional Rent. 

9.3 Janitorial Services. Notwithstanding anything to the contrary herein, Tenant shall contract and pay, at its sole cost and expense,
for all janitorial services necessary to maintain the Premises in the condition required under this Lease, which costs shall be payable in addition to and not as part of Tenant’s Pro Rata Share of CAM Charges payable under § 2.3 above.
Notwithstanding the foregoing, if certain areas of the Building shall be shared as common area, Landlord shall provide janitorial services and bill Tenant for its Pro Rata Share of those expenses as Additional Rent under § 2.3 above. 

9.4 Fume Hood Maintenance. Tenant shall be responsible for obtaining the required annual certification and maintenance as required for
any and all fume hoods in the Premises. Notwithstanding the foregoing, Landlord may elect to undertake the maintenance and annual certification of any such fume hoods in the Premises, in which case Tenant agrees to reimburse Landlord for all
reasonable costs incurred, promptly after receipt of Landlord’s bill therefor and as Additional Rent hereunder, for all costs incurred in connection with such maintenance and certification. 

10 ENTRY AND INSPECTION. Tenant shall permit Landlord or Landlord’s agents to enter
upon the Premises at reasonable times and upon reasonable notice for the purpose of inspecting the same, will permit Landlord at any time within one hundred twenty (120) days prior to the expiration of this Lease to place upon the Premises any
usual “To Lease” or “Available” signs, and will permit persons desiring to lease the same to inspect the Premises thereafter. 
 11
INDEMNIFICATION OF LANDLORD. Landlord shall not be liable for any damage or injury to Tenant, to any other person, or to any property occurring on the demised Premises or any part
thereof, and Tenant agrees to indemnify, defend, protect, and hold Landlord harmless from any liabilities and/or claims for damages, no matter how caused, which may arise in connection with Tenant’s use or occupancy of the Premises, except
those caused by any grossly negligent act or intentional misconduct of Landlord or Landlord’s agents acting in the course of their agency. 

  
 626 Bancroft Way
Office Lease 
 Bancroft Way, LLC:: Oncologic, Inc. 

page 13 of 23 
 Suite 3C
(8,073 rsf) 

 12 LANDLORD’S INSURANCE. Landlord shall,
as part of Insurance Costs, maintain “all risk” property damage insurance containing an agreed amount endorsement covering not less than one hundred percent (100%) of the full insurable replacement cost valuation of (1) the
Building and the tenant improvements, betterments, and the alterations thereto; and (2) Landlord’s personal property, business papers, furniture, fixtures, and equipment (collectively “Landlord’s Property”), exclusive of the
costs of excavation, foundations, footings, and risks required to be covered by Tenant’s insurance, and subject to commercially reasonable deductibles. Landlord shall also, as part of Insurance Costs, obtain and keep in full force the following
policies of insurance: (a) commercial general liability insurance; (b) loss of rent insurance (also known as rent continuation insurance); (c) workers’ compensation insurance, if required by applicable Law; and (d) such
other insurance as Landlord deems appropriate or as may be required by any Holder or ground lessor. 
 13 TENANT’S
INSURANCE. Tenant shall obtain arid maintain in effect at all times during Tenant’s possession of the Premises the following insurance coverages and policies: 

(a) Liability Insurance. Tenant shall maintain a policy of commercial general liability insurance, which shall include coverages for
(1) personal injury; (2) broad-form contractual liability; (3) owner’s (i.e., Tenant’s) & contractor’s protective; and (4) broad-form property damage liability. The minimum limits of liability shall
be a combined single limit with respect to each occurrence of not less than One Million Dollars ($1,000,000) and an aggregate limit of not less than Two Million Dollars ($2,000,000). The policy shall contain a cross-liability endorsement and a
severability of interest clause. Tenant shall increase the insurance coverage as required by Landlord’s lender or if Landlord’s insurance consultant believes that the coverage is not adequate. 

(b) Tenant’s Business Personal Property Insurance. Tenant shall maintain on all of its business personal property, including
valuable business papers and accounts receivable; operating supplies; inventory; and furniture, fixtures, and equipment (whether owned, leased, or rented) (collectively “Business Personal Property”) an “all risk” property damage
insurance policy including coverages for sprinkler leakage and containing an special form replacement cost (or, if applicable, a business owner’s policy with a no-coinsurance provision) in an amount not less than one hundred percent
(100%) of the full replacement cost valuation of such Business Personal Property. The proceeds from any such policy shall be used by Tenant for the replacement of such Business Personal property. 

(c) Business Interruption/Extra Expense Insurance. Tenant shall maintain business interruption or (if applicable) contingent business
interruption and extra expense insurance in such amounts as will reimburse Tenant for direct or indirect loss of earnings and incurred costs attributable to the perils commonly covered by Tenant’s property insurance described in § 13(b)
above but in no event less than the average total of Tenant’s annual gross receipts during the three-year period immediately preceding such interruption or loss. Such insurance will be carried with the same insurer that issues the insurance for
Tenant’s Business Personal Property pursuant to §13(b) above. Notwithstanding the foregoing, this coverage condition may be waived upon obtaining 100% annual Rental Coverage Expense in lieu of Business Interruption/Extra Expense Insurance.

  
 626 Bancroft Way
Office Lease 
 Bancroft Way, LLC:: Oncologic, Inc. 

page 14 of 23 
 Suite 3C
(8,073 rsf) 

 13.2 Tenant’s Insurance Criteria. All insurance required to be maintained by Tenant
under this Lease shall conform to the following criteria: 
 (i) Tenant’s insurance shall be issued by insurance companies
authorized to do business in the State of California with a financial rating of at least B+ for any property insurance and at least B+ for any liability insurance, as rated in the most recent edition of Best’s Insurance Reports; 

(ii) Tenant’s insurance shall be issued as primary and noncontributory; 

(iii) Tenant’s liability and property insurance policies shall name Tenant as the insured and Landlord, Landlord’s agents,
and any ground lessors and Holders (as such terms are defined in § 26) whose names shall have been furnished to Tenant as additional insureds; 

(iv) Tenant’s insurance shall contain an endorsement requiring at least thirty (30) days’ written notice from the
insurance company to each insured and additional insured before cancellation or any material change in the coverage, scope, or amount of any policy; and 

with respect to damage to or loss of Tenant’s Business Personal Property, a waiver of subrogation must be obtained, as required under
§ 14 below. 
 13.3 Blanket Coverage. All of the insurance requirements set forth herein on the part of Tenant to be observed
shall be deemed satisfied if the Premises are covered by a blanket insurance policy complying with the limits, requirements, and criteria contained in this § 13 et. seq. insuring all or most of Tenant’s facilities in California.

 13.4 Evidence of Coverage. A duplicate original policy or a certificate of insurance shall be deposited with Landlord at the
commencement of the Term or, if earlier, upon Tenant’s taking possession of the Premises; and on renewal of the policy a certificate of insurance listing the insurance coverages required hereunder and naming the appropriate additional insureds
shall be deposited with Landlord not less than seven (7) days before expiration of the policy. 
 14 WAIVER OF
SUBROGATION. To the maximum extent permitted by insurance policies which Landlord and Tenant are required to maintain under §§ 12 and 13 above, Tenant and Landlord, for the benefit of each other, waive any
and all rights of subrogation which might otherwise exist. Landlord and Tenant intend that their respective property loss risks shall be borne by responsible insurance carriers to the extent above provided, and Landlord and Tenant hereby agree to
look solely to, and seek recovery only from, their respective insurance carriers in the event of a property loss to the extent that such coverage is agreed to be provided hereunder. The parties each hereby waive all rights and claims against each
other for such losses and waive all rights of subrogation of their respective insurers, provided such waiver of subrogation shall not affect the right of the insured to recover thereunder. The parties agree that their respective insurance policies
are now, or shall be, endorsed such that said waiver of subrogation shall not affect the right of the insured to recover thereunder, so long as no material additional premium is charged therefor. 

15 UTILITIES AND SERVICES. Tenant shall be responsible for the payment directly to their
suppliers of the charges for all utilities, including, gas, water, electricity, heat, and other services delivered to or consumed in the Premises. If any such services are not separately metered to Tenant, Tenant shall pay to Landlord pursuant to
§ 2.3 above a reasonable proportion, as determined by Landlord by means of submetering or good-faith estimation, of all charges jointly metered with other premises. Notwithstanding the foregoing, Landlord may apply, and bill Tenant as
Additional Rent for, an equitable allocation, as determined in Landlord’s reasonable judgement, of the costs of any unmetered services consumed by Tenant in the Premises in any case where Tenant’s usage of such unmetered services is
reasonably calculated to be disproportionate to that of other Tenants in the Building. 
 15.1 Interruption of Services. Landlord does
not warrant that any services or utilities provided hereunder for Tenant’s use in the Premises will be free from shortages, failures, variations, or 

  
 626 Bancroft Way
Office Lease 
 Bancroft Way, LLC:: Oncologic, Inc. 

page 15 of 23 
 Suite 3C
(8,073 rsf) 

 
interruptions caused by repairs, maintenance, replacements, improvements, alterations, changes of service, strikes, lockouts, labor controversies, accidents, inability to obtain services, fuel,
steam, water, or supplies, governmental requirements or requests, or other causes beyond Landlord’s reasonable control, including interference with light or other incorporeal hereditaments and any interruption in services or any failure to
provide services to Landlord by a designated utility company at the demarcation point at which Landlord accepts responsibility for such service or at any point prior thereto, which interference impedes Landlord in furnishing plumbing, HVAC,
electrical, sanitary, life safety, elevator, telecommunications, or other Building services, utilities, or the Systems and Equipment. None of the same shall be deemed an eviction or disturbance of Tenant’s use and possession of the Premises or
any part thereof, shall render Landlord liable to Tenant for abatement of Rent, or shall relieve Tenant from performance of Tenant’s obligations under this Lease. Landlord in no event shall be liable for damages by reason of loss of profits,
business interruption, or other compensatory or consequential damages. 
 15.2 Additional Services or Utilities. Landlord shall,
subject to all applicable Laws, seek to provide such utilities or services in excess of those Landlord is required to provide under § 15 as Tenant may from time to time request, if the same are reasonable and feasible for Landlord to provide
and do not involve modifications or additions to the Building or the Systems and Equipment and if Landlord shall receive Tenant’s request within a reasonable period prior to the time such extra utilities or services are required. Landlord may
comply with written or oral requests by any officer or employee of Tenant, unless Tenant shall notify Landlord of, or Landlord shall request, the names of authorized individuals and procedures for written requests. Use of the Premises, or any part
thereof, in a manner exceeding the design conditions (including occupancy and connected electrical load) for the heating or cooling units in the Premises, or rearrangement of partitioning which interferes with normal operation of the HVAC system in
the Premises, may require changes in the HVAC system servicing the Premises. Such changes shall be made by Tenant at its expense. Tenant shall not change or adjust any closed or sealed thermostat or other element of the HVAC system without
Landlord’s express prior written consent. Tenant shall, for such extra utilities or services, pay such charges as Landlord shall from time to time establish. All charges for extra utilities or services or those requested outside business hours
shall be due at the same time as the installment of Base Rent with which the same are billed, or if billed separately, shall be due within twenty (20) days after such billing. All invoices for such additional services or utilities shall include
a service charge in the amount of fifteen percent (15%) of the invoiced cost or any such additional utilities or services supplied by Landlord at Tenant’s request. 

15.2.1 Additional Building Expenses. In addition to the cost of Tenant’s Utilities payable under § 15 above and the CAM
Charges payable under § 2.3(a) above, Tenant agrees to pay, as Additional Rent hereunder, its Pro Rata Share of (i) the cost to Landlord, if arty, to guard or monitor the parking lot associated with the Building, as provided in §
1.1.3 above; and (ii) the cost to Landlord of scavenger services for the Building, as provided under § 15 above. 
 16
SIGNS. Landlord reserves the exclusive right to the roof, side and rear walls of the Premises. Tenant shall not construct any projecting sign or awning without the prior written consent of Landlord. 

17 CONDEMNATION. If any part of the Premises shall be taken or condemned for public use, and a part thereof remains which
is susceptible of occupation hereunder, this Lease shall, as to the part taken, terminate as of the date the condemnor acquires possession, and thereafter Tenant shall be required to pay such proportion of the rent for the remaining term as
remaining square footage of the Premises bears to the total original square footage of the Premises at the date of condemnation; provided, however, that Landlord at its option may terminate this Lease as of the date the condemnor acquires
possession. In the event that the demised Premises are condemned in whole, or that a portion is condemned of such size that the remainder is not suitable for Tenant’s beneficial enjoyment of the Premises for their intended purposes, this Lease
shall terminate upon the date upon which the condemner acquires possession. All sums which may be payable on 

  
 626 Bancroft Way
Office Lease 
 Bancroft Way, LLC:: Oncologic, Inc. 

page 16 of 23 
 Suite 3C
(8,073 rsf) 

 
account of any condemnation shall belong to the Landlord, and Tenant shall not be entitled to any part thereof; provided however, that Tenant shall be entitled to retain any amount awarded to him
for his trade fixtures or moving expenses. 
 18 SURRENDER AND RESTORATION. At or before
the Expiration Date or the date of any earlier termination of this Lease, or as promptly as practicable using Tenant’s best efforts after such an earlier termination date, Tenant, at its expense, shall do all of the following: 

(a) surrender possession of the Premises in the condition required under § 5 above, ordinary wear and tear excepted; 

(b) surrender all keys, any key cards, and any parking stickers or cards to Landlord and give Landlord in writing the combinations of any
locks or vaults then remaining in the Premises; 
 (c) remove from the Premises all of Tenant’s Property, except such items thereof as
Tenant shall have expressly agreed in writing with Landlord were to remain and to become the property of Landlord, which shall include the cold room and additional fume hoods; and 

(d) fully repair any damage to the Premises or the Property resulting from such removal. 

Tenant’s obligations herein shall survive the termination of the Lease. All improvements and other items in or upon the Premises (except Tenant’s
Property), whether installed by Tenant or Landlord, shall be Landlord’s property and shall remain upon the Premises, all without compensation, allowance, or credit to Tenant; provided, however, that if prior to such termination Landlord so
directs by notice, Tenant shall promptly remove such of the Improvements in the Premises as are designated in such notice and shall restore the Premises to their condition prior to the installation of such Improvements. Notwithstanding the
foregoing, Landlord shall not require removal of customary office improvements installed pursuant to the Work Letter Agreement, if any (except as expressly provided to the contrary therein), or installed by Tenant with Landlord’s written
approval (except as expressly required by Landlord in connection with granting such approval). 
 18.2 Tenant’s Failure to Remove or
Restore. If Tenant shall fail to perform any repairs or restoration or fail to remove any items from the Premises as required under this Article 18, Landlord may do so, and Tenant shall pay Landlord the cost thereof upon demand. All property
removed from the Premises by Landlord pursuant to any provisions of this Lease or any Law may be handled or stored by Landlord at Tenant’s expense, and Landlord shall in no event be responsible for the value, preservation, or safekeeping
thereof. All property not removed from the Premises or retaken from storage by Tenant within thirty (30) days after expiration or earlier termination of this Lease or Tenant’s right to possession shall at Landlord’s option be
conclusively deemed to have been conveyed by Tenant to Landlord as if by bill of sale without payment by Landlord. Unless prohibited by applicable Laws, Landlord shall have a lien against such property for the costs incurred in removing and storing
the same. 
 19 DESTRUCTION OF PREMISES. Landlord and Tenant agree that their respective
rights and obligations in the event of any damage or destruction of the Premises or Building shall be governed exclusively by this Lease. Tenant, as a material inducement to Landlord entering into this Lease, irrevocably waives and releases
Tenant’s rights under California Civil Code §§ 1932(2), 1933(4), and 1942, as the same may be modified or replaced hereafter. No damages, compensation, or claim shall be payable by Landlord for any inconvenience, interruption, or
cessation of Tenant’s business or any annoyance arising from any damage to or destruction of all or any portion of the Premises or Building. 

19.1 Partial Destruction of Premises. In the event of a partial destruction of the Premises during the term hereof from any cause,
Landlord shall forthwith repair the same at Landlord’s expense, provided 

  
 626 Bancroft Way
Office Lease 
 Bancroft Way, LLC:: Oncologic, Inc. 

page 17 of 23 
 Suite 3C
(8,073 rsf) 

 
that such repairs can be made within sixty (60) days under existing Laws; but such partial destruction shall not terminate this Lease, except that Tenant shall be entitled to a proportionate
reduction of Rent while such repairs are being made, based upon the extent to which the making of such repairs shall interfere with Tenant’s beneficial enjoyment of the Premises for their intended purposes. If such repairs cannot be made within
sixty (60) days, Landlord at its option may make the same within a reasonable time, this Lease continuing in effect with the rent proportionately abated as aforesaid; and in the event that Landlord shall not elect to make such repairs which
cannot be made within sixty (60) days, this Lease may be terminated by either party upon written notice, effective as of the date of such notice. 

19.2 Destruction of Building. In the event that the Building is destroyed to an extent of not less than one-third of the replacement
costs thereof, Landlord may elect to terminate this Lease, whether the Premises be injured or not. A total destruction of the Building shall terminate this Lease. 

19.3 Disputes. In the event of any dispute between Landlord and Tenant with respect to the provisions hereof, the matter shall be
settled by arbitration in accordance with the provisions of § 25 below. 
 20 TENANT’S
DEFAULT. The occurrence of any one or more of the following events shall constitute a material breach and default (“Event of Default”) of this Lease by Tenant: 

(a) Tenant’s failure to pay any Rent or any other charges required to be paid by Tenant under this Lease, where such failure continues
for ten (10) days after such payment is due and payable; 
 (b) Tenant’s failure promptly and fully to perform any other covenant,
condition, or agreement contained in this Lease, where such failure continues for thirty (50) days after written notice thereof from Landlord to Tenant; 

(c) Tenant’s failure to comply with the Rules, unless such failure is cured within five (5) days after notice; provided, that if the
nature of Tenant’s failure is such that more than five (5) days are reasonably required in order to cure, Tenant shall not be in Default if Tenant commences to cure within such period and thereafter diligently and continuously prosecutes
such cure to completion; 
 (d) Tenants abandonment or vacation of the Premises; 

(e) any material misrepresentation or omission herein or in any financial statements or other materials provided by Tenant or any Guarantor in
connection with negotiating or entering this Lease or in connection with any Transfer under § 6 above; 
 (f) cancellation of any
guaranty of this Lease by any Guarantor; 
 (g) Failure by Tenant to clue within any applicable Limes permitted thereunder any default under
any other lease for space any other building owned or managed by Landlord or its affiliates now or hereafter entered by Tenant; and any Default hereunder not cured within the times permitted for cure herein shall, at Landlord’s election,
constitute a default under any other such lease or leases; 
 (h) The levy of a writ of attachment or execution on this Lease or on any of
Tenant’s property; 
 (i) Tenant’s or any Guarantor’s general assignment for the benefit of creditors or arrangement,
composition, extension, or adjustment with its creditors; or 

  
 626 Bancroft Way
Office Lease 
 Bancroft Way, LLC:: Oncologic, Inc. 

page 18 of 23 
 Suite 3C
(8,073 rsf) 

 (j) In any proceeding or action in which Tenant is a party, the appointment of a trustee,
receiver, agent, or custodian to take charge of the Premises or Tenant’s Property for the purpose of enforcing a lien against the Premises or Tenant’s Property. 

The parties expressly agree that any notice which Landlord may give to Tenant that an Event of Default has occurred under this § 20 above shall satisfy
the requirements of § 1161 of the California Code of Civil Procedure, and it shall not be necessary to give another notice to Tenant under § 1161. 

20.2 Landlord’s Remedies. Upon the occurrence of an Event of Default hereunder, Landlord shall have the right, in addition to any
other rights or remedies Landlord may have, at Landlord’s option, without further notice or demand of any kind, to elect to do one of the following alternatives: 

(a) Terminate this Lease and Tenant’s right to possession of the Premises, re-enter the Premises, and take possession thereof; and Tenant
shall have no further claim to the Premises or under this Lease; or 
 (b) Continue this Lease in effect and collect any unpaid Rent or
other charges which have theretofore accrued or which thereafter become due and payable. It is intended hereunder that Landlord have the remedy described in California Civil Code § 1951.4, which provides that a landlord may continue a lease in
effect after a tenant’s breach and abandonment and recover rent as it becomes due, if tenant has the right to sublease or assign, subject only to reasonable limitations. 

In the event of any re-entry or retaking of possession by Landlord, Landlord shall have the right, but not the obligation, to remove all or any
part of Tenant’s Property from the Premises and to place such property in storage at a public warehouse at the expense and risk of Tenant. 

20.3 No Waiver of Default. The waiver by Landlord of any Event of Default or of any other breach of any term, covenant, or condition of
this Lease shall not be deemed a waiver of such term, covenant; or condition or of any subsequent breach of the same or any other term, covenant, or condition. Acceptance of Rent by Landlord subsequent to any Event of Default or breach hereof shall
not be deemed a waiver of any preceding Event of Default or breach other than the failure to pay the particular Rent so accepted, regardless of Landlord’s knowledge of any breach at the time of such acceptance of Rent. Landlord shall not be
deemed to have waived any term, covenant, or condition of this Lease, unless Landlord gives Tenant written notice of such waiver. Tenant should not rely upon Landlord’s failure or delay in enforcing any right or remedy hereunder. 

20.4 Landlord’s Right to Cure. If Tenant defaults in the performance of any of its obligations under this Lease, Landlord may (but
shall not be obligated to), without waiving such default, perform the same for the account and at the expense of Tenant. Tenant shall pay Landlord all costs of such performance promptly upon receipt of a bill therefor. 

20.5 Damages. Should Landlord elect to terminate this Lease under the provisions of § 20.2(a) above, Landlord may recover as
damages from Tenant the following: 
 (i) Past Rent: The worth at the time of the award of any unpaid Rent which had been earned at
the time of termination; plus 
 (ii) Rent Prior to Award: The worth at the time of the award of the amount by which the unpaid Rent
which would have been earned after termination until the time of award exceeds the amount of such rental loss that Tenant proves could have been reasonably avoided; plus 

  
 626 Bancroft Way
Office Lease 
 Bancroft Way, LLC:: Oncologic, Inc. 

page 19 of 23 
 Suite 3C
(8,073 rsf) 

 (iii) Rent After Award: The worth at the time of the award of the amount by which the
unpaid Rent for the balance of the Term after the time of award exceeds the amount of the rental loss that Tenant proves could have been reasonably avoided; plus 

(iv) Proximately Caused Damages: Any other amount necessary to compensate Landlord for all detriment proximately caused by
Tenant’s failure to perform its obligations under this Lease or which in the ordinary course of things would be likely to result therefrom, including, but not limited to, any costs or expenses (including attorneys’ fees), incurred by
Landlord in (I) retaking possession of the Premises; (ii) maintaining the Premises after Tenant’s default; (iii) preparing the Premises for reletting to a new tenant, including any repairs or alterations; and (iv) reletting
the Premises, including brokers’ commissions. 
 “The worth at the time of the award” as used in subsections (a) and
(b) above is to be computed by allowing interest at the rate of ten percent (10%) per annum. “The worth at the time of the award” as used in subsection (c) above is to be computed by discounting the amount at the discount
rate of the Federal Reserve Bank situated nearest to the Premises at the time of the award plus one percent (1%). 
 21
RULES. Tenant agrees that it will abide by, keep and observe all reasonable rules and regulations which Landlord may make from time to time for the management, safety, care, and cleanliness of the Building and
grounds, the parking of vehicles and the preservation of good order herein as well as for the convenience of other occupants and tenants of the Building. The violations of any such rules and regulations shall be deemed a material breach of this
Lease by Tenant. 
 22 NOTICES. Any notice required or permitted under this Lease shall be in writing and shall be
delivered in at least one of the following ways: (1) personally or by private hand-delivery messenger service; (2) by depositing the same in the United States mail, postage prepaid, registered or certified, return receipt requested; or
(3) by depositing such notice, postage prepaid, with Federal Express, DHL, UPS, or another nationally-recognized private overnight delivery service. Each such notice shall be addressed to the intended recipient at such party’s address set
forth as follows, or at such other address as such party has theretofore specified by written notice delivered in accordance with this § 22: 

if to Landlord: 
 BANCROFT
WAY, LLC 
 Attn: Manager 
 2332
Fifth Street 
 Berkeley, CA 94710 

if to Tenant: 
 ONCOLOGIC,
INC. 
 Attn: Director of Operations 

626 Bancroft Way, Suite 3C 

Berkeley, CA 94710 
 Every notice given to a party
shall state the section of the Lease pursuant to which the notice is given and the period of time within which the recipient of the notice must respond 

23 HOLDING OVER. Any holding over after the expiration of this Lease, with the consent of Landlord, shall
be construed as a month-to-month tenancy at a base monthly rental of one hundred twenty five percent (125%) of the monthly rental which was in effect under the Lease on the Expiration Date, and otherwise in accordance with the terms hereof, as
applicable, except that Tenant shall have no extension or renewal option. 

  
 626 Bancroft Way
Office Lease 
 Bancroft Way, LLC:: Oncologic, Inc. 

page 20 of 23 
 Suite 3C
(8,073 rsf) 

 24 ESTOPPEL CERTIFICATE. Tenant shall at any time upon not
less than ten (10) days’ prior written notice from Landlord execute, acknowledge, and deliver to Landlord a statement in writing certifying (1) that this Lease is unmodified and in full force and effect (or, if modified, stating the
nature of such modification and certifying that this Lease, as so modified, is in full force and effect), the amount of any security deposit, and the date to which the rent and other charges are paid in advance, if any; and (2) acknowledging
that there are not, to Tenant’s knowledge, any uncured defaults on the part of Landlord hereunder, or specifying such defaults if any are claimed. Any such statement may be conclusively relied upon by any prospective purchaser or encumbrancer
to the Premises. At Landlord’s option, Tenant’s failure to deliver such statement within such time shall be a material breach of this Lease or shall be conclusive upon Tenant that (1) this Lease is in full force and effect, without
modification except as may be represented by Landlord, (2) there are no uncured defaults in Landlord’s performance, and (3) not more than one month’s rent has been paid in advance or such failure maybe considered by Landlord as a
default by Tenant under this Lease. If Landlord desires to finance, refinance, or sell the Premises, or any part thereof, Tenant hereby agrees to deliver to any lender or purchaser designated by Landlord such financial statements of Tenant as may be
reasonably required by such lender or purchaser. Such statements shall include the past three years’ financial statements of Tenant. All such financial statements shall be received by Landlord and such lender or purchaser in confidence and
shall be used only for the purposes herein set forth. 
 25 ARBITRATION. In the event of any dispute between Landlord
and Tenant arising under this Lease that is not resolved by the parties within ten (10) days after the date either party gives notice to the other of its desire to arbitrate the dispute (the “Outside Agreement Date”), the dispute
shall be settled by binding arbitration as provided in this § 25 and under the Commercial Arbitration Rules of the American Arbitration Association then in effect; provided, however, that nothing in this § 25 shall limit Landlord’s
right to bring an unlawful detainer action against Tenant if appropriate. All arbitration proceedings shall be conducted at Berkeley, California. Judgement upon the arbitration award may be entered in any court having jurisdiction. The arbitrators
shall have no power to change the Lease provisions. Both parties shall continue performing their Lease obligations pending the award in the arbitration proceeding. The arbitrators shall award the prevailing party reasonable expenses and costs,
including reasonable attorneys’ fees pursuant to § 25.3 below, plus interest on the amount due at eighteen percent (18%) per annum or the maximum then allowed by Law, whichever is less. 

25.1 Procedure. Not later than fifteen (15) days following the Outside Agreement Date, Landlord and Tenant shall each appoint one
arbitrator who shall be a real estate professional who shall have been active over the five (5) year period ending on the date of such appointment in the appraisal and/or leasing of commercial properties in the vicinity of the Building, The two
arbitrators so appointed shall within fifteen (15) days of the date of the appointment of the last appointed arbitrator agree upon and appoint a third arbitrator who shall be qualified under the same criteria set forth hereinabove for
qualification of the initial two arbitrators. Within three (3) business days following the appointment of the third arbitrator, each party shall submit to the arbitrators its best estimate of the correct solution to the dispute under submission
(the “Estimated Determination”). The determination of the arbitrators shall be limited solely to the issue of whether Landlord’s or Tenant’s Estimated Determination of the dispute under arbitration is closer to the
arbitrators’ independent determination of the dispute, taking into account any definitions or other sections of the Lease which may be applicable to the dispute. The three arbitrators shall within thirty (30) days of the appointment of the
third arbitrator reach a decision as to whether the parties shall use Landlord’s or Tenant’s Estimated Determination and shall notify Landlord and Tenant thereof. The decision of the majority of the three arbitrators shall be binding upon
Landlord and Tenant. 
 25.2 Failure to Agree. If either Landlord or Tenant fails to appoint an arbitrator within fifteen
(15) days after the Outside Agreement Date, or if the two arbitrators fail to agree upon and appoint a third arbitrator, both arbitrators shall be dismissed; and the matter to be decided shall be forthwith submitted to arbitration under the
current rules of the American Arbitration Association, but subject to any definitions or sections of the Lease which may be applicable to the dispute under submission. 

  
 626 Bancroft Way
Office Lease 
 Bancroft Way, LLC:: Oncologic, Inc. 

page 21 of 23 
 Suite 3C
(8,073 rsf) 

 25.3 Payment. The losing party shall pay to the prevailing party the amount of the final
arbitration award. If payment is not made within ten (10) business days after the date the arbitration award is no longer appealable, then in addition to any remedies under the law, if Landlord is the prevailing party, it shall have the same
remedies for failure to pay the arbitration award as it has for Tenant’s failure to pay Rent; and if Tenant is the prevailing party, it may deduct any remaining award from its monthly payment of Rent or other charges. 

26 SUBORDINATION. Tenant agrees that this Lease shall be automatically subordinate to any mortgage or trust deeds that
are now or may hereafter be placed upon said Premises. Notwithstanding the foregoing, Tenant agrees that any mortgagee of the Building, the holder of any note, or beneficiary of any deed of trust (collectively “Holders”) encumbering the
Building shall have the right upon written notice to Tenant to subordinate the lien of any such note or deed of trust to this Lease. 
 27
LANDLORD’S LIABILITY. The liability of Landlord to Tenant for any default by Landlord under this Lease or arising in connection herewith or with Landlord’s operation,
management, leasing, repair, renovation, alteration, or any other matter relating to the Building or the Premises shall be limited to the interest of Landlord in the Building (and the rental proceeds thereof). Under no circumstances shall Landlord
ever be liable for consequential or punitive damages, including damages for lost profits or for business interruption. Tenant agrees to look solely to Landlord’s interest in the Building (and the rental proceeds thereof) for the recovery of any
judgement against Landlord, and Landlord shall not be personally liable for any such judgement or deficiency after execution thereon. The limitations of liability contained in this § 27 shall apply equally and inure to the benefit of
Landlord’s present and future partners, beneficiaries, officers, directors, trustees, shareholders, agents, and employees, and their respective partners, heirs, successors, and assigns. Under no circumstances shall any present or future general
or limited partner of Landlord (if Landlord is a partnership), or trustee or beneficiary (if Landlord or any partner of Landlord is a trust) have any liability for the performance of Landlord’s obligations under this Lease. 

27.1 Liability Upon Transfer. The term Landlord as used herein shall mean only the owner or owners, at the time in question, of
the fee title of leased Premises and in the event of any transfer of such title or interest, Landlord herein named shall be relieved from and after the date of such transfer of all liability as respects Landlord’s obligations thereafter to be
performed, provided that any funds in the hands of Landlord at the time of such transfer, in which Tenant has an interest, shall be delivered to the grantee. The obligations contained in this Lease to be performed by Landlord shall, subject as
aforesaid, be binding on Landlord’s successors and assigns, only during their respective periods of ownership. 
 28
MISCELLANEOUS. The following provisions shall apply generally to terms, provisions, and covenants of this Lease: 

28.1 No Offer. The submission of this document for examination and negotiation does not constitute an offer to lease, or a reservation
of, or option for, the Premises. This document becomes effective and binding only upon execution and delivery hereof by Tenant and by Landlord. No act or omission of any employee or agent of Landlord or of Landlord’s broker shall alter, change,
or modify any of the provisions hereof. 
 28.2 No Partnership. It is expressly understood that Landlord does not, in any way or for
any purpose, become a partner of Tenant in the conduct of its business, or otherwise, or joint adventurer or a member of a joint enterprise with Tenant, and that the provisions of this Lease relating to the percentage rental payable hereunder, if
any, are included solely for the purpose of providing a method whereby the rental is to be measured and ascertained. 

  
 626 Bancroft Way
Office Lease 
 Bancroft Way, LLC:: Oncologic, Inc. 

page 22 of 23 
 Suite 3C
(8,073 rsf) 

 28.3 Heirs, Assigns, Successors. This Lease is binding upon and inures to the benefit of
the heirs, assigns and successors in interest to the parties. 
 28.4 Time. Time is of the essence of this Lease. 

28.5 Waiver. No failure of Landlord to enforce any term hereof shall be deemed to be a waiver. 

28.6 Attorney’s fees. In case arbitration or suit should be brought for recovery of the Premises, or for any sum due hereunder, or
because of any act or omission which may arise out of the possession of the Premises, by either party, the prevailing party shall be entitled to all costs incurred in litigation, arbitration, or otherwise in connection with such action, including a
reasonable attorneys’ fee. 
 29 ENTIRE AGREEMENT. This Lease, together with its exhibits, contains
all the agreements of the parties hereto and supersedes any previous negotiations. There have been no representations made by the Landlord or understandings made between the parties other than those set forth in this Lease and its exhibits. This
Lease may not be modified except by a written instrument duly executed by the parties hereto. 
 In witness whereof, the parties have
executed this Lease as of the date first above written. 
  

			
	Landlord:	  	Tenant:
		
	 BANCROFT WAY, LLC, a California limited liability company
	  	 ONCOLOGIC, INC., a California corporation

		
	            By:    /s/ Michael Goldin	  	            By:    /s/ Roy K. Steven
		
	                      Michael Goldin, Manager	  	                      Roy K. Steven
                                
		
		  	            Its:    Pres. + CEO

 EXHIBITS 

Exhibit A - Site Plan of Development 

Exhibit B - Floor Plan of Premises 

Exhibit C - Commencement Date Agreement 

Exhibit D - Work Letter Agreement (none) 

CORPORATE AUTHORITY: If Lessee is a corporation, each individual executing this Lease on behalf of said corporation represents and warrants that he/she is
duly authorized to execute and deliver this Lese on behalf of said corporation in accordance with duly adopted resolution of the Board of Directors of said Corporation or in accordance with the Bylaws of said Corporation, and that this Lease is
binding upon said Corporation in accordance with its terms. 
 ***** 

  
 626 Bancroft Way
Office Lease 
 Bancroft Way, LLC:: Oncologic, Inc. 

page 23 of 23 
 Suite 3C
(8,073 rsf) 

 

 

 

 

 May 21, 2008 

NANOTX CORP., DBA
ADURO BIOTECH 
 Attn: David Rose, Director of Operations 

626 Bancroft Way 
 Berkeley, CA 94710 

 

	 	re:	    Extension of Term of Lease at 625 Bancroft Way, Berkeley, California 

 Dear
Steve, 
 This letter will confirm the agreement of Landlord and Tenant that the Term of your lease dated June 1, 2005 (the
“Lease”) of Suite 3C at 626 Bancroft Way, Berkeley, California (collectively the “Premises”) as defined under the Lease, will be extended for a period of twenty-four (24) months commencing on September 1, 2008, upon the
following terms and conditions: 
  

	 	1.	You have informed Landlord that the Lease has heretofore been transferred or assigned by Oncologic, Inc. to NanoTx Corp., a California corporation dba Aduro BioTech. In consideration of the extension of the Lease
hereby effected pursuant to Tenant’s exercise of its Extension Option thereunder, Landlord consents to such assignment of the Lease. Landlord’s consent to the assignment does not constitute its consent to any further assignment of the
Lease, for which Landlord’s consent shall be required in accordance with the provisions of § 6 of the Lease. 

  

	 	2.	The Term of The Lease respect to the entire Premises is hereby extended for a period of Twenty-four (24) months commencing on September 1, 2008, and expiring on August 31, 2010 (the “Extension
Term”). 

  

	 	3.	The Base Rent payable with respect to the entire Premises shall be One Dollar and fifty five cents ($1.55) per rentable square foot per month, payable when and as specified in the Lease. 

 

	 	4.	Base Rent for the month of September, 2008, for the entire Premises shall be due payable on September 1, 2008. 

  

	 	5.	Additional Rent shall be payable with respect to the entire Premises as specified under § 2.3 et seq. of the Lease. 

  

	 	6.	Landlord shall have no obligation to improve or alter the Premises or pay for the same in preparation for Tenant’s continued occupancy thereof for the Extension Term, and Tenant agrees to accept the same in their
current “as is” condition on August 1, 2008. 

 Thank you for your prompt and courteous attention to this
matter. It has been a pleasure to have you as a tenant at Bancroft Way, and we look forward to extending your presence in the property for the duration of the Extension Term. 

 
	
	 Very truly yours,

	
	Bancroft Way, LLC
	
	            /s/ Steven Goldin
	 Steven Goldin, Manager

 Read, agreed, and subscribed as the binding agreement of the parties. 

NanoTx Corp., a California corporation dba Aduro BioTech 

 

					
			By:		/s/ Steve Isaacs
					Steve Issacs, CEO
			
			Date:		 May 21, 2008

 February 11, 2010 

ADURO BIOTECH 

Attn: Steve Isaacs 
 626 Bancroft Way 

Berkeley, CA 94710 
  

	 	re:	    Extension of Term of Lease at 626 Bancroft Way, Berkeley, California 

 Dear
Steve, 
 This letter will confirm the agreement of Landlord and Tenant that the Term of your lease dated June 1, 2005 (the
“Lease”) of Suite 3C at 626 Bancroft Way, Berkeley, California (collectively the “Premises”) as defined under the Lease, and extended by Letter Agreement September 1, 2008, will be extended for a period of twenty four months
(24) months commencing on September 1, 2010, upon the following terms and conditions: 
  

	 	1.	The Term of the Lease respect to the entire Premises is hereby extended for a period of Twenty four (24) months commencing on September 1, 2010, and expiring on August 31, 2012 (the
“Extension Term”). 

  

	 	2.	The Base Rent payable with respect to the entire Premises shall be One Dollar and sixty five cents ($1.65) per rentable square foot per month, payable when and as specified in the Lease. 

 

	 	3.	Base Rent for the month of September, 2010, for the entire Premises shall be due payable on September 1, 2010. 

  

	 	4.	Additional Rent shall be payable with respect to the entire Premises as specified under § 2.3 et seq. of the Lease. 

  

	 	5.	Landlord shall have no obligation to improve or alter the Premises or pay for the same in preparation for Tenant’s continued occupancy thereof for the Extension Term, and Tenant agrees to accept the same in their
current “as is” condition on September 1, 2010. 

 Thank you for your prompt and courteous attention to this
matter. It has been a pleasure to have you as a tenant at Bancroft Way, and we look forward to extending your presence in the property for the duration of the Extension Term. 

 Letter to David Rose 

May 21, 2008—page 2 

 
	
	Very truly yours,
	
	Bancroft Way, LLC
	
	 /s/ Steven Goldin

	Steven Goldin, Manager

 Read, agreed, and subscribed as the binding agreement of the parties. 

Aduro BioTech., a California corporation 
  

			
	By:		/s/ Steve Isaacs 2/25/2010
			Steve Issacs, CEO
		
	Date:		February 11, 2010

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}]]